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Abstract
Under the orchestration of the circulating steroid hormones, oestrogen and
progesterone, the human endometrium undergoes a well-defined cycle of
proliferation, differentiation and shedding (menstruation). This cyclical process has
been described as a recurrent physiological injury and repair. Problems of
menstruation account for a large proportion of female morbidity and many women
who are referred to secondary care with a menstrual complaint undergo a
hysterectomy. No differences in either circulating hormone levels or specific
histological findings have been discovered to account for menstrual pathologies such
as heavy menstrual bleeding. It is therefore important to examine the local mediators
present in the endometrium if we are to further our understanding of aberrations of
endometrial function. Disturbed angiogenesis has been implicated in many
endometrial pathologies, however the mechanism for control of the endometrial
vasculature is poorly understood. Prostaglandins have been implicated in both
endometrial pathologies and disturbances of angiogenesis. This thesis is based on the
hypothesis that menstrual dysfunction, including heavy menstrual blood loss (MBL)
is due to (a) up-regulated expression/synthesis of cyclooxygenase enzymes and
prostaglandin receptors, and (b) initiation of enhanced intracellular signalling
pathways in response to prostaglandins.
This thesis describes the use of an endometrial epithelial cell line to explore
the molecular signalling pathways involved with the activation of a prostaglandin
receptor - the prostacyclin receptor. A rapid activation of ERK1/2 signalling is
demonstrated with alterations in expression of angiogenic factors via crosstalk with
the epidermal growth factor receptor.
By using endometrium collected from women with the complaint of heavy
menstrual bleeding, the pattern of expression of the various components of the COX-
prostaglandin signalling pathways present in the endometrium of women with normal
and heavy MBL is elucidated. There is a significant elevation in expression of COX-
1 and COX-2 mRNA in endometrium obtained from women with heavy MBL
compared with endometrium obtained from women with normal MBL. Significant
alterations in expression of downstream prostanoid synthase and prostanoid receptor
mRNAs were also detected. Furthermore, enhanced prostaglandin stimulated
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production of cyclic AMP observed in endometrium of women with heavy MBL
compared with normal MBL.
By identifying the prostanoid receptors/signalling pathways that are
responsible for disturbed endometrial function, this thesis aims to establish
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The uterus plays a crucial role in the propagation of the species. Implantation
of the fertilised ovum is a critical event common to all species. Humans and other old
world primates differ from most other animals in that, in the absence of pregnancy,
the endometrium undergoes well-defined cycles of proliferation, differentiation and
shedding (menstruation) in response to the prevailing endocrine and paracrine
environment. The endometrium is therefore a very dynamic target organ, the
development and function of which is orchestrated by the action of sex steroids,
predominantly oestrogen and progesterone. The endocrine influences of the major sex
steroid hormones exert a controlling influence upon the whole reproductive tract. It is
however essential to have a detailed knowledge of the local mechanisms at work
within the endometrium if we are to understand the mechanisms responsible for
aberrations in endometrial function such as disorders of menstrual bleeding.
Prostaglandins are bioactive lipids produced from arachidonic acid by
cyclooxygenase enzymes (COX) and specific terminal prostanoid synthase enzymes.
Following biosynthesis, prostaglandins exert an autocrine/paracrine function by
coupling to specific receptors to activate intracellular signalling and gene
transcription. A role for COX enzymes and prostaglandins has been ascertained in
reproductive tract pathology, including painful menstruation (dysmenorrhoea), heavy
menstrual bleeding (menorrhagia), endometriosis and cancer (Lundstrom et al., 1976;
Morita, 2002; Ota et al., 2001; Sales et al., 2002; Smith, S. K. et al., 1981a).
Emerging evidence supports a role for COX enzymes, prostaglandins and
prostaglandin receptor signalling pathways in a multitude of phenotypic changes
within reproductive tissues including the promotion of angiogenesis and vascular
function (Sales et al., 2005; Tsujii et al., 1998).
This thesis summarises the published data regarding prostaglandins and their
receptors in the human endometrium and highlights the roles of prostaglandins in
benign disorders of the endometrium. Furthermore, new data are presented that will
contribute to our understanding of the role of prostaglandins in endometrial
physiology.
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1.2 The Human Uterus and Endometrium
Essential for reproduction, the uterus is a fibromuscular organ composed of a
smooth muscle outer layer lined by endometrium. The uterus is composed of the body
of the uterus and the uterine cervix. The body of the uterus is composed of smooth
muscle cells that are steroid responsive, undergoing hyperplastic and hypertrophic
changes at developmental milestones during a woman's reproductive life. Under the
influence of oestrogen, the body of the uterus doubles in size from a pre-pubertal size
approximately equal to the size of the cervix. During pregnancy, the cells undergo
hyperplasia and hypertrophy under the influence of placental steroids, allowing for
growth of the developing fetus.
The endometrium lines the body of the uterus and is a dynamic steroid
responsive tissue that must undergo regeneration and remodelling during each
menstrual cycle to prepare for possible implantation. Menstruation signals the end of
one cycle and the beginning of the next. The proliferative phase follows menses and
during this stage oestradiol levels rise, leading to endometrial growth and
proliferation. Following ovulation the corpus luteum produces progesterone, the
dominant hormone of the secretory phase. Together with oestrogen, progesterone
prepares the endometrium for possible blastocyst implantation. In the absence of
pregnancy, the corpus luteum regresses and sex hormone levels decline, triggering
the mechanisms that lead to menstruation.
1.2.1 Endometrial Morphology
The two layers of the endometrium are the superficial functional layer, which
is shed during menstruation and the basal layer from which the endometrium has
always been considered to regenerate. There are three well-characterised phases of
endometrial development: a preovulatory proliferative phase, a postovulatory
secretory phase involving tissue differentiation and a menstrual phase involving
tissue break down. Consequently, the endometrium may be considered a site of
recurrent physiological injury and repair (Critchley et al., 2001b). Markee and
colleagues (Markee, JE, 1940) first described an orchestrating role for the ovarian sex
steroids in regulating the changes in endometrial morphology across the menstrual
cycle. Progesterone is essential for maintaining and establishing a pregnancy and this
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action is dependent upon the transformation of an oestrogen-primed endometrium.
Menstruation is the response of the endometrium to the withdrawal of sex steroid
hormones that occurs with the demise of the corpus luteum in the absence of
pregnancy (Critchley et al., 2001b).
Endometrial dating has historically been related to the timing of ovulation.
The series of classical morphological changes that occur in response to cyclical
ovarian activity have been well detailed (Noyes RW, 1950). However, much
controversy exists over endometrial dating (Coutifaris et al., 2004; Murray et al.,
2004). There are arguments that exist which suggest histological dating according to
traditional histological methods lacks both the accuracy and precision to provide a
guide for clinical management within the infertility setting. More robust methods for
endometrial dating are likely to involve combining histological dating with reporting
of last menstrual period and quantification of circulating oestrogen and progesterone
levels. Detailed gene microarray studies support this method for characterizing
endometrial samples with consistency across these three parameters (Critchley et al.,
2006; Talbi et al., 2006). It is notable that exogenous administration of steroids
produces a deviation from the classical histological features of glandular structure,
mitotic status of glandular cells and secretions in the lumen of the glands (Habiba et
al., 1998) when compared with accurately dated endometrium collected during a
physiological cycle (Noyes RW, 1950).
1.2.2 Proliferative Stage
The following descriptions of endometrial morphology are based upon criteria
originally described by Noyes and colleagues (Noyes RW, 1950). Oestrogen is the
steroid hormone that dominates in the pre-ovulatory (follicular) half of the cycle.
During the proliferative phase, the surface epithelium regenerates and short, narrow
epithelial glands gradually lengthen and curve. Mitosis is evident in the epithelial and
stromal cells. The stroma is compact, containing spindle like cells and stromal
oedema tends to regress through the proliferative phase. Prior to ovulation, during the
late proliferative phase, the surface epithelium becomes more undulant and glands
become more tortuous. Nuclei appear to be pseudostratified. The stroma by this stage
is moderately dense and actively growing.
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1.2.3 Secretory Stage
The secretory phase of the endometrial cycle is dominated by the action of
progesterone upon the oestrogen-primed endometrium. This phase of the cycle may
be divided into three stages; early, mid and late, representing the widely changing
physiology that occurs during this time frame.
Early Secretory Phase (Post Ovulation Days 1 to 4)
Subnuclear glycogen-rich vacuolation of the glandular epithelium becomes
prominent in at least 50% of cells (CH Buckley, 1989). The nuclei lose the
pseudostratification configuration with an accompanying increase in the diameter and
tortuosity of the glands. Mitosis cease to be seen.
Mid Secretory Phase (Post Ovulation Days 5-9)
Acidophilic intra-luminal secretions reach a peak. Stromal oedema is
characteristically marked in the mid-secretory phase, peaking about day 8-9. The
stroma at this phase looks like small, dense, nuclei with only filamentous cytoplasm.
The spiral arterioles, previously difficult to distinguish in the oedematous stroma,
become much more prominent. These findings constitute the earliest visible pre-
decidual change.
Late Secretory Phase (Post Ovulation Days 10-Menses)
Eosinophilic pre-decidual cells may be seen located around the arterioles and
stromal proliferation recurs, evident by mitosis. There is a sharp increase in leukocyte
infiltration. Accompanying the pre-decidual change there is stromal regression and
loss of endometrial height (CH Buckley, 1989). In the absence of pregnancy, gland
secretion decreases and involution of the epithelial gland occurs. The glands dilate
and take on a characteristic "saw toothed" effect; but the previously tall columnar




The menstrual cycle commences with the first day of menstrual bleeding. The
upper two thirds of the endometrium (the superficial layer) are shed. The
endometrium exhibits focal areas of sub-epithelial necrosis with subsequent glandular
collapse and further necrosis. As menses ceases, a typical shallow dense
endometrium remains that is composed of the basal layer and residual deeper
functional layer. Regeneration starts to occur from the third day and commences in
the glandular and stromal elements (Smith, S. K., 2001).
1.2.5 Sex steroid hormones and their receptors
Oestrogen and progesterone are the two principal sex steroids influencing
endometrial growth, differentiation and function. The development of specific
monoclonal antibodies to the oestrogen receptor (ER) and the progesterone receptor
(PR) has advanced immunohistochemical localisation. The ER and PR
immunolocalise to the nuclear compartment of cells within the endometrium. The
endometrium consists of stromal, epithelial (glandular), endothelial (vascular) and
perivascular cellular compartments. The expression of endometrial sex steroid
receptors varies both temporally and spatially within the endometrium (Critchley et
al., 2001a; Lessey et al., 1988). However, with the discovery of further receptor
subtypes, our understanding of their distribution and function is changing.
Oestrogen is the steroid responsible for endometrial proliferation and
progesterone exerts an anti-oestrogenic affect with inhibition of endometrial growth
and induction of glandular differentiation. These progesterone effects require PR to
be present which paradoxically only exists in an oestrogen primed endometrium. The
presence of PR is considered evidence of a functional ER pathway. Both oestrogen
and progesterone receptors are upregulated in stromal and glandular tissue during the
proliferative phase of the menstrual cycle, with the ER expression reaching a peak in
the late proliferative/early secretary phase. During the secretory phase, ER and PR are
down regulated in the glands by the action of progesterone acting at the
transcriptional and post-transcriptional level (Chauchereau et al., 1992). ER
expression is suppressed in the stroma with moderate stromal suppression of PR
(Critchley 2003).
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Steroids receptors are expressed as various subtypes. The ER has two
structurally related subtypes, commonly known as ER-a and ER-p. These subtypes
are derived from separate genes (Enmark et al., 1997). The endometrium
demonstrates differing levels of ER subtype expression within all cellular
compartments (Saunders et al., 2002). ERa and ERp mRNAs are present in glandular
epithelial cells, stromal cells and smooth muscle cells of the uterine wall at every
stage of the menstrual cycle with higher levels of ERa expression than ERp. ERa,
which may be thought of as the classical ER, does however show the greater decline
within the superficial layer of the endometrium during the secretory stage (Saunders
and Critchley, 2002). A similar decline in ERa protein expression has also been
reported within a study that demonstrated the only oestrogen receptor expressed
within the endometrial endothelial cells of the vasculature was ERp. Both ER
subtypes were however expressed in the perivascular cells (Critchley. et al., 2001a).
The PR also exists as two subtypes; PRA and PRB. These structurally related
gene products are expressed from a single gene as a result of transcription from two
alternative promoters (Mulac-Jericevic et al., 2004). The A isoform, 779 amino acids
in length, is a truncated version of the B isoform which is 993 amino acids in length
(Tung et al., 1993). The two isoforms can display distinct transactivational properties
that are specific to cell type and ligand. For the few genes regulated by both
receptors, PRB appears to function as a stronger activation of transcription (Turgeon
et al., 2004). PRA and PRB are differentially regulated with spatio-temporal
variations in expression. Both subtypes are demonstrated within the glandular and
stromal compartments during the proliferative phase, with both receptor subtypes
dramatically declining in the glandular cells during the secretory stage. However
PRA remains the predominant progesterone receptor within the stroma during the
secretory phase and would appear to mediate progesterone effects on endometrium
during this phase of the cycle (Wang et al., 1998).
The actions of oestrogen and progesterone may also involve membrane as
well as nuclear receptors. Rapid extra-nuclear signalling has been demonstrated for
both steroids (Boonyaratanakornkit et al., 2004). These actions may be mediated via
intra-cellular second-messenger or other non-nuclear signal transduction pathways.
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1.2.6 Endometrial Vasculature
Blood supplies the uterus via the uterine arteries. In the myometrium, arcuate
arteries then form by branching at 90° towards the endometrium to form radial
arteries. These radial arteries then branch to form basal arteries and spiral arterioles.
The basal arteries supply the basal layer of the endometrium and the larger spiral
arterioles supply the functional layer of the endometrium (Hickey et al., 2000). The
endometrial microvasculature of capillaries and venous plexuses are formed
downstream of the spiral arterioles.
The spiral arterioles are involved in leukocyte entry and vasoconstriction and
are implicit in the process of menstruation. These vessels are under the control of
steroid hormones (Perrot-Applanat et al., 2000), with both growth and differentiation
mediated by the presence of ER and PR within the vascular smooth muscle cells.
However, direct endothelial steroid receptor expression has been difficult to prove
with recent data demonstrating human endometrium endothelial cells do not express
ERa or PR but do express ERp (Critchley et al., 2001a). The mechanism for control
of the microvasculature is poorly understood. Endometrial microvessels consist only
of endothelial cells linked by tight junctions and supported by their basal lamina. This
specialised form of extracellular matrix contributes more than support, aiding vessel
growth, differentiation and permeability (Hickey and Fraser, 2000).
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1.3 Prostaglandins
In 1935, von Euler first proposed the name "prostaglandin" for one of the
active extracts that he was studying. It was not until 30 years later that interest
returned to these substances as their physiological roles were being uncovered.
Prostaglandins, thromboxanes and leukotrienes, collectively known as eicosanoids,
are lipid soluble, bioactive metabolites, derived from the action of COX and
lipooxygenase upon arachidonic acid (AA). Much work in general has been done to
elucidate the roles of COX enzymes in health and disease. Advances in knowledge
have helped to evolve the commonly used non-steroidal anti-inflammatory drugs
(NSAIDs) whose action is to inhibit COX enzymes. Non-selective NSAID use has
been associated with gastrointestinal toxicity, ulceration, platelet dysfunction and
kidney damage in at least 1% of users (Fosslien, 1998). In addition, well-publicised
and unforeseen cardiovascular problems have arisen with selective COX-2 inhibitors
(Krumholz et al., 2007) that dramatically highlight the need for a further
understanding of these enzymes, metabolites and their receptors.
The multiple roles played by COX enzymes in reproductive biology have
been highlighted following establishment of COX-deficient mice. Studies in COX-1-
deficient mice have shown that the gestation period is prolonged and parturition is
reduced coincident with a reduction in the number of viable offspring. Interestingly,
conception and fetal development are unaltered suggesting that prostanoids produced
by COX-1 are not critical for ovulation, fertilization or implantation, but are essential
for bringing on normal labour at term. This is confirmed by observations between
wild type mice giving natural birth and COX-1 deficient females having their young
delivered by caesarean section, where there are no noticeable differences in the
number or size of the offspring delivered (Gross et al., 1998; Langenbach et al.,
1995). By contrast, ablation of the COX-2 gene in mice results in multiple
reproductive failures, including ovulation, fertilization, implantation and
decidualization, confirming that prostaglandins produced by COX-2 play a crucial
role in these processes (Dinchuk et al., 1995; Langenbach et al., 1999; Langenbach et
al., 1999; Lim et al., 1997). Prior to ovulation, pituitary gonadotropins trigger the
expression of COX-2 and synthesis of PGE2 to promote follicle expansion and
ovulation. In COX-2 deficient mice, absence of PGE2 in preovulatory follicles
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disrupts follicle expansion and results in anovulation. Under these conditions
administration of exogenous PGE2 has been shown to rescue ovulation (Davis et al.,
1999). Thus, although both COX isoforms essentially catalyze the same reaction, in
the reproductive tract there are clear differences in the prostanoid profile and
functions of the two COX enzymes.
The focus of this thesis is to provide insight into the role of cyclooxygenase
(COX) enzymes, prostaglandins and their receptors in the human endometrium.
Observations have been made over the years implicating a role for prostaglandins in
benign pathologies of the endometrium such as heavy menstrual bleeding
(menorrhagia), endometriosis and dysmenorrhoea. The role of prostaglandins within
these endometrial pathologies will be further outlined in section 1.4.3.
1.3.1 The prostaglandin pathway
Prostaglandin is a generic term for a closely related family of C20 carboxylic
acids. Their biochemical structure is based upon the hypothetical prostanoic acid
(Figure 1.1)
Figure 1.1 Hypothetical prostanoic acid skeleton
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Prostaglandins may be divided into the A, B, C, D, E, F or J series and they
are named according to the substituents in the cyclopentane ring. There is no
significance to the letters. Prostacyclin (PGI2) has an unusual ring structure that
differs from this simplified biochemical description. The subscripted number refers to
the number of double bonds in the prostaglandin. Thus PGE2 has 2 double bonds, one
originating from the 5-position and the second from the 13-position, whereas PGEi
has only one double bond (originating from the 13-position) and PGE3 has 3 double
bonds (originating at the 5,13, and 17-positions).
Prostaglandin Biosynthesis
The kinetics of the prostaglandin biosynthetic pathway is driven by the
availability of free arachidonic acid (AA). Following activation of phospholipase A2
(PLA2), AA is released from plasma membrane phospholipids or dietary fats and is
cyclized and oxygenated by COX via the addition of the 15-hydro-peroxy group to
form prostaglandin G2 (PGG2). A reduction of the hydro-peroxy group to a hydroxy
group forms the intermediary prostaglandin H2 (PGH2). This intermediate serves as
the substrate for terminal prostanoid synthase enzymes. These are named according to
the prostaglandin they produce such that prostaglandin D2 is synthesised by
prostaglandin-D-synthase (PGDS), prostaglandin E2 (PGE2) by prostaglandin-E-
synthase (PGES), prostaglandin F2a by prostaglandin-F-synthase (PGFS),
prostacyclin (PGI2) by prostaglandin-I-synthase (PGIS) and thromboxane (TXA2) by
thromboxane synthase (TXS) (Narumiya et al., 1999); figure 1.2). After biosynthesis,
prostaglandins are transported out of the cell by a prostaglandin transporter (PGT)
(Chan et al., 1998). The expression of PGT has been shown in both bovine models
(Banu et al., 2003) and human endometrium (Kang et al., 2005). Once released
outside the cell, the prostaglandin can then act in a paracrine or autocrine manner on
their cognate heptahelical transmembrane G-protein coupled receptor (GPCR). The
physiological endpoint to the prostaglandin signalling pathway within specific cells
and tissues, is in part dependent upon the expression of terminal synthase enzymes
and respective receptors for the specific prostanoids produced.
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Figure 1.2 The cyclooxygenase and prostanoid biosynthetic and signalling
pathways
Arachidonic acid (AA) is released from plasma membrane phospholipids by
phospholipase A2 (PLA2) and acted upon by COX enzymes and specific terminal
prostanoid synthase enzymes to form prostaglandin D2 (PGDf), PGE2, PGF2C0 PGf
and thromboxane (TXA2). These mediators are actively transported out of the cell by
a prostanoid transporter (PGT). They are then able to exert an autocrine or
paracrine effect by coupling to their specific heptcihelical transmembrane receptors
to activate intracellular signalling. (cAMP: cyclic AMP, IP3: inositol trisphosphate.




PGD2, PGE2, PGF2a, PGI2 and TXA2 exert their biological effect through the
DP, EP, FP, IP and TP prostanoid receptors respectively (Narumiya et al., 1999).
PGE2 interacts with four subtypes of receptor, which have been pharmacologically
divided into EP1, EP2, EP3 and EP4. These receptors are coupled to their own
second messenger systems using alternate and in some cases opposing intracellular
pathways (Ashby, 1998); figure 1.2). Separate genes encode for each receptor and in
addition there are several splice variants for EP3, TP and FP receptors, which differ
only in their C-terminal tails (Narumiya et al., 1999).
In general, prostanoid receptor isoforms exhibit similar ligand binding but
differ in their signalling pathways, their sensitivity to agonist-induced desensitisation
and their tendency toward constitutive activity. Phylogenetic analyses indicate that
receptors sharing a common signal pathway have higher sequence homology than
receptors sharing a common prostanoid as their preferential ligand (Jabbour et al.,
2006). Among the different receptors, the IP, DP, EP2 and EP4 receptors elevate
intracellular cAMP accumulation via Gas and have been termed "relaxant" receptors
since they induce smooth muscle relaxation. TP, FP and EP1 receptors induce
calcium mobilisation via Gaq and constitute a "contractile" receptor group since they
cause smooth muscle contractions. The remaining receptor, EP3, is generally
associated with a decline in cAMP levels and has been termed the "inhibitory"
receptor and usually stimulates smooth muscle contraction, however depending on
the splice variant and cell type, the EP3 receptor can also elevate intracellular cAMP
and mobilise calcium (Narumiya et al., 1999).
Plasma membrane ligand-receptor interaction remains the principle
mechanism whereby prostanoids can exert their effects. Flowever, the picture is
complicated yet further with the discovery of alternate nuclear locations for certain
prostanoid receptors (Bhattacharya et al., 1999; Wise, 2003). This indicates that
certain prostanoids may be able to directly regulate the transcription of target genes,
forgoing the requirement of intracellular signalling pathways.
In summary, prostanoids are released in high local concentrations, exerting an

















































TISSUE INVASION AND METASTASIS
Figure 1.3 Autocrine /paracrine prostaglandin signalling mechanisms
Prostaglandin (PG) produced by the cyclooxygenase (COX) enzyme is transported
out of the cell and is able to act upon locally situated heptahelical transmembrane G-
protein coupled receptors (GPCRs). This initiates second messengers such as cyclic
AMP (cAMP) and mitogen activated protein kinases (MAPK). Nuclear receptors for
prostanoids have also been described. This diagram demonstrates a mechanism for




Cross-communication with the epidermal growth factor receptor (EGFR) has
been demonstrated for EP2 and FP receptors (Sales et al., 2004a; Sales et al., 2004b).
Support for these findings is provided by evidence demonstrating that prostanoid
GPCRs activate receptor tyrosine kinases (RTKs) (Buchanan et al., 2003; Pai et al.,
2002). These cross-communications result in an increased auto-phosphorylation and
dimerisation of RTKs, such as the EGFR, culminating in the activation of mitogen-
activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K), amongst
other signalling mechanisms (Buchanan et al., 2003; Sales et al., 2004a; Sales et al.,
2004b). Details of the diversity in mechanisms of RTK activation, the exact
intracellular mechanisms of cross talk and the significance of the functional endpoint
of these cross communications have yet to be fully elucidated. Several mechanisms
have been proposed which include extracellular and intracellular mechanisms (Daub
et al., 1996; Pierce et al., 2001); figure 1.4). One of these mechanisms involves
activation of transmembrane matrix metalloproteinases and extracellular release of
heparin-binding EGF (HB-EGF) from its latent membrane-spanning precursor in the
plasma membrane. Once cleaved, the HB-EGF ligand can associate with and activate
the EGFR, and thereby induce downstream signalling events such as phosphorylation
of the MAPK extracellular-signal-regulated kinases 1 and 2 (ERK1/2). In addition,
several studies have shown that activation of the c-Src family of non-receptor
tyrosine kinases is involved in GPCR-mediated transactivation of the EGFR (Kraus et












Figure 1.4 Prostanoid receptor signalling with epidermal growth factor receptor
(EGFR) cross talk and the downstream effects on biologicalfunction.
Prostaglandins (PG) activate specific prostanoid receptors coupled to G proteins
leading to production of the second messenger cyclic AMP (cAMP) or inositol
trisphosphate (IP3). These second messengers initiate kinase signalling (protein
kinase A (PKA) and protein kinase C (PKC)) by the mitogen activated protein kinase
(MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways and target gene
transcription. Postulated mechanisms for prostanoid-mediated transactivation of
EGFR include the release ofheparin-bound EGF-like molecule (HB-EGF) to activate
the receptor tyrosine kinase (RTK) directly or by intracellular mechanisms involving
non-receptor tyrosine kinases such as cSrc. (AA, arachidonic acid; MMPs, matrix
metalloproteinases; PLA2, phospholipase A2; PGT, prostaglandin transporter.
Adaptedfrom (Jabbour and Sales, 2004) ).
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1.4 Menstruation
The menstrual cycle is clinically described according to its regularity and
duration of bleeding (Chiazze et al., 1968; Treloar et al., 1967). The average length
between menses is between 28 and 32 days with the duration of bleeding lasting 4-5
days.
Menstrual problems account for much of the morbidity that occurs in women
of reproductive age. Menstrual problems are a leading indication for women to
undergo the major surgery of hysterectomy for which there is a lifetime risk of
around 20% (Vessey et al., 1992). It is this health burden, which drives intense
research into the exact mechanisms of the menstrual process despite the gross
physiological aspects being well established.
1.4.1 Mechanism of menstruation
Menstruation is an active process whereby the upper two thirds of the
endometrium, the functional layer, is shed and regenerated on a cyclical basis. During
the luteal (secretory) stage of the menstrual cycle, in the absence of fertilisation, there
is regression of the corpus luteum leading to a decline of the steroid hormone,
progesterone. As described in section 1.2.5, during the secretory phase, prior to the
decline in circulating hormone levels, there is a decline of sex steroid receptor
expression in the superficial layer of the endometrium. The epithelial glands within
the superficial layer of the endometrium are essentially negative in their
immunostaining for progesterone and oestrogen receptors (PR and ER). It is therefore
hypothesised that the declining levels of steroids can only be directly detected in the
stromal cells of the superficial layer, which persistently stain for PR (Critchley et al.,
2001a). Coupled with evidence demonstrating that menstruation can be blocked by
progesterone add-back up to 36 hours after steroid decline (Brenner et al., 2002),
suggests that menstruation specifically occurs in response to the decline of
progesterone levels.
Markee and colleagues were able to perform classical studies (Markee, 1940)
into the mechanism of menstruation. By transplanting explants of human endometrial
tissue into the anterior chamber of Rhesus monkey's eye, they were able to visualise
direct events that occurred in response to progesterone withdrawal. In response to
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steroid decline, they observed stromal shrinkage, increased coiling of spiral arterioles
and vascular stasis. These changes were followed by a period of vasodilation and
perivascular bleeding and 24 hours later, a subsequent intense vasoconstriction and
tissue necrosis prior to menstruation itself.
The molecular mechanism of menstruation in response to progesterone
withdrawal is a complex cascade of events that have yet to be fully elucidated. It in
part involves the production of prostaglandins that are able to induce vasoconstriction
leading to a reduced blood flow to the endometrium. Subsequently there is increased
expression of a range of locally acting mediators including cytokines, angiogenic
factors, protease enzymes and further prostaglandins. The cumulative endpoint of
these changes in local mediators, together with an influx of migratory leukocytes is
the process of menstruation (Brenner et al., 2002; Critchley, H. O. et al., 2001b;
Jabbour et al., 2005); figure 1.5). Interestingly, in the PRA + PRB knockout mouse,
there is a dramatic influx of inflammatory leucocytes, which can not be prevented
with exogenous progesterone (Lydon et al., 1995). This suggests that progesterone
somehow suppresses the inflammatory process within the endometrium of the wild
type animal.
Figure 1.5 Hypothetical mechanism ofmenstruation
Coincident events ofprogesterone withdrawal and hypoxia. Progesterone withdrawal
results in an up-regulation of inflammatory mediators, production of matrix
metalloproteinases (MMPs), a leukocyte influx and expression ofstromal KDR (type
2 receptor for vascular endothelial growth factor (VEGF)) in the upper endometrial
zones. There is coincident hypoxia and an up-regulation of VEGF. VEGF binds to
KDR and there is a paracrine/autocrine action on the up-regulation of MMP
production in the same endometrial upper zone stromal cells. Menstrual sloughing
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Figure1.5
Prostaglandins and local mediators in menstruation
Because of the leukocyte invasion and subsequent production of inflammatory
mediators, menstruation has been described as an inflammatory event. Prostaglandins
(see section 1.3) have been shown to play a role in menstruation (Baird et al., 1996)
and have been found in high concentrations within menstrual fluid (Pickles et al.,
1965). Regulation of prostaglandin levels by circulating steroid hormones has been
demonstrated (Abel et al., 1983). More recent evidence has demonstrated an increase
in COX-2 expression in response to a decline in progesterone levels (Hapangama et
al., 2002). This work also demonstrated a decline in prostaglandin dehydrogenase
(the enzyme responsible for breakdown of prostaglandins) as progesterone levels fell.
COX-2, together with other inflammatory mediators such as Interleukin-8 and
Monocyte Chemotactic Peptide-1 have all been localised to the perivascular region
with significant upregulation in the late secretory phase (Jones et al., 1997).
Additionally, PGE2 expression has been demonstrated within this perivascular area
(Cheng et al., 1993).
The rise of inflammatory mediators, including prostaglandins, therefore
occurs subsequent to a declining progesterone level. The predominance in expression
of inflammatory mediators in the perivascular areas may allow for local recruitment
of leucocytes and also provides a possible mechanism for vasoconstriction of the
spiral arterioles, demonstrated prior to the onset of menses. Hence, following
progesterone withdrawal, there is an increase in the stromal density of a unique
population of leukocytes, named NK cells (CD56 Bright CD 16-) associated with an
increase in local cytokine production and matrix metalloproteinase (MMP)
expression (Critchley et al., 2001b; Kelly et al., 2001). The increase and activation of
matrix metalloproteinases (MMPs) are considered key elements of the menstrual
process (Lockwood et al., 1998; Salamonsen et al., 1996). These enzymes are
principally responsible for tissue breakdown. During the luteal phase, the circulating
levels of progesterone inhibit expression and activity of MMPs in endometrial
stromal cells. Sex steroid withdrawal at the end of the cycle reverses the inhibition of
many MMPs, including MMP-1, which can degrade the interstitial collagens of the
extracellular matrix (ECM) surrounding pre-decidual cells, especially in the
superficial endometrium. There is also evidence that the focal expression of MMPs
within peri-menstrual and menstrual endometrium involves local regulatory factors.
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Leukocytes can directly release MMPs and there are important interactions between
leukocytes, stromal and epithelial cells which result in induction and activation of
MMPs (Salamonsen et al., 2000).
The vascular endothelial growth factor (VEGF) receptor KDR is almost
exclusively expressed by vascular endothelium. However, following progesterone
withdrawal, during the premenstrual phase there is a dramatic up-regulation in
expression of KDR within the stromal cells of the superficial endometrium (Nayak et
al., 2000). Adding back progesterone upto to 24 hours after progesterone withdrawal
can reverse this stromal expression of KDR (Critchley et al., 2001b; Nayak et al.,
2000). Progesterone withdrawal therefore leads to an up-regulation of inflammatory
mediators in addition to causing a degree of tissue hypoxia as a result of the noted
vasoconstriction. The hypoxic conditions have been shown to lead to an increase in
stromal VEGF production (Sharkey et al., 2000), which has an additional positive
feedback on the expression of KDR. VEGF increase is therefore concurrent with the
up-regulation of its receptor, KDR, and indeed the expression of MMPs. All these
changes occur within the stromal compartment of the superficial layer of the
endometrium and provide a possible mechanism whereby the menstrual cascade can
be initiated (figure 1.5).
Angiogenic changes of menstruation
In addition to replenishment of the superficial epithelium, the vascular
compartment of the endometrium comprising the spiral arteries and arterioles also
needs to be reconstructed following menstruation. Hence, new endothelial cells are
encouraged to sprout and recruit pericytes to form capillaries and smooth muscle cells
to form larger vessels (Gargett et al., 2001; Smith, S. K., 2001). This process involves
degradation of the extracellular matrix, endothelial cell proliferation and migration
and organisation of the endothelial cells into capillary networks. Several angiogenic
factors have been identified to-date, which are believed to be involved in
angiogenesis of the human endometrium (Gargett and Rogers, 2001). Of the known
angiogenic factors, VEGF, also known as vascular permeability factor, is a major
specific stimulator of endothelial cell proliferation and vascular permeability in the
endometrium. VEGF acts through two tyrosine kinase receptors, VEGFR-1 and
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VEGFR-2 (KDR), the latter being considered the most important in regulation of
angiogenesis.
Organisation of blood vessel formation, stabilisation, maintenance and
regression also involves other factors. These include the angiopoietins, Ang-1 and
Ang-2, which stabilise and destabilise blood vessels respectively to facilitate
angiogenesis (Maisonpierre et al., 1997). Although the precise mechanism of action
of the angiopoietins remains to be clarified, it is proposed that Ang-2, acting through
its tyrosine kinase receptor, Tie-2, enhances the action of VEGF by reducing
endothelial contact with the extracellular matrix, and hence with adjacent endothelial
cell interactions. In contrast, Ang-1 acting as a competitive antagonist via Tie-2
enhances the stability of the newly formed blood vessels by recruiting pericytes
(Maisonpierre et al., 1997). Several other factors including basic fibroblast growth
factor (bFGF) and platelet-derived growth factor (PDGF), endocrine gland VEGF
(EG-VEGF) and their respective receptors (Battersby et al., 2004b; Weston et al.,
2000) are also known to stimulate angiogenesis. Thus, the remodelling of the
endometrial vasculature is a complex and multifactorial process, under the influence
of multiple effector molecules.
As discussed, in the premenstrual phase, concomitant with the withdrawal of
progesterone, COX-2 expression increases in the endometrium and lasts through the
proliferative phase of the cycle (Hapangama et al., 2002; Jones et al., 1997). Once
COX-2 expression and prostanoid biosynthesis is induced, a positive feedback system
is set in motion to regulate the COX-PG biosynthetic signalling pathway and target
genes involved in vascular function (figure 1.3). Auto-regulation of COX-2
expression has been reported in several in vitro studies (Fujino et al., 2003; Maldve et
al., 2000; Tjandrawinata et al., 1997; Tjandrawinata et al., 1997). Following up-
regulation of COX-2 expression, the subsequent elevated prostanoid biosynthesis and
signalling can promote the expression of pro-angiogenic factors, such as VEGF,
bFGF, PDGF, Ang-1 and Ang-2 (figure 1.4) (Sales et al., 2002; Tsujii et al., 1998) or
down-regulate the expression of anti-angiogenic genes such as cathepsin-D (Perchick
et al., 2003).
These data suggest that endometrial angiogenesis may be under direct control
of prostaglandins, produced by COX enzymes in the endometrium. Recently the role
of specific prostaglandin receptors in modulating angiogenesis has been described. In
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endometrial epithelial cells (Sales et ah, 2004a) and murine model systems (Seno et
al., 2002; Sonoshita et al., 2001), elevated PGE2-EP2 receptor interaction promotes
the expression of pro-angiogenic genes such as VEGF. Similarly, elevated PGF2a-FP
receptor interaction in endometrial epithelial cells can also elevate the expression of
VEGF in a similar manner to that of PGE2 via the EP2 receptor. This promotes
angiogenesis in the endometrium via the activation of convergent intracellular
signalling effector molecules and signal transduction cascades, such as the ERK1/2
cascade (Sales et al, 2005).
1.4.2 Heavy menstrual bleeding (HMB; menorrhagia)
Menorrhagia is the clinical definition describing heavy menstrual blood loss.
Heavy menstrual bleeding has been accepted internationally as a more accurate
description for this condition and this terminology shall be used in preference to
menorrhagia during the rest of this thesis (Fraser et al., 2007). Unacceptable heavy
menstrual blood loss affects 10-30% of women of reproductive age and up to 50% of
perimenopausal women (Prentice, 1999; Prentice, 2000). In the United Kingdom, 5%
of women will seek help for this symptom annually (Vessey et al., 1992) and the risk
of hysterectomy performed for menstrual disorders is 20% (Coulter et al., 1988). In
2002-3, over 13000 surgical procedures (hysterectomy and endometrial ablation)
were performed in England for complaints of heavy bleeding (Reid PC and Virtanen-
Kari, 2005). An estimated 3.5million workdays are lost annually (Weeks et al., 2000).
In research studies, the objective definition of menorrhagia is often based on
measurement of menstrual haemoglobin content. Scandinavian studies demonstrated
that the mean menstrual blood loss was around 40ml and that regular menstrual blood
loss in excess of 63ml was associated with iron deficiency anaemia (Hallberg, L. et
al., 1966). The 90th centile for measured blood loss was 80ml and this was taken as
the upper limit of normal (Hallberg, L. et al., 1966). However, in the clinical setting
only 40 to 60% of women with perceived heavy menstrual blood loss have an
objective measurement of greater than 80 ml (Chimbira et al., 1980; Fraser et al.,
1981).
Dysfunctional uterine bleeding (DUB) describes heavy menstrual blood loss
in the absence of any pathology (Fraser et al., 2007). This condition accounts for the
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majority of cases of heavy menstrual bleeding and is ovulatory in 80% of cases
(Cameron, 1989; Livingstone et al., 2002). Other causes of heavy menstrual bleeding
are pelvic pathologies such as fibroids and systemic disease including blood clotting
disorders such as von Willebrand disease (Kouides, 2001; Makarainen et al., 1986).
13% of women with heavy MBL have a previously undiagnosed bleeding disorder of
von Willebrand disease (Lukes et al., 2005). Reduced clotting is a known feature of
menstruation (Livingstone and Fraser, 2002) however the exact mechanisms that lead
to heavy menstrual blood loss for many systemic diseases are poorly understood.
Pelvic pathologies such as fibroids are common, affecting between 20 and 25% of
women and it is reported that around a third of women with fibroids complain of
heavy menstrual blood loss (Buttram et al., 1981).
The role of prostaglandins in the aetiology of heavy menstrual bleeding and
other endometrial disorders is described in section 1.4.3.
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1.4.3 The role of prostaglandins in benign pathologies of the
human endometrium
Prostaglandin signalling in the normal human endometrium
Receptor-ligand interaction initiates second messenger signalling via
activation and dissociation of the G-protein complex. Various soluble second
messengers (including cAMP, IP3 and Ca2+), whose production is dependent upon the
heterotrimeric subtypes (Gas, Gai and Gaq; figure 1.2) lead to divergent signalling
cascades. The described diversity of ligands, receptors and coupled signalling
pathways may confer a delicate homeostatic control that if disrupted, could cause an
imbalance of locally mediated signalling.
In the normal human endometrium, it has been demonstrated that PGE2
activation of the EP receptors (Milne et al., 2001) and PGI2 activation of the IP
receptor (Battersby et al., 2004a) result in an increase in the accumulation of
intracellular cAMP, whereas PGF2a-FP receptor coupling mobilizes inositol
triphosphates and intracellular Ca2+ (Milne et al., 2003). Activation of these second
messenger systems is greatest during the middle to late proliferative phase of the
menstrual cycle, when levels of the prostanoid receptors are at their highest (Jabbour
and Sales, 2004). However, the divergent signalling pathways that are involved in
both endometrial function and dysfunction have not yet been fully elucidated.
Initial studies of menstrual fluid identified vasoactive substances with the
capabilities of inducing contractions in strips of ileal muscle (Pickles, 1957). These
were subsequently identified as the prostaglandins PGF2oi and PGE2, the two most
abundant prostaglandins found in human endometrium and menstrual fluid (Lumsden
et al., 1983). Evidence has since continued to mount, supporting a role for
disturbances of prostaglandin synthesis, secretion and metabolism in several
pathologies of the endometrium. Endometrial pathologies in which prostaglandins
appear to have an aetiological role, are those in which the clinical symptoms of pain
or bleeding disturbances are prominent. The common disorders described here are
those of pain associated with menstruation (dysmenorrhoea), the troublesome
pathology of endometriosis and heavy menstrual blood loss (menorrhagia).
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Dysmenorrhoea
Dysmenorrhoea describes painful periods and is a significant public health
burden with up to 50% of women suffering from the condition at some point in their
reproductive life time (Brosens JJ, 2000; Dawood, 1985).
Primary dysmenorrhoea is an extremely common condition, typically
occurring in adolescence and in the absence of any recognisable pathology.
Secondary dysmenorrhoea is recognised as a condition associated with other pelvic
pathologies such as endometriosis, pelvic inflammatory disease and uterine fibroids.
It is much less common than primary dysmenorrhoea and the role of prostaglandins is
less well documented.
Primary dysmenorrhoea is associated with uterine hypercontractility. During
contractions, uterine blood flow decreases which leads to relative uterine ischaemia.
Good correlation has been found between uterine blood flow and pain (Brosens JJ,
2000; Dawood, 1985; Fraser, 1992). However, pain has been documented in the
absence of uterine contractility and it is recognised that prostaglandins have an
important alternate role in the aetiology. Prostaglandins have a known role in
inflammatory nocosomial pathways and may have a direct effect in stimulating nerve
pain pathways (Bley et al., 1998). Excessive synthesis and secretion of prostaglandins
by the endometrium have been detected in menstrual fluid taken form women with
primary dysmenorrhoea (Lundstrom et al., 1976; Pickles et al., 1965). A clear
demonstration of increased PGE2 and PGF201 levels in menstrual fluid of women with
dysmenorrhoea compared to controls shows that this increase was most prominent in
the first two days of menstruation and that there is a greater proportional increase in
PGF2a levels (Lumsden et al., 1983). Furthermore, infusion of PGF2a into the uterine
cavity produces an increase in uterine contractility and dysmenorrhoea like pain
(Lundstrom, 1977). The role of prostaglandins in dysmenorrhoea is additionally
confirmed by the effective use of COX enzyme inhibitors (Lundstrom, 1978; Rees,
1989) including selective COX-2 enzyme inhibitors (Daniels et al., 2002). In
summary, the vasoconstrictive properties of PGF2a together with the ability to cause
myometrial contractions could contribute to dysmenorrhoea and in addition the
increase availability of PGE2 could have additional direct pain inducing properties
(Bley et al., 1998).
36
Endometriosis
Endometriosis occurs when tissue histologically similar to the endometrium is
found in extrauterine sites with tissue implants most often found over visceral and
peritoneal surfaces (Farquhar, 2007). The extent of disease is highly variable and
endometriosis can be associated with pelvic pain and infertility. Although not a
malignant disorder, endometriotic tissue exhibits all the hallmarks of tumorigenic
tissue, namely proliferation, cellular invasion and angiogenesis. According to
Sampson's classical theory of retrograde menstruation; peritoneal adhesion of
endometrial tissue and outgrowth are essential in the pathogenesis of endometriosis.
However, retrograde menstruation is a common occurrence with viable endometrial
cells found in 76-90% of women (Bartosik et al., 1986), a much higher incidence
than endometriosis (2-3%). Other factors must therefore determine the susceptibility
of women to develop endometriosis. This susceptibility is likely to be a result of
changes to both the peritoneal environment and to the characteristics of the menstrual
tissue.
The aetiology of endometriosis is multifactorial and requires a number of
peritoneal substances, in particular angiogenic factors, to facilitate implantation in
ectopic sites (Oral et al., 1996). The peritoneal fluid contains a variety of free-floating
cells including macrophages, natural killer (NK) cells and lymphocytes. These cells
all have immune mediating roles and can promote cellular growth and viability
through the secretion of growth factors and cytokines. Macrophages are the most
abundant cell type in the peritoneal fluid and have their highest endometrial
expression in menstrual tissue. Once activated, they can release products including
prostaglandins (Gazvani et al., 2002). It has been demonstrated that peritoneal
macrophages from women with endometriosis release more PGE2 and PGF2tt
compared to those without endometriosis (Karck et al., 1996). Further evidence
implicating prostaglandins in the aetiology of endometriosis arises from histological
analysis of endometrial tissue. A higher degree of immunostaining for COX-2, the
rate-limiting enzyme in prostaglandin production, is found in endometrial glandular
epithelium in women suffering from endometriosis compared to control endometrium
(Ota et al., 2001). The increased prostaglandin synthesis and expression (in particular
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PGE2 and PGF2tt) may play a role in the regulation of cytokines and various growth
factors within this disorder.
Although the exact mechanism whereby prostanoids exert their function in
endometriosis is unclear, PGE2 is known to be a potent inducer of aromatase activity
in endometrial stromal cells (Noble et al., 1997). Aromatase gives rise to the
synthesis of oestrogen, which in turn will feedback positively on further
prostaglandin synthesis. Endometriosis is classically described as an oestrogen
dependent disease, but the lack of ER expression in pre- menstrual and menstrual
tissue (Brenner et al., 2002; Critchley et al 2001a) suggests that initiation of the
disease is independent of oestrogen. However once implantation has occurred,
prostaglandins provide a mechanism for stimulating oestrogen production to sustain
the endometriotic lesions.
COX enzymes, PGE2 and PGF2a and their receptors have been shown to
promote the transcription of angiogenic factors such as VEGF and the angiopoietins
(Tsujii et al., 1998, Sales et al., 2002) The peritoneal fluid of women with
endometriosis displays greater angiogenic activity than women without endometriosis
(Gazvani and Templeton, 2002). Angiogenic factors may be important for creating a
microvascularised peritoneal environment that would allow for establishment of
endometriotic lesions. In this regard, it is interesting that VEGF and its receptor KDR
are dramatically and specifically up regulated in the superficial stromal cells of the
endometrium in response to the decline of progesterone (Brenner et al., 2002). It is
postulated that VEGF has a unique role in stimulating matrix metalloproteinases
(MMP) expression within the endometrium. Therefore, the rich content of MMPs,
VEGF and inflammatory prostaglandins found simultaneously in menstrual fragments
could facilitate attachment and angiogenesis of endometriotic lesions within the
pelvis (Brenner et al., 2002).
Heavy Menstrual Bleeding (Menorrhagia)
Treatment of menorrhagia using non steroidal anti-inflammatory drugs
(NSAIDs) which are inhibitors of COX enzymes have repeatedly been shown to
reduce menstrual blood loss (Anderson et al., 1976; Cameron et al., 1990;
Makarainen and Ylikorkala, 1986; Reid et al., 2005), thus implicating disturbances of
prostaglandin pathways in the aetiology of heavy menstrual bleeding.
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As stated in section 1.4.2, the majority of cases of heavy menstrual bleeding
occur in the absence of any pathology, a condition known as dysfunctional uterine
bleeding (DUB). There is a large body of evidence linking local mediators, in
particular prostaglandins, to ovulatory DUB and this is discussed below. However,
the role of prostaglandins in heavy menstrual blood loss secondary to pathologies
such as fibroids is unclear. There is evidence that the use of NSAIDs is less effective
in treating women with menorrhagia when fibroids exist (Makarainen and Ylikorkala,
1986).
Investigations into the aetiology of ovulatory DUB have not been able to
discover any differences in circulating steroid hormone levels in women with heavy
menstrual blood loss compared to women with normal menstruation (Eldred et al.,
1994). Additionally, there are no specific histological differences within the
endometrium of women with heavy menstrual blood loss (Rees et al., 1984). Of note,
no differences in expression of oestrogen and progesterone receptors have been
discovered (Critchley et al., 1994). However, substantial evidence does exist
implicating local mediators, in particular disturbances of arachidonic acid metabolism
and disturbances of angiogenic processes. Elevated levels of PGE2 have been found
in endometrium of women complaining of heavy periods (Willman et al., 1976).
Further experiments confirmed an elevation of total prostaglandins with an apparent
shift in synthesis in favour of PGE2 over PGF2a in the endometrium of women with
DUB (Smith, S. K. et al., 1981a). Additionally, an increase in PGE2 binding sites has
been reported in uterine tissue associated with menorrhagia (Adelantado et al., 1988),
although the specific receptors mediating this pathology remain to be elucidated.
Mefanamic acid, a COX inhibitor and member of the Fenmate family of drugs, is
routinely used as a first line treatment for menorrhagia. A dual mode of action has
been documented for this family of drugs; as well as inhibiting prostaglandin
synthesis they also inhibit binding of PGE2 to its receptor (Rees et al., 1988). PGE2
has vasodilatory properties and it is interesting to note that prostacyclin and nitric
oxide synthesis, vasodilatory substances, are also both elevated in uterine tissue of
women with heavy menstrual blood loss (Smith, S. K. et al., 1981b; Zervou et al.,
1999). It appears that local mediators with vasodilatory effects on the endometrial
vasculature are implicated in menorrhagia.
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As mentioned prostaglandin and PGE2 signalling has been shown to promote
angiogenesis via autocrine-paracrine mechanisms. Endothelial cells in the
endometrium of women with heavy periods have been shown to proliferate more as
compared to controls (Kooy et al., 1996). In addition the spiral arterioles in
menorrhagic endometrium have a less established covering of vascular smooth
muscle cells (Abberton et al., 1996; Abberton et al., 1999). Lack of cellular support
to the spiral arterioles prevents sufficient vasoconstriction of these blood vessels,
hence potentially increasing menstrual blood loss. However, hysteroscopic
appearance of endometrial surface vessels appears to be very similar between women
with DUB compared to normal endometrium (Hickey et al., 2000). The hypothesis
that heavy menstrual bleeding arises as a result of poor vascular maturation is
supported by the finding of decreased angiopoetin-1 mRNA expression in the
endometrium of women with heavy MBL (Hewett et al., 2002).
Immunohistochemical studies have additionally demonstrated an increase in
expression of Ang-2 and it is receptor Tie-2 in menorrhagic endometrium
(Blumenthal et al., 2002). Since there is evidence that Ang-1 and Ang-2 are regulated
by PGE2 (Sales et al., 2002), immature vessels in turn could be more susceptible to
the vasodilatory actions of prostaglandins such as PGE2, leading to heavier
menstruation, and this may be enhanced via the autocrine/paracrine actions of PGE2
via one or multiple EP receptors and their intracellular signalling pathways.
Further investigation into the diversity of signalling events triggered by one or
multiple prostanoid receptors is needed to define the roles of prostanoid receptor
signalling pathways in reproductive function and pathology.
Selective Progesterone Receptor Modulators (SPRMs)
Early studies into the effects of the selective progesterone receptor modulators
(SPRMs; see chapter 6) have provided hope for advancements in the treatments of
abnormal menstruation, endometriosis associated pelvic pain and also fibroid disease.
Phase II trials have shown that asoprisnil, a SPRM, produces a dose dependent
amenorrhoea, reduces endometriosis associated pain and shrinks the volume of
fibroid uteri (Chwalisz et al., 2005). The mechanism of action for this family of
compounds is complex, exerting a tissue-selective agonist, antagonist or partial
agonist/antagonist effect on the progesterone receptor. Interestingly, evidence
40
demonstrates that asoprisnil causes the formation of unusual, thick-walled arterioles
in the endometrium when compared to progesterone agonists or antagonists. Overall,
early trials suggest that asoprisnil induces its therapeutic benefits such as suppression
of menstruation via an endometrial specific vascular effect. The molecular
mechanisms that lead to these vascular changes have yet to be elucidated and may
well involve changes in local mediators such as prostaglandins and hence subsequent
alterations in angiogenic factors and altered vessel formation. The effects of






The events of normal menstruation involve complex interactions between the
endocrine system, locally produced inflammatory mediators and angiogenic growth
factors (Critchley et al., 2001b). The causes of menstrual disturbances and benign
pathologies of the endometrium are poorly understood (reviewed in section 1.4.3). It
is recognised that they involve disturbances in local cellular and molecular signalling
events that subsequently lead to defective vascular function within the endometrium.
This thesis is based on the hypothesis that menstrual dysfunction, including
heavy menstrual blood loss is due to (a) up-regulated expression/synthesis of
cyclooxygenase enzymes and prostaglandin receptors, and (b) initiation of enhanced
intracellular signalling pathways in response to prostaglandins.
Aims
1) The first aim of this thesis is to outline the expression of the
cyclooxygenase enzymes in human endometrium and to examine the expression of
these enzymes in women with both normal (<80ml) and heavy (>80ml) menstrual
blood loss.
2) The second aim of this thesis is to determine the pattern of expression of
various components of the COX-prostaglandin signalling pathways present in the
endometrium of women with both normal and heavy menstrual blood loss.
3) The third aim of this thesis is to examine the functional capabilities of the
PGE2 signalling pathways within endometrium taken from women with normal and
heavy menstrual blood loss.
The above aims centre on work utilising endometrium collected from women
who have consented to both an endometrial biopsy and also measurement of their
menstrual blood loss. However, whilst exploring the role of prostaglandins within
human endometrium, access to well characterised human tissue from consenting
patients is too limited to explore molecular signalling pathways in detail.
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4) The fourth aim of this thesis is to therefore explore intracellular signalling
pathways using an endometrial epithelial cell line (Ishikawa) and human endometrial
tissue. The intracellular signalling transduction pathways activated following PGI2-IP
ligand-receptor interaction have been chosen as the target of this more detailed
signalling investigation.
5) The fifth and final aim of this thesis is to explore the effect of the selective
progesterone receptor modulator, asoprisnil, upon the endometrial expression of COX
enzymes and the various component genes involved in prostanoid signalling.
Asoprisnil is a selective progesterone receptor modulator (SPRM), which has
undergone early phase I and II trials, demonstrating favourable safety and tolerability.
It induces cessation of menstruation, reduces fibroid volume and reduces non-
menstrual pain and dysmenorrhoea in women with endometriosis (Chwalisz et al.,
2005). Overall, early results suggest that menstrual suppression by asoprisnil in
humans is primarily due to a local endometrial-specific vascular effect. The exact




This chapter provides information for procedures used widely for this thesis.
Methodologies more specific to individual chapters are contained therein.
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3.1 Human Endometrial Tissue Collection and
Characterisation
Human endometrial tissue samples were obtained from patients attending the
Royal Infirmary of Edinburgh gynaecology department. Local Lothian Regional
Ethical Committee (LREC) approval was obtained and all patients provided written
informed consent (contained within Appendices).
3.1.1 Endometrial Specimens
All women participating in the study were aged between 18 to 50 years old
and had regular menstrual cycles lasting between 25 and 35 days. Patients had been
referred to the outpatient department by their general practitioner with a complaint of
heavy menstrual bleeding. A patient history was taken to exclude the use of any
hormonal preparations for the proceeding three months and subjects with endometrial
pathology or unexplained vaginal bleeding were excluded. Abnormal gynaecological
examination at initial presentation led to anatomical survey of the pelvis by
ultrasound investigation. Abnormalities such as uterine fibroids (> 3cm) excluded use
of endometrial tissue from experimentation. Samples were obtained in the out patient
setting using a Pipelle endometrial sampler. Endometrial samples were additionally
obtained at the time of minor procedures in theatre by curettage of the endometrium.
In addition, full thickness endometrial biopsies (figure 3.1) had previously been
collected from women undergoing hysterectomy for benign gynaecological
indications. These samples therefore include the surface epithelium and endometrial-
myometrial junction, thus upper functional and deeper basal zones.
Endometrium was collected from women during all stages of the menstrual
cycle. Following collection, the specimens were immediately divided as follows:
1) A proportion of endometrium was fixed in 4% NBF overnight before being
embedded in paraffin wax the following day.
2) A proportion was transferred into RNA Later (Ambion Inc, Huntingdon, UK)
to prevent RNA degradation before early transfer to storage at -80°C.
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3) Finally, if quantities of endometrial tissue allowed, endometrium was
incubated overnight in RPMI 1640 culture medium for experimentation the
following day.
Histological dating was carried out according to the criteria of Noyes et. al.
(Noyes, 1950) to confirm the stage of the menstrual cycle. All endometrial samples
were consistent for; patient's reported last menstrual period (LMP); histological stage
and; circulating oestradiol and progesterone concentrations in venous blood obtained
at the time of tissue collection. This is a robust method for characterizing endometrial
samples. Detailed gene microarray studies support this method for characterizing
endometrial samples with consistency across these three parameters (Critchley, H. O.
et al., 2006; Talbi et al., 2006).
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Figure 3.1
Images illustrate the bisection of the uterus enabling identification of the uterine
cavity. A biopsy incorporating the endometrium and a portion of the myometrium is
removed. The sample is then divided into separate portions for subsequent processing










































3.1.2 Measuring Menstrual Blood Loss
Measurement ofMenstrual Blood Loss
To further investigate and understand the endometrial signalling mechanisms
that may cause aberrant heavy menstrual bleeding, this study set out to objectively
measure menstrual blood loss (MBL) in order to allow grouping of associated
endometrial samples based on this valuable clinical characteristic. Measurement of
menstrual blood loss was based on a modified alkaline-haematin method as described
by Hallberg et al (Hallberg, Nilsson, 1964). This method involves extraction of the
haem from used sanitary towels using 5% sodium hydroxide. Although expensive and
labour intensive, it is an objective, reproducible technique for measuring blood loss
during menses. For the purposes of research regarding menstrual blood loss, this
technique is recognised as the "gold standard" for objective measurement of MBL.
All women were given packages containing a standard choice for sanitary
protection (tampons or pads) and detailed oral and written instructions on how to
collect all sanitary wear during one period. Care was taken to minimise blood loss
that could not be recovered for measurement. After menstruation, packages of
sanitary wear were recovered and stored in refrigeration (4°C).
For measurement of menstrual blood loss, pads and tampons were added to a
known volume of 5% sodium hydroxide (between 2 to 4 litres, approximately 100ml /
sanitary product) within a bucket with fitted lid. The contents were then left for 48
hours to allow conversion of haemoglobin to haem.
During the same time period a stored sample of the patient's venous blood
was used to create a 1 in 200 dilution of blood with 5% sodium hydroxide. An aliquot
was stored alongside the menstrual blood collection.
After 48 hours, tampons and pads were thoroughly mixed within the sodium
hydroxide. An aliquot was removed from the bucket and filtered through hardened
filter paper (Whartman no. 54, Maidstone, UK). A known volume was then carefully
diluted by a measured addition of further sodium hydroxide, to create a close colour
match with the control venous blood solution. Theoretical total volume of sodium
hydroxide added was therefore possible to calculate by multiplying the added volume
by dilution factor. The optical density (OD) of menstrual blood loss solution and
venous blood sample were then measured using spectrophotometry at 546nm (A546).
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Menstrual blood loss was then calculated as a quantity of patients own venous
blood using the following equation (van Eijkeren et al., 1986);
(OD of Menstrual Blood Solution x Total Volume of added NaOH)
MBL =
(OD of Venous Blood x 200)
All patients had provided informed consent for collection of an endometrial




Standard immunohistochemical techniques were performed to localise a
number of cellular proteins within the human endometrium. All protocols were
optimised to determine the best conditions for maximal immunostaining with
minimal background staining. The protocols used for individual primary antibodies
are summarised in section 3.2.4
3.2.1 Theory of Immunohistochemical Staining Methods
Theory of Antibodies
The antibody is the pivotal reagent to all IHC techniques. Antibodies belong
to a group of proteins termed immunoglobulins, which comprise of five major
classes; IgA, IgM, IgD, IgE and IgG. All primary antibodies used within this research
were of the IgG class and were polyclonal in nature.
The structure of the immunoglobulin molecule is depicted in figure 3.2. The
variable domain is specific to the target protein and is responsible for antigen binding.
Polyclonal antibodies are produced by a variety of cells within an animal species. As
such, they are immunochemically dissimilar and may react against various epitopes
on the antigens against which they have been raised (figure 3.3).
Basic Immunohistochemistry
Antibodies vary with regard to their affinity for their target antigen and their
non-specific binding. Basic IHC methods are optimised in order to obtain the highest
quality, specific immunostaining pattern possible.
In order to visualise the areas of antibody-antigen binding, IHC methods
utilise enzyme-substrate reactions to convert colourless chromagens into coloured
end products. Horse-radish peroxidase and alkaline phosphatase are two enzymes




Immunoglobulin molecule; comprising two identical heavy (H) chains and two
identical light (L) chains. Inter- and intra-chain disulfide bonds contribute to
structural stability. Variable domain (V) is responsible for antigen binding.
Figure 3.3
Polyclonal antibodies raised against an antigen (Ag) may react against a variety of
epitopes upon such antigen.
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Fixation
The use of a fixative prevents tissue autolysis by inactivating lysosomal
enzymes and inhibiting bacterial growth. Furthermore, stabilisation of the tissue is
obtained to reduce degradation during the rigorous process of IHC staining. All
endometrial tissue samples in this study were fixed overnight in Neutral Buffered
Formalin (NBF) solution, a well-tolerated fixative with good tissue penetration. Some
shrinkage and distortion of tissue architecture is recognised but in general good
results are obtained. Overnight tissue incubation within NBF was consistent, as
varying fixative times can alter antibody penetration of the tissue during IHC
staining. Formaldehyde fixes by reacting primarily with basic amino acids to form
cross-linking "methylene bridges". This leads to relatively low permeability to
macromolecules and a structural preservation of intracytoplasmic protein structures.
Once fixed, endometrial tissue blocks were then embedded in paraffin wax for
preservation. It is important to beware of variation in IHC staining that can be
attributed to differences in tissue fixation e.g. type of tissue, time in fixative and
tissue size.
Antigen Retrieval (AR)
Fixation may unfortunately result in the loss of immunoreactivity by many
antigens. The use of an antigen retrieval step is designed to "improve" the
immunoreactivity of formalin-fixed antigens.
The principal of AR relies on the application of heat to the tissue sections in
an aqueous medium. Within this study, all tissue slides were pressure cooked for five
minutes in 0.01 M sodium citrate buffer which has a pH of 6. Cooling then occurred
over twenty minutes before resumption of IHC staining protocols. The exact
mechanism of AR is not completely understood. In some way a degree of fixative
cross-bridges are reversed therefore allowing antigenicity whilst the remaining cross¬
links (methylene bridges) are unaltered thereby preventing complete heat
denaturation.
Staining Methods
All IHC performed used an indirect staining method, whereby an enzyme
labelled secondary antibody directed against the primary antibody (now the antigen)
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is applied (figure 3.4). This allows for amplification of the primary antibody-antigen
complex thereby enhancing the target signal. To visualize the enzyme labelled
secondary antibody, a substrate-chromagen solution is applied to allow ultimate
visualization of the target antigen.
Further amplification of the signal can be obtained by use of the high affinity
(k = 10"15M) that avidin has for biotin. Avidin has four binding sites for biotin,
therefore the use of a biotinylated secondary antibody allows for a subsequent
incubation with pre-formed avidin-biotin complexes. Because the affinity of avidin
for biotin is over one million times higher than that of an antibody for most antigens,
the binding can be essentially thought of as irreversible. If these complexes are
attached to an enzyme-substrate system, visualization of the now amplified antibody-
antigen complex can be obtained. This tertiary signal amplification increases the
sensitivity of staining techniques, which helps to reduce unwanted background
staining. Visualisation is concluded with the substrate solution.
Tyramide Amplification
An alternate method of signal amplification involves the phenolic substrate,
tyramide, which is catalysed by peroxidase to from insoluble biotinylated phenols.
Extreme signal amplification can be obtained by using a biotinylated labelled
secondary antibody, followed by a streptavidin-biotin-peroxidase complex. The
peroxidase enzyme will act upon a tertiary tyramide substrate to cause biotin
deposition, which in turn acts with the streptavidin-enzyme to form additional
complexes that can be detected.
Controls
Validation of all IHC protocols was carried out by the inclusion of control
tissue slides. To assure the primary antibodies were working specific to their target,
the inclusions of positive and negative controls were required. For negative controls,
the use of a blocking peptide was used where available. Affinity absorbtion of the
primary antibody with a blocking peptide was carried out 24 hours prior to
commencing the IHC protocol. This preparation renders the primary antibody "pre-
absorbed" thereby preventing specific complex formation with the tissue target
antigen, leading to reduced staining. When the blocking peptide was not
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commercially available, an immunoglobulin fraction from the same species as the
primary antibody was used at a matching protein concentration for the negative
control. Identical methodology was used on control experimental tissue sections.
For a positive control, a tissues sample, which is known to express the protein
of interest, was also included in the experiment. This inclusion is required to ensure
that the immunostaining achieved is within the expected cellular compartments.
Background immunostaining
All additional steps within the protocols were included to reduce background
staining which can occur via a variety of causes. Specifically, the following steps
were carried out:
• Prior to application of the primary antibody, separate incubation of the tissue
with a blocking serum was performed in order to prevent non-specific binding
of the primary antibody to tissue as a result of hydrophobic interactions.
• Endogenous peroxidase activity was quenched by the incubation of the
sections in 3% hydrogen peroxidase (H2O2) for ten minutes. This is required in
order to prevent non-specific activity of a peroxidase labelled secondary
antibody.
• Endogenous (strept) avidin binding activity is a problem for all biotin-based
techniques and is primarily due to endogenous biotin. This activity is
suppressed by sequential 15-minute incubations of the sections first with an





Indirect staining method: Enzyme labelled secondary antibody binds with primary
antibody bound to tissue target antigen.
/\/\
Figure 3.5
Streptavidin-biotin complexes react with biotinylated secondary antibody
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3.2.2 General Immunohistochemistry Protocol
Immunohistochemical staining techniques were optimised for each individual
protein of interest. Below is a general account of staining techniques; more detailed
methods are included in sections 3.2.4 to 3.2.6 and within the specific methods
sections of each data chapter.
Tissue sections embedded in paraffin wax were cut to a width of 5 microns
and mounted on superfrost glass slides (BDH, Merck House, Poole). Slides were then
dewaxed by placement in histoclear for two five-minute episodes. Sections were then
rehydrated through graded alcohols, 100% ethanol (2x2 min), 95% ethanol (2 min)
and 70% ethanol (2 min) before receiving two five-minute washes in distilled water.
Thereafter washes were performed in 0.01M phosphate buffered saline (PBS).
After two washes in PBS, antigen retrieval was then carried out to unmask
antigenic sites that may be hidden due to tissue fixation (section 3.2.1). Antigen
retrieval was performed by pressure-cooking in 0.01M sodium citrate for 5 minutes,
followed by a 20 minute cooling period. Sections were then washed twice in PBS for
five minutes each time.
To reduce background staining, it was necessary to quench endogenous
peroxidase activity by submerging tissue sections in 3% H2O2 in distilled water for 10
minutes followed by two further five minute washes in PBS. Next, endogenous avidin
/ biotin activity was blocked with a 15 minute incubation within an avidin solution
(Vector Laboratories, Peterborough, UK) followed by a biotin solution with a two
minute PBS wash separating incubations. Finally, non-specific binding was further
reduced by 20 min incubation with non-immune serum, of the same species as the
secondary antibody, in a humidified chamber at room temperature. Primary antibody
incubation overnight then occurred at 4°C. During the optimization experiments for a
specific immunohistochemical staining, various concentrations of antibody were
utilised. The time and temperature for the incubation period could also be altered in
order to achieve optimal immunostaining i.e. one hour incubation at 37°C instead of
overnight incubation at 4°C.
All single antigen staining techniques used a standard Avidin-Biotin
Peroxidase immunohistochemical protocol, requiring the use of a biotinylated
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secondary antibody (an antibody with biotin covalently linked to its structure; figure
3.5).
Excess primary antibody was washed with PBS containing 0.01% Tween 20
(PBST) for two five minute washes. A biotinylated secondary antibody (raised
against the specific species of the primary antibody) is then applied, diluted in serum
as a concurrent non-immune block for 60 minutes. During this incubation time, a
solution of preformed avidin-biotin-peroxidase enzyme complex (ABC Elite,
Vectastain, Peterborough, UK) was prepared. The ABC-Elite system can be
employed to improve antigen detection. The avidin-biotinylated peroxidase
complexes are small and highly active, allowing greater tissue diffusion and binding
to the biotinylated secondary antibody. As the most sensitive peroxidase-based
detection system, providing five to ten times more sensitivity than regular ABC
methods, this was most often used. This greater sensitivity allowed for better
detection of biotinylated targets and hence less detection of non-specific background
antigens.
After excess secondary antibody was removed with two five minute PBST
washes, incubation with the ABC Elite tertiary detection solution was performed for a
further 60 minutes. The peroxidase substrate, diaminobenzidine tetra hydrochloride
(DAB, DAKO Corp, Ca, USA) was then employed as the chromagen. The peroxidase
enzyme leads to oxidation of the DAB substrate, resulting in a stable enzyme-
substrate complex and a brown precipitation, allowing visualization of the sites of
positive immunoreactivity.
Sections were washed in distilled water before counter staining with Harris'
Haematoxylin and then subsequently dehydrated in ascending grades of alcohol.
Final incubation in xylene was performed prior to mounting in Pertex.
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3.2.3 Scoring and analysis of immuno reactivity
The immunostaining intensity of epitopes in all tissue sections was assessed in
a semi-quantitative manner on a 4-point scale: 0 = no immunostaining, 1= mild
immunostaining, 2 = moderate immunostaining, 3 = intense immunostaining. All
tissue sections were scored blind by two independent observers. This scoring system
has been previously validated in a subset of tissue sections in which
immunoreactivity was measured with a computerised image analysis system, a strong
correlation between quantitative data derived from the image analysis and subjective
scores by a trained observer was obtained (regression coefficient of 0.963 (Wang et
al., 1998)).
Due to the discontinuous nature of this semi-quantitative data, analysis was
performed using a non-parametric method, the Kruskall-Wallis test, followed by
Dunn's post-hoc multiple comparison test. Results with a p value <0.05 were
considered to be significant.
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3.2.5 Automated immunohistochemistry for localisation of
cyclooxygenases 1 (COX-1) and 2 (COX-2)
The immunostaining protocols for COX-1 and COX-2 followed the general
immunohistochemical protocol outlined in section 3.2.2. However the timings and
concentrations of reagents used were markedly different. This deviation from
previous staining methodology was due to the utilisation of a Bond™ Automated
immunohistochemistry system. This system was able to deliver a more efficient
staining method with an improved quality and reproducibility of immunostaining.
Slide identification details were pre-programmed into the machine and slide
labels applied. Slides were the dewaxed and underwent antigen retrieval as per
normal protocol (section 3.2.2) before being mounted on the automated machine. The
Bond™ system facilitates tissue staining by applying a series of pre-optimised
reagents to tissue sections under tight control of conditions including, accurate
timings for each stage of the staining procedure (step times) and slide temperatures.
Cross contamination of reagents is carefully avoided.
The machine is fully automated and could offer batch processing if required.
Sections were automatically counterstained and washed. Slides were then removed
from the system and dehydrated in ethanol and xylene prior to being mounted in
Pertex.
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3.2.6 Immunofluorescent confocal laser microscopy
Immunohistochemical co-localisation of the site of expression of prostacyclin
receptor (IP) with epidermal growth factor receptor (EGFR) or the endothelial cell
marker CD31 was performed in human endometrium by dual immunofluorescence
immunohistochemistry and confocal laser microscopy (see chapter 4).
Human endometrial sections (5 pm) were dewaxed, rehydrated and washed as
previously described in section 3.2.2. The immunohistochemical methodology was
repeated for antigen retrieval by pressure cooking, quenching of hydrogen peroxidase
activity and blocking of endogenous streptavidin activity. Non-specific binding was
further reduced by 20 minute incubation with 5% non-immune rabbit serum diluted in
PBS before overnight incubation at 4°C with the polyclonal mouse anti-EGFR
primary antibody (NCL-EGFR-384, Nova-Castra, Newcastle-upon-Tyne, UK) at a
dilution of 1 in 25. For co-localization of the IP receptor with CD31. a monoclonal
mouse anti CD31 antibody (Dako Cytomation, CA, USA) was used at a dilution of 1
in 20. Control sections were incubated with polyclonal goat anti-IP primary antibody
at a dilution of 1 in 100 in order to demonstrate specificity of the secondary antibody
for the mouse primary antibodies. The following day, sections were washed with PBS
tween and incubated with a 1 in 500 dilution of biotinylated rabbit anti-mouse IgG for
one hour. A further one hour incubation with the fluorochrome streptavidin 488
Alexifluor (Molecular Probes Inc. Cambridge Bioscience, Cambridge, UK) diluted at
1 in 200 in PBS was performed. Next, sections were incubated for 20 minutes in a
PBS solution containing biotin in order to enhance fluorescent signal before re-
blocking with 5% non-immune rabbit serum. Incubation with the goat anti-IP
antibody (Santa Cruz Inc.) at a 1 in 100 dilution at 4°C overnight was then performed.
A second control slide was incubated with mouse anti-EGFR or mouse anti-CD31
primary antibody. Incubation with a 1 in 200 dilution of rabbit anti-goat peroxidase
(Vector Laboratories, Peterborough, UK) secondary antibody was performed for 30
minutes. Tertiary detection was performed with an 8 minute incubation with
Tyramide Cy3 solution (PerkinElmer Life Sciences, Boston, USA) at a 1 in 50
dilution as per manufacture's instructions. Slides were counterstained with To Pro
(Molecular probes Inc.), at a 1 in 2000 dilution for 2 minutes and then mounted in
permafluor.
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3.3 Real Time Quantitative Reverse Transcription
Polymerase Chain Reaction (Q-RT PCR).
3.3.1 General Theory
Transcription is the process in which the DNA sequence of a gene acts as a
template for mRNA synthesis. The enzyme driven reverse-transcription (RT) reaction
is used to generate complementary DNA (cDNA) from mRNA. The polymerase
chain reaction (PCR) is used to amplify specifically defined regions of a particular
gene. Combining RT and PCR (RT-PCR) has revolutionised the study of gene
expression providing a highly sensitive and rapid method for mRNA analysis.
Once synthesised cDNA is used as a template for cycles of amplification of
specific target sequences. Following denaturing of secondary structures by heating,
short oligonucleotides (primers) are added and allowed to anneal to the target cDNA
strands by cooling of the mixture. Primers are designed to be complementary to the 5'
ends of the sequence chosen for amplification, ideally they will result in a product
containing a spliced intron-exon boundary, thereby ruling out any possibility of
genomic DNA contamination exerting an effect. A thermostable polymerase enzyme
is then employed to extend the sequence complementary to the cDNA. The template
and nascent strand are then separated by heating, allowing them to be used as
template stands for the next cycle of amplification. Subsequent cycles allow the
exponential generation of DNA fragments of a size defined by the added primers.
Real-time quantitative PCR analysis involves the simultaneous amplification
and detection of target complimentary DNA (cDNA), such that quantification is
performed once per cycle. The system used in this thesis is based on the taqman assay
developed by PerkinElmer-Applied Biosystems (Ca, USA). This system relies on the
same principles as normal PCR, rounds of annealing, polymerisation and denaturation
(figure 3.7). Flowever, this more sensitive technique employs an additional short
oligonucleotide designed to anneal to sequences within a region to be amplified. This
additional oligonucleotide, known as the hybridisation probe, is chemically altered
such that it cannot initiate polymerisation and contains a fluorescent reporter dye at
its 5' end and a quencher dye at its 3' end. Due to the proximity of the quencher dye,
fluorescence from the reporter dye is undetectable from an intact probe. Detection
64
only becomes possible due to the 5' nuclease activity of DNA polymerase, which will
hydrolyse the hybridisation probe only when it is bound to the target DNA sequence.
Because the hybridisation probe anneals within the region bound by the forward and
reverse amplification primers it will encounter the DNA polymerase. Once
hydrolysed the reporter dye loses its proximity to the quencher and can now be
detected. It is therefore possible to follow the accumulation of PCR products by
monitoring the increase in fluorescence of the reporter dye (see section 3.3.5).
Figure 3.6. Summary ofprocesses involved in real time RT-PCR.
Practical Aspects of PCR
Theoretically, the PCR reaction should occur at an exponential rate, as it is a
cyclical process incorporating the product of one cycle in the pool of templates for
the next cycle. However, in practice the exponential increase is not unlimited and
occurs only relatively early on because one or more factors become limiting, resulting
in a reduced rate that eventually tails off to give the so-called "plateau effect". For
example, products may accumulate such that template re-association competes with
primer annealing and extension, or the molar ratio between polymerase and template
is no longer correct. Small differences in efficiency of the RT and PCR reactions,
inevitable in such complex reactions, can result in large apparent differences in
expression in similar samples following product amplification. Thus, it is necessary
to carefully optimise each PCR reaction, such that the plateau phase is not reached
and incorporated into quantification data.
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Figure 3.7 Schematic drawing of the PCR cycle.
(I) Denaturing at 96°C. (2) Annealing at 68°C. (3) Elongation at 72°C
(P=Polymerase). (4) The first cycle is complete. The two resulting DNA strands make
up the template DNA for the next cycle, thus doubling the amount ofDNA duplicated
for each new cycle.
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3.3.2 RNA Extraction
All tissue or cell lysate handling was conducted to minimise the possibility of
RNAse contamination. All instruments and disposables used in the procedure were
autoclaved or certified as RNAse free.
Tissue RNA Extraction
Upon collection, endometrial tissue was immediately transferred to a solution
of RNA Later (Ambion, Huntington, UK) to aid RNA stability before processing
could occur at the laboratory. On arrival at the laboratory, tissue was transferred to
storage at -80°C.
RNA was extracted using RNAeasy midispin columns (Qiagen, Crawley, UK)
as per manufacturer's protocols, in combination with on-column DNase-I treatment
(Qiagen).
In summary, 100-250mg samples of endometrium were homogenized, in a
RNA- stabilizing buffer medium (provided by Quiagen), using a hand held rotator
blade homogenizer. This solution was then centrifuged prior to passing the
supernatant through a RNA extracting column pre-prepared by Quiagen. The column
is designed to efficiently bind RNA out of solution and maintain its stability at room
temperature. A wash solution was then passed through the column prior to a 15
minute incubation with DNase I to remove contaminating genomic DNA. After a
further wash the RNA is then eluted from the column in a known volume of RNase
treated sterile water.
Ishikawa Cell Extraction
For this study, total RNA was isolated from Ishikawa cells using a single-step
extraction reagent, Total RNA Isolating Reagent (TRIR, Abgene, Surrey, UK). This
method of RNA extraction is based on the one-step acid guanidinium method first
described by Chomczynski and Sacchi (Chomczynski et al., 1987). The procedure
was carried out according to a modified protocol provided with the reagent. Briefly,
TRIR is a combination of guanidine salts and urea, which act as denaturing agents.
Cells were lysed in 1ml of TRIR and allowed to stand at room temperature for 5
minutes to allow complete dissociation of nucleoprotein complexes. Addition of
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0.2ml chloroform followed by centrifugation separates the solution into an aqueous
phase and an organic phase. RNA remains exclusively in the aqueous phase and can
be precipitated by the addition of isopropanol, washed with ethanol and solubilised in
DEPC treated water.
3.3.3 Assessing the Quality and Quantity of total RNA
extracted.
The concentration of the RNA extracted from Ishikawa cells was determined
by measuring the optical density (OD) at 260nm (A260nm) using an automated
spectrophotometer (Genequant), with 1 A260nm unit being an equivalent of 40ng of
RNA in lmL dH20.
A 1:10 dilution of RNA was made in nuclease free water. A ratio of the
optical density at a wavelength of 260nm to a wavelength of 280nm (260:280) was
additionally calculated. If the ratio was less than 1.6, the sample was considered not
to have sufficient purity for use in further work.
For total RNA extracted from endometrial tissue, in addition to the above
method of assessment, aliquots (lpl) of purified RNA were removed for
quantification and quality assessment using the Agilent 2100 Bioanalyser system in
combination with RNA6000nano chips (Agilent Technologies, Cheshire, UK). Only
RNA that displayed intact 18S and 28S peaks was reverse transcribed (RT) to cDNA
for real-time PCR analysis. This quality-control step was included for each
experimental run to avoid generation of false-negative results due to RNA
degradation before and during extraction steps, and also as a quantification method to
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Figure 3.8 Bioanalyzer Images of Total RNA Preparations.
These electropherograms (from the Agilent 2100 bioanalyzer) show RNA samples
with decreasing integrity. The trace labelled "Intact Total RNA " represents the ideal
for a bioanalyzer trace of total RNA. Notice how the ribosomal RNA peaks are at a
ratio of about 2 (28S:18S) in this sample; this represents ultrahigh quality RNA in
terms of integrity. Most RNA samples will more closely resemble the right trace
where there are nearly equal amounts of28S and 18S rRNA. The lower trace shows a
degraded RNA preparation with rRNA peaks that are lower than in the other two
traces and where lower molecular weight degradation products become apparent.
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3.3.4 Synthesis of Complementary DNA - Reverse
Transcription and Polymerase Chain Reaction (RT-PCR).
The reverse transcription polymerase chain reaction (RT-PCR) is a sensitive
method for detecting low abundance mRNA. RNA is unable to form a template for
PCR; therefore the initial step in an RT-PCR reaction is the reverse transcription in
order to form complementary DNA (cDNA). Exponential amplification of this cDNA
is then achieved in a PCR reaction. These steps are carried out individually.
Reverse transcription was carried out in a 20pl volume of reaction solution.
400ng of RNA was diluted in nuclease free H2O to a volume of 7.7pl. 12.3 pi of
master mix solution containing; MgCfi (5.5mM), deoxy (d)-NTPs (0.5 mM each),
random hexamers (2.5 pM), ribonuclease inhibitor (0.4 U/pl) and multiscribe reverse
transcriptase (1.25U/pl) were then added to the 400ng of RNA, (all solutions supplied
from Applied Biosystems, Warrington, UK). After mixing by brief centrifugation,
samples were reverse transcribed on a thermal cycler. Reverse transcription involved
incubation for 90 min at 25°C, 45 min at 48°C and 5min at 95°C for one cycle.
Thereafter, cDNA samples were stored at -20°C. A tube with no reverse transcriptase
was included to control for any DNA contamination.
Several techniques based on RT-PCR technology are available, including
detection of mRNA by conventional (non-quantitative PCR), semi-quantitative PCR
or 'real-time' quantitative PCR. The method used in this project was "real time"
quantitation.
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3.3.5 Real Time Quantitative RT-PCR
The Taqman assay (Perkin-Elmer - Applied Biosystems, CA, USA) is a real
time RT-PCR assay. It requires the use of the ABI Prism 7700 - a combined thermal
cycler/detector, which utilises sequential laser stimulation of its 96 reaction wells to
detect fluorescence between 500nm and 660nm. Detected fluorescence is then
analysed to quantify the amount of target gene of interest in the samples being
analysed.
To successfully detect the target gene within cDNA, two specific
oligonucleotide primers are designed to flank the endpoints of the gene or amplicon.
This allows for specificity of amplification, which is additionally improved by the
incorporation of an oligonucleotide probe that hybridizes to the amplicon during the
annealing/extension phase of the PCR. To avoid amplification of contaminant DNA,
the primers should be designed to span an intron. If this is not possible, the RNA to
be quantified should be treated with RNAse-free DNAse to minimise the potential for
genomic DNA contamination of the cDNA.
The assay utilises the 5'-3' nuclease activity of the DNA polymerase, Taq
polymerase, to hydrolyse the hybridization probe that is bound to the amplicon. The
probe used for Taqman is a 5'labelled FAM (6-carboxyfluorescene; a fluorophore),
3'labelled TAMRA (6-carboxytetramethylrhodamine; a quencher) FRET
(Fluorescene Resonance Energy Transfer) probe. In FRET probes, the fluorophore
donor transfers its energy to the quencher, suppressing fluorescence due to its close
proximity. If the probe is correctly bound to an area within the target amplicon during
the denaturing step of the PCR, subsequent action by the Taq polymerase, extends
from the primers until it reaches and displaces the 5' end of the probe. Continued
movement of the polymerase enzyme results in cleavage of the probe, separating the
FAM reporter and TAMRA quencher dyes, allowing fluorescence to be produced and
hence measurement of PCR product (figure 3.10).
Real-time PCR probe validation and calibration
The Taqman system incorporates its own design program, Primer Express, to
facilitate adherence to the design specifications required for Taqman
oligonucleotides. This ensures successful hybridization and amplification of template
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cDNA during the procedure. An endogenous reference is also required within the
experimental well to ensure there are similar amounts of starting material between
experimental samples. A multiplexing strategy was utilised to allow relative
quantitation of cDNAs between samples. Multiplexing is the use of more than one
pair of primers within the same well. In real time quantitation, one primer pair
amplifies the target and the other amplifies the endogenous reference within the same
experimental well. The endogenous reference used in these experiments was
ribosomal RNA (rRNA). rRNA constitutes 85-95% of cellular RNA and levels are
unlikely to vary under conditions that might effect expression of mRNA (Barbu et al.,
1989). It has also been shown to be more reliable than normalisation with genes such
as p-actin or GAPDH in a comparison study of human malignant cell lines (Zhong et
al., 1999). PE Applied Biosystems supplied VIC-labelled ribosomal 18S
housekeeping primers and probe, which were multiplexed in reactions with the
primers and probes for the mRNAs of interest. VIC is an alternative fluorescent probe
that is detected at a different wavelength from FAM hence allowing discrimination
between the two different labelled probes.
Prior to using the designed primers and probes for real time RT-PCR, the
linearity of the response was determined. Serial dilutions of a cDNA standard
(containing the target gene of interest) up to a 1/32 dilution were amplified with the
reaction mixture containing target gene and endogenous 18s rRNA primers and
probes.
It is vital to ensure a linear relationship between template concentration and
threshold cycle value for both target gene and endogenous housekeeping gene. The
threshold cycle value is the cycle number at which logarithmic PCR plots cross a
calculated threshold line (Ct value) with Ct values decreasing as template
concentration increases. The difference between the values for the target amplicon
and the housekeeping 18s is called the delta Ct. The log of the total RNA
(concentration prior to cDNA conversion) was plotted against the delta Ct and a best
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Figure 3.9 Validation ofEGFR primers and probes.
Representative plotfor Taqman primers andprobe validation. Validation was
performedfor each set ofprimers andprobes used in this thesis. The mean delta Ct is
represented on the y-axis and the log concentration oftotal RNA is represented on
the x-axis. The equation for the gradient ofthe slope is shown and is <0.1
Taqman Protocol
The expression of target enzymes in both endometrium from across the
menstrual cycle and Ishikawa cells were investigated by quantitative RT-PCR. Total
RNA was extracted, quantified and reverse transcribed to cDNA according to
methods previously described (sections 3.3.2-3.3.4).
To measure cDNA expression, a reaction mix was prepared containing
Taqman buffer (5.5 mM MgCl2, 200 pM dATP, 200 pM dCTP, 200 pM dGTP, 400
pM dUTP), ribosomal 18S forward and reverse primers and probe (all at 50 nM),
forward and reverse primers for the target gene / amplicon (300 nM), specific probe
(100 nM), AmpErase UNG (O.OlU/pl) and AmpliTaq Gold DNA Polymerase (0.025
U/pl; PE Biosystems).
After mixing, 48 pi was aliquoted into separate tubes and 2 pi (40 ng) of
cDNA added and mixed before placing duplicate 24 pi samples into a PCR plate. To
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assess for genomic DNA contamination, two negative controls were added to the
plate in duplicate; a no template (containing water) control and a no reverse
transcriptase (containing RNA) control. Wells were sealed with optical caps and the
PCR reaction run on the ABI prism 7700 using standard conditions.
All primers and probes were designed using the PRIMER express program




























Figure 3.10 Diagrammatic representation ofRT-PCR
Polymerisation
Two fluorescent dyes, a reporter (R) and a quencher (Q), are attached to the probes
used with the TaqMan PCR Reagent Kit. The probe specifically anneals to the target
gene between forward and reverse primer sites. The 3' end of the probe is blocked, so
it is not extended during the PCR reaction.
Strand Displacement
When both dyes are attached to the probe, reporter dye emission is quenched due to
fluorescence energy transfer from the reporter dye to the quencher dye. During each
extension cycle, the probe is displaced at the 5' end by the DNA polymerase.
Cleavage
Taq DNA polymerase then cleaves the reporter dye from the probe via its 5'-3'
exonuclease.
Polymerisation Complete
Once separated from the quencher, the reporter dye emits its characteristic
fluorescence which can then be measured by the 7700 detector. The amount of
fluorescence measured is proportional to the amount of PCR product made.
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3.3.6 Taqman Analysis and Statistics
Data were processed using Sequence Detector version 1.6.3 (Applied
Biosystems, Warrington, UK) according to manufacturer's instructions. Expression
of target genes were normalised to RNA loading for each sample using 18S
ribosomal RNA as an internal standard. All results were expressed relative to a
control standard (cDNA obtained from a single sample of endometrial tissue and
included in all experiments).
Analysed data was imported into a spreadsheet and analysed using the
formula
2"aact Ct is the cycle number at which the PCR signal crosses a designated threshold.
The ACT is the difference between the Ct value for the target gene and the internal
normalisation control (18S). AACT is the difference between the ACT and the control
standard mentioned above.
Data were subjected to statistical analysis with analysis of variance (ANOVA)
and Least Significance Difference (LSD) post testing (Fishers PLSD tests; Statview
4.0; Abacus Concepts Inc., Piscataway, NJ, USA) and statistical significance
accepted when p<0.05.
77
3.4 Cell Culture and Protein Signalling
3.4.1 Ishikawa Cell culture and cell experimentation
The Ishikawa Cell
The cyclical changes undergone by the human endometrium are orchestrated
by the circulating sex steroids, progesterone and oestrogen. The regulation of the
progesterone and oestrogen receptors is tightly controlled and their expression has
been shown to vary throughout the menstrual cycle as discussed in the section 1.2.5.
It is difficult to study protein signalling in the normal human endometrium because of
the limited availability of suitable model systems, which contain functional oestrogen
and progesterone receptors. Ishikawa cells are derived from a well-differentiated
endometrial carcinoma cell line that expresses both oestrogen receptors (ER) and
progesterone receptors (PR). (Hata et ai, 1992; Lessey et al., 1996).
Cell Culture
Human Ishikawa endometrial adenocarcinoma cells (European Collection of
Cell Culture, Centre for Applied Microbiology, Wiltshire, UK) were routinely
cultured under sterile conditions in culture flasks with a surface area of 170 cm
(Corning Science Products, UK). Cells were maintained in Dulbecco's modified
Eagle's medium (DMEM) nutrient mixture F-12 with glutamax-1 and pyridoxine
(Life Technologies, Paisley, UK), supplemented with 10% fetal calf serum (FCS),
and 1% antibiotics (stock 500IU/ml penicillin and 500ug/ml streptomycin, PAA
Laboratories Ltd, Middlesex, UK) at 37°C and 5% CO2 (v/v). Cells grew as a
monolayer on the bottom of the flask and were observed using inverted light
microscopy (Olympus CK40) to determine confluence. At about 80% confluency,
cells were passaged. For passage of cells, growth medium was removed by pipette
and cells washed twice with PBS before 2 ml of trypsin-EDTA (0.1% trypsin and
0.04% EDTA in PBS) was added to the culture flask. The trypsin was allowed to
flow over the monolayer of cells at 37°C for 2 minutes. Flasks were then tapped to
allow cells to loosen from the flask and 10 ml of DMEM was added to re-suspend
cells and inhibit trypsinization. 1 ml of re-suspended cells was added to a new culture
flask and then diluted 1 part to 30 in DMEM containing FCS.
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For experimentation, Ishikawa cells were seeded out to sterile petri dishes
(number of cells calculated according to dish size) and grown to the required
confluence; 60 to 80% for all experimentation except transient transfection (section
3.4.3). The culture medium was then replaced with serum free DMEM and 8.4pM
Indomethacin (a dual COX-enzyme inhibitor used to inhibit endogenous prostanoid
biosynthesis) for overnight incubation in order to achieve cell synchronization prior
to experimentation. Details of specific experimentation can be found in chapters 4
and 5.
3.4.2 Cell Lysis and Protein Concentration
Protein extraction
After experimental stimulation of Ishikawa cells, two washes with cold PBS
were carried out to stop further cellular signalling. Cells were then lysed by addition
of protein lysis buffer (1% Triton X-100, 150mM NaCl, lOmM Tris/HCl pH7.4,
ImM EDTA, 5mM EGTA, 0.1% SDS containing 2mM PMSF, ImM Na3V04 and
5pg/ml aprotinin). Proteins were extracted by allowing experimental dishes to sit on
ice for 10 minutes prior to scraping of cells using a plate scraper and collection by
sterile pipette. The collected suspension of cells in lysis buffer was centrifuged at 14
000 rpm for 15 minutes at 4°C to cause insoluble material to pellet. The clarified
lysate was then transferred to a new eppendorf tube for protein quantification prior to
immunoprecipitation or SDS-PAGE.
For endometrial tissue experiments, following stimulation, tissue was snap
frozen in dry ice and stored at -20°C for subsequent protein extraction. Protein was
later harvested by homogenization of tissue (kept on ice to limit protein degradation)
in protein lysis buffer (as described above). The collected suspension of tissue
homogenate in lysis buffer was centrifuged at 14 000 rpm for 15 minutes at 4°C to
cause insoluble material to pellet. The clarified lysate was then transferred to a new




Proteins were quantified according to the BIO-RAD DC colorimetric protein
microassay (Biorad, UK) as per manufacturer's instructions. This is a method based
upon the Method of Lowry in which colour development results from the reaction
between protein and an alkaline copper tartrate solution and the subsequent reduction
of Folin reagent. This reaction results in the formation of several reduced species all
with a characteristic blue colour, the absorbance of which can be measured between
650 and 750nm.
Samples were diluted in distilled water to a ratio of 1:30. A range of bovine
serum albumin (BSA, supplied with the assay) protein standards (0 - 200 pg/ml) was
additionally made up in the same distilled water to achieve an OD595 response from
0.1 to 1.0 OD units. For the assay, 25pl of each standard and sample (Ishikawa cell or
tissue homogenate) were dispensed in duplicate into individual wells of a 96-well
plate. To each aliquot 25pil of Reagent A (alkaline copper tartrate solution) was added
followed by lOOpl of Reagent B (dilute Folin reagent). The reactions were allowed to
proceed for 5 minutes at room temperature before the OD 690nm was recorded using
a spectrophotometric plate reader (Multiskan Biochromatic Eliza Plate-Reader,
Labsystems, UK).
A standard curve (x-axis; pg of protein against y-axis; OD690nm) was
produced using the AssayZap computer software program (Biosoft) and used to
determine the average protein concentration of each sample.
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3.4.3 Transient Transfections and Immmunoprecipitation
Cell signalling to ERK1/2 (Chapter 4) was determined using a dominant
negative (DN) mutant isoform targeted against epidermal growth factor receptor
(EGFR).
Ishikawa cells were seeded to a density of 5xl05 per well in 6cm dishes and
then transfected with a c-myc-tagged ERK1/2 cDNA construct together with either
empty vector cDNA (pcDNA3; Invitrogen, de Schelp, The Netherlands) or DN-
EGFR cDNA using Superfect (Qiagen, Crawley, UK) as per the manufacturer's
protocol (The DN-EGFR and c-myc tagged ERK constructs were a kind gift from
Professor Zvi Naor, Department of Biochemistry, Tel-Aviv University, Israel).
Optimal concentrations of cDNA for transfection had been determined by titration.
The transfection efficiency of the Ishikawa cell line was determined by transfection
with a pcDNA6/V5/His/lacZ cDNA construct (Invitrogen) and P-Galactosidase assay.
Transfection efficiency as reported previously for this cell line using standard
procedures according to the manufacturer protocol is 45 ± 5 percent (Sales et al.,
2005). The following day, cells were starved by overnight incubation in serum free
medium containing 3pg/ml indomethacin and then underwent experimentation.
Cells were then lysed and protein quantified as described in section 3.4.2. The
tagged ERK1/2 allowed immunoprecipitation from whole cell lysate. For
immunoprecipitation, equal amounts of protein were incubated with specific c-myc
antibody pre-conjugated to protein A Sepharose overnight at 4°C with gentle rotation.
Beads were washed extensively with lysis buffer and immune complexes eluted and
solubilised in Laemmli buffer (125 mM Tris-HCl pF16.8, 4% SDS, 5% 2-
mercaptoethanol, 20% glycerol and 0.05% bromophenol blue), boiled for 5 minutes
and subjected to Western blot analysis.
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3.4.4 Theory of protein analysis
Proteins examined in this thesis were derived from Ishikawa cells or from
normal human endometrium.
Most of the methods used in protein purification can be divided into four distinct but
interrelated groups depending upon protein characteristics:
Methods based on surface features of proteins
Surface features include charge distribution and surface distribution of
hydrophobic amino acid side chains amongst others. Most methods exploiting these
surface properties depend mainly on protein solubility in various solvents. Also
included in this category is the highly specific technique of immunoaffininty, in
which an antibody directed against an epitope on the protein surface is used to pull
out the desired protein from a mixture. This method is utilised in
immunoprecipitation described in section 3.4.3.
Methods based on whole structure: Protein size and shape
Proteins range in size from 5000 to many million Daltons (Da) and the chief
methods of exploiting size and shape of a protein is gel-filtration chromatography and
preparative gel electrophoresis (section 3.4.5).
Methods based on net charge
Separation methods exploiting the overall charge of a protein are not utilised
in this thesis, however protein charge would in part determine travelled distance in
preparative gel electrophoresis.
Methods based on bioproperties (affinity)
This method exploits the strong affinity of a protein for its ligand thereby
separating a desired protein from a mix. Although not specifically utilised in this
thesis, the immunoaffinity of a protein for a specific antibody is a closely related
method of isolation used in immunoprecipitation (section 3.4.3)
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3.4.5 Sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) and Western Blotting
Western blot analysis can detect one protein in a mixture of any number of
proteins while giving you information about the size of the protein. The proteins must
be separated by size using SDS-polyacrylamide gel electrophoresis and then
transferred to a nitrocellulose membrane to provide a protein imprint, which can be
detected using standard immunological techniques. A negative charge is created on
the side of the gel and the positive charge on the side of the membrane to drive the
negatively charged proteins over to the positive charged nitrocellulose membrane.
SDS-PAGE
SDS-PAGE was performed using pre-cast 4%-20% Tris-Glycerine gels
(Novex, Invitrogen, UK). Gels were set up in the gel running tank with running
buffer (25 mM Tris-HCL, 0.2M glycine, 0.1% SDS). An equal amount of protein
(40pg) was resuspended in a total volume of 25pl sample loading buffer (125mM
Tris-HCL pH 6.8, 4% SDS, 20% glycerol, 5% 2-mercaptoethanol and
0.05%bromophenol blue), boiled for 5 minutes at 95°C to denature the protein
content and then loaded into separate wells of the gel. 15pi of Seeblue (Novex) pre-
stained molecular weight markers were loaded into a separate well. Gels were run at
4mA constant current for about 90 minutes prior to immunoblotting.
Western Blotting
Following electrophoresis, the gel was transferred to a protein-free tray and
equilibrated with transfer buffer (25 mM Tris/HCL, 0.192M glycine, 20% methanol)
for 5 minutes. Whatman No.3 filter paper and polyvinylidene difluoride membrane
(PVDF, Millipore, Watford, UK) were cut to the gel dimensions and equilibrated in
the transfer buffer. The PVDF membrane was pre-soaked in methanol for 1 minute
followed by a rinse in distilled water prior to equilibration in transfer buffer. The blot
was assembled by overlaying three pieces of Whatman paper with the PVDF
membrane followed by the gel and finally three further pieces of Whatman paper.
Care was taken to remove any air bubbles prior to protein transfer to the membrane
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for 1 hour 45 minutes at 14V constant voltage using a semi-dry blotter (BioRad, UK).
Following transfer, membranes were incubated with the relevant primary antibody at
4°C overnight. After washing with TBS-Tween, membranes were subsequently
incubated for one hour with the relevant alkaline phosphatase conjugated secondary
antibody.
Immunoreactive proteins were visualised by the ECF chemiluminescence
system according to manufacture's instructions. Specific proteins were revealed and
quantified by and normalized to total protein expression using STORM 860
Phosphorimager (Molecular Dynamics, Amersham Biosciences, UK). The molecular
weight of the proteins was identified relative to the mobility of the pre-stained
markers on SDS-PAGE.
©
Figure 3.11 Diagrammatic representation of the Western Blotting process
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3.5 Cyclic AMP Assay
PGE2 signalling was assessed in endometrial biopsies obtained from
proliferative and secretory phases of the menstrual cycle. Tissue was minced finely
with scissors and incubated overnight at 37°C in a humidified 5% CO2 incubator in 2
ml RPMI medium (Sigma, Poole, UK) containing, 2 mmol/1 L-glutamine, 100 IU
penicillin and lOODg streptomycin and 3pg/ml indomethacin (Sigma, Poole, UK).
Following overnight treatment, approximately 1/3 of the tissue was removed and
stored at -20°C. The remaining tissue was incubated in the same medium containing
ImM l-methyl-3-isobutylxanthine (Sigma, Poole, UK) at 37°C for 30 minutes. It was
then divided in two and treated with control medium or 1 OOnM PGE2 for 10 minutes
at 37°C. Tissue was then lysed in 0.1 M HC1 and frozen until assayed.
Cyclic AMP concentration was measured by ELISA (Biomol, Affiniti, Exeter,
UK) according to manufacturer's instructions and normalised to protein concentration
determined by a modification of the method of Lowry (section 3.4.2). The ELISA was
performed using a 96 well microtitre plate provided in the assay kit. The wells of the
plate were pre-coated with goat anti-rabbit IgG. cAMP standards (lOOpl of each),
ranging form 200 pmol/ml up to 0.78pmol/ml, were added to the plate to produce a
standard curve. A lOOpl volume of sample was then added to the plate in duplicate.
50pl of alkaline phosphatase-cAMP conjugate and 50pl of polyclonal rabbit anti-
cAMP antibody (both provided in kit) were added to each well of the plate.
The plate was then incubated at room temperature for two hours on a plate
shaker at ~500rpm. Thereafter, the wells were aspirated and washed three times with
the provided wash buffer (TBST; 50mM Tris-FICL, 150mM NaCl, 0.5% Tween20,
pH 7.4; containing sodium azide).
The assay was developed by the addition of 200pl/well of p-nitrophenyl
phosphate. The colour reaction was allowed to develop for twenty minutes before
being stopped with the addition of 200ul/well of provided "stop solution" (trisodium
phosphate in water). Colour reaction was measured at 405nm by spectrophotomery.
The concentration of cAMP per sample was extrapolated from the standard curve




signalling in the Ishikawa cell
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4.1 Introduction
Prostacyclin (PGP) was discovered in 1976 during the generation of unstable
eicosanoids in blood vessels (Bunting et al., 1976) and is best known for its
anticoagulant effect on platelets and vasodilatory effect on the vascular endothelium,
where expression is found in abundance (Smyth et al., 2002). Like many eicosanoids,
PGp is produced via the prostaglandin signalling pathways, which are described in
detail in section 1.3.1. Briefly, arachidonic acid (AA) is released from plasma
membrane phospholipids and is cyclized, oxygenated and reduced to the unstable
intermediary prostaglandin fp (PGPp) by COX enzymes (Marnett, 1992; Narumiya
et al., 2001). The action of the COX enzymes is the rate limiting and committing step
of prostaglandin signalling. The PGfp intermediary serves as a substrate for terminal
prostaglandin synthase enzymes, such as prostacyclin synthase (PGIS), which
completes the synthesis of prostacyclin (figure 4.1). PGp has a mode of action via
coupling to the heptahelical G-protein coupled prostacyclin receptor (IP receptor)
(Battersby et al., 2004a; Narumiya et al., 1999). The IP receptor is known to mediate
a cAMP rise and has been termed a "relaxant" receptor (Narumiya and FitzGerald,
2001) with routine activation of the IP receptor activating adenylate cyclase via the
Gs subunit in a dose dependent manner.
Temporal expression of prostaglandins such as PGE2 and PGF2a and their
receptors (EP2/EP4 and FP receptors) has been demonstrated in the human
endometrium and has been shown to vary with the phase of the menstrual cycle
(Milne and Jabbour, 2003; Milne et al., 2001). Recent data implicate a role for PGE2
and PGF2a in proliferation of glandular epithelial cells via diverse signalling
pathways (Jabbour et al., 2003; Milne and Jabbour, 2003). In contrast, little is known
of the expression pattern and function of IP receptor in human endometrium,
although PGIS and IP receptor expression have been demonstrated in pregnant and
non-pregnant myometrium (Chegini et al., 1989; Giannoulias et al., 2002; Moonen et
al., 1986) and prostacyclin is known to act as a smooth muscle relaxant (Dyal et al.,
1988; Lumsden et al., 1986a).
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IP ^ Second Messenger
Signalling
Figure 4.1 Prostacyclin signalling pathway
Arachidonic acid (AA) is released from plasma membrane via the action of
phospholipase A2 (PLA2). AA is acted upon by cyclooxygenase enzymes (COX) to
form the prostaglandin intermediary PGH2. Terminal synthase enzymes then convert
this intermediary to the respective prostanoid. Prostacyclin (PGL) acts upon its
cognate receptor (IP) to initiate second messenger signalling.
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Knockout studies disrupting the IP gene in mice have demonstrated
thrombotic tendencies and decreased inflammatory responses (Murata et al., 1997;
Ueno et al., 2000). The cyclical regeneration and repair undergone by the human
endometrium during the menstrual cycle (section 1.4.1) necessarily involves
physiological processes involving clotting and inflammation. Production of uterine
prostacyclin may be involved in myometrial smooth muscle relaxation, vasodilatation
and also prevention of clot formation. These physiological actions are all involved in
the process of menstruation and a role for PGT in menstruation and menstrual
disturbances can be hypothesised. Indeed, endometrium collected from women with
heavy menstrual blood loss (MBL) has a greater capability of enhancing myometrial
prostacyclin production compared to endometrium collected from women with
normal MBL (Smith, S. K. et al., 1981b). Previous studies have also demonstrated an
increase in expression of PGIS and IP receptor rnRNA during the menstrual
compared with proliferative and secretory stages of the cycle (Battersby et al.,
2004a).
The remodelling of the human endometrium required during the menstrual
cycle requires tight control of angiogenic growth factors to coordinate the growth of
new vessel formation. Previous studies have reported that COX enzymes, in
particular COX-2 (Gately et al., 2004), and prostaglandins such as PGE2 (Sales et al.,
2004a) and PGF2a (Sales et al., 2005) can modulate the expression of target
angiogenic genes within the human endometrium. The angiopoietins (Ang-1 and
Ang-2) are a family of growth factors that act as ligands for the largely endothelial
restricted Tie-2 receptor tyrosine kinase which is essential for vascular development.
Investigation into the expression of the angiopoietins 1 and 2 in human endometrium
showed minor variations in expression of Ang-1 mRNA at different stages of the
cycle and a significant up regulation of expression of Ang-2 mRNA during the
secretory stage of the cycle (Hirchenhain et al., 2003). Ang-1 binds and causes
autophosphorylation of Tie-2, promoting endothelial cell migration, sprouting and
survival. In contrast, Ang-2 binds to Tie-2 without eliciting a signal. The effect of this
natural antagonism is to cause vessel destabilization with vascular regression in the
absence of additional vascular endothelial growth factor (VEGF) or indeed neo¬
vascularization in its presence (Smith, O. P. et al., 2005).
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The aim of this chapter is to examine the prostacyclin receptor within the
human endometrium. Whilst exploring the role of prostaglandins within human
endometrium, access to well characterised human tissue from consenting patients is
too limited to explore molecular signalling pathways in detail. Using an endometrial
epithelial cell line (Ishikawa) and human endometrial tissue, the intracellular




Patients and tissue collection
Ethical approval was obtained from Lothian Research Ethics Committee and
written informed consent was obtained from all subjects before tissue collection. (The
patient information sheet and ethical approval are included in Appendices.)
Endometrial biopsies were collected at different stages of the menstrual cycle
with an endometrial suction curette (Pipelle, Laboratoire CCD, Paris, France) from
women attending the gynaecological outpatient setting. In addition, full thickness
endometrial biopsies (section 3.1.1) at all stages of the menstrual cycle, were
collected from women undergoing hysterectomy for benign gynaecological
indications. All subjects were aged between 18 to 50 and reported regular menstrual
cycles (cycle length, 21-35 days) with no unscheduled, non-menstrual bleeding. No
woman had received hormonal preparation in the 3 months preceding biopsy
collection. Patients were clinically examined and clinical pelvic abnormalities, such
as an enlarged uterus, were further investigated by pelvic ultrasound imaging.
Patients with known uterine pathology such as fibroid disease and endometriosis
were excluded from the study.
Immediately after collection, tissue was divided, transferred into RNA Later
(Ambion Inc, Huntingdon, UK) and stored at -70°C (for RNA extraction), fixed in
neutral buffered formalin and wax embedded (for immunohistochemical analysis) or
placed in RPMI 1640 medium (containing 2 mM L-glutamine, 100 U penicillin and
100 pg/ml streptomycin) and transported to the laboratory for in vitro culture.
All biopsies were dated according to stated last menstrual period (LMP) and
dating was confirmed by histological assessment according to criteria of Noyes and
co-worker (Noyes, 1950). Furthermore, circulating oestradiol and progesterone serum
levels were measured at the time of biopsy collection and were consistent for both
LMP and histological assignment of menstrual cycle stage. This is a robust method
for characterizing endometrial samples. Detailed gene microarray studies support this
method for characterizing endometrial samples with consistency across these three
parameters (Critchley et al., 2006; Talbi et al., 2006). Inconsistencies between
measured circulating hormone levels, stated day of last menstrual period and/or
histological assessment led to exclusion of three tissue biopsies from the study.
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Tissue Culture
Tissue samples were finely minced using sterile forceps and scissors before
overnight incubation in serum free RPMI medium (as described above) and 3pg/ml
indomethacin (a dual COX enzyme inhibitor to inhibit endogenous prostanoid
production). The next day, tissue was pre-treated with a specific chemical inhibitor of
EGFR kinase (AG1478, lOOnM) for 1 hour prior to stimulation with lOOnM Iloprost
for time period stated in figure legend. Following stimulation, tissue was either snap
frozen in dry ice and stored at -20°C for subsequent protein extraction or stored at -
70°C for RNA extraction. Protein was harvested by homogenization of tissue in
protein lysis buffer. Protein content was determined using a protein assay kit (Bio-
Rad, Hemel Hempstead, UK) as described in section 3.4.2.
Cell culture
Ishikawa human endometrial epithelial cells (European Collection of Cell Culture,
Wiltshire, UK) were maintained as described in section 3.4.1. The cells were grown
on monolayer in 6cm dishes to 60-80% confluence after which the culture medium
was replaced with serum free DMEM containing 3pg/ml indomethacin for overnight
incubation. The next day cells were pre-treated with specific inhibitors of either
EGFR kinase (AG 1478, lOOnM) or mitogen-activated protein kinase kinase (MEK;
PD98059, 50 pM) for 1 hour prior to stimulation with lOOnM Iloprost or v/v 100%
ethanol as a vehicle control for the time period specified in the figure legend.
Following stimulation with Iloprost, proteins were harvested and extracted and the
protein content in the supernatant fraction was determined using a protein assay kit
(Bio-Rad) (see section 3.4.2).
Taqman quantitative Reverse Transcription Polymerase Chain Reaction (RT-
PCR)
The expression of IP receptor across the menstrual cycle and the effects of
Iloprost on pro-angiogenic gene expression in Ishikawa cells or endometrial tissue
were investigated by Taqman quantitative RT-PCR analysis. Total RNA was
extracted from endometrial biopsies using an RNeasy Midi Kit (Qiagen Ltd, Sussex,
UK) according to the manufacturer's instructions (section 3.3.2). Samples were
treated for DNA contamination by DNA digestion during RNA purification.
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Following extraction, total RNA was eluted in 150pl of nuclease free water and
stored at -80°C. RNA was extracted from Ishikawa cells using Total RNA Isolating
Reagent (TRIR, Abgene, Surrey) as described in section 3.3.2. Extracted RNA was
again eluted in nuclease free water and stored at -80°C. Quality and concentration of
RNA was assessed using the Agilent 2100 Bioanalyser system in combination with
RNA6000nano chips (Agilent Technologies, Cheshire, UK). Only RNA that
displayed intact 18S and 28S peaks was reverse transcribed to cDNA for real-time
PCR analysis. Additionally, the concentration of the RNA extracted was confirmed
by measuring the optical density (OD) at 260nm (A260nm) as described in section
3.3.3. Once extracted and quantified, RNA samples were reverse transcribed (section
3.3.4) and subjected to real time quantitative PCR using an ABI Prism 7700
Sequence Detection System (Applied Biosystems, Warrington, UK) as previously
described in section 3.3.5. All primers and probe were designed using the PRIMER
express program (Applied Biosystems, Warrington, UK; Table 4.1)
Data were analysed and processed using Sequence Detector version 1.6.3
(Applied Biosystems, Warrington, UK) according to manufacturer's instructions.
Expression of IP receptor and pro-angiogenic genes was normalised to RNA loading
for each sample using the 18s RNA as an internal standard. Results were expressed
relative to an internal positive control of pooled human endometrial cDNA, which
was included in all reactions. Fold increase was determined by dividing the relative
expression in Iloprost-treated cells/tissues by the relative expression of the vehicle
control.
Transient transfections and immunoprecipitation
To confirm the role of EGFR in Iloprost-mediated ERK1/2 phosphorylation,
we used a dominant negative (DN) mutant EGFR. Ishikawa cells were seeded to a
density of 5x1 Cf per well in 6cm dishes and then transfected with a c-myc-tagged
ERK1/2 cDNA construct together with either empty vector cDNA (pcDNA3;
Invitrogen, de Schelp, The Netherlands) or DN-EGFR cDNA using Superfect
(Qiagen, Crawley, UK) as per the manufacturer's protocol described in section 3.4.3.
The DN-EGFR and c-myc tagged ERK constructs were a kind gift from Professor
Zvi Naor, Department of Biochemistry, Tel-Aviv University, Israel. Optimal
concentrations of cDNA for transfection were determined by titration. The
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transfection efficiency of the Ishikawa cell line had previously been investigated by
transfection with a pcDNA6/V5/His/lacZ cDNA construct (Invitrogen) and utilizing a
p-Galactosidase assay. Transfection efficiency as reported previously for this cell line
using standard procedures according to the manufacturer protocol is 45 ± 5 percent
(Sales et al., 2005). The following day, cells were starved by overnight incubation in
serum free medium containing 3pg/ml indomethacin and then treated with lOOnM
Iloprost or vehicle for 10 minutes. Cells were then lysed and protein quantified as
described above. The tagged ERK1/2 was immunoprecipitated from whole cell
lysate. For immunoprecipitation, equal amounts of protein were incubated with
specific c-myc antibody pre-conjugated to protein A Sepharose overnight at 4°C with
gentle rotation. Beads were washed extensively with lysis buffer and immune
complexes eluted and solubilised in Laemmli buffer (125 mM Tris-HCl pH6.8, 4%
SDS, 5% 2-mercaptoethanol, 20% glycerol and 0.05% bromophenol blue), boiled for
5 minutes and subjected to Western blot analysis.
Western blot analysis
Western blot analysis was conducted to investigate ERK1/2 expression in
Ishikawa cells and human endometrial tissue. A total of 50 pg of protein from whole
cell lysate was resuspended in 20 pi of Laemmli buffer. Proteins were resolved on 4-
20% Tris-Glycine gels (NOVEX, Invitrogen), transferred onto polyvinylidene
difluoride membrane (PYDF, Millipore, Watford, UK) and subjected to immunoblot
analysis as described in section 3.4.5. Blots were incubated with anti-phospho-
p42/p44 ERK (9101, Cell signalling technologies/New England Biolabs, Herts, UK)
and alkaline-phosphatase conjugated secondary antibodies (Sigma). Immunoblots
were stripped and reprobed with antibody recognizing total ERK (sc-93, Santa Cruz
Biotechnology/Autogen-Bioclear, Wiltshire, UK). Immunoreactive proteins were
visualized by the ECF chemiluminescence system according to the manufacturers
instructions (Amersham Biosciences, Amersham, UK). Proteins were revealed and
quantified by Phosphorimager analysis using a Typhoon 9400 Phosphorimager
(Molecular Dynamics, Amersham Biosciences, UK). Relative density in
immunoblots was calculated by dividing the value obtained from the phosphorylated
immunoblots by the value obtained from the total immunoblots in the same
experiment and expressed as fold increase above vehicle control.
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Immunohistochemistry
To investigate the expression of the prostacyclin receptor (IP) in human
endometrium, endometrial sections (5pm) from across the menstrual cycle were
dewaxed in xylene and rehydrated using decreasing grades of ethanol followed by
water. All washes were carried out in 0.01M phosphate buffered saline (PBS; Sigma-
Aldrich Ltd, Ayrshire, UK). Antigen retrieval was performed by pressure-cooking in
0.01M sodium citrate, pH 6.0, for 5 minutes, followed by a 20 minute cooling down
period. Thereafter, slides were sequentially incubated with 3% hydrogen peroxide
(H202; VWR Inc. Poole, UK) in distilled water for 10 minutes (to quench endogenous
peroxidase activity) followed by a 15 minute incubation with avidin and biotin
solutions (Vector Laboratories, Peterborough, UK) to block endogenous steptavidin
activity. Non-specific binding was further reduced by 20 minutes incubation with
non-immune horse serum (Vector Laboratories, Peterborough, UK) in a humidified
chamber at room temperature before overnight incubation with the primary antibody
at 4°C. For localization of IP receptor, slides were incubated with a goat polyclonal
antibody raised against a peptide mapping near the carboxy terminus of IP receptor of
human origin (sc-20436, Santa Cruz Biotechnology Inc. CA, USA) at a 1:30 dilution
in normal horse serum. Pre-absorption of the antibody with a specific blocking
peptide (Santa Cruz Biotechnology Inc.) was used as the negative control in addition
to a control goat IgG antibody at matched protein concentration to the IP antibody.
Following a wash in PBS with 0.01% Tween 20, the slides were incubated in
biotinylated horse anti-goat secondary antibody (Vector Laboratories, Peterborough,
UK) in normal horse serum at a 1:200 dilution for 60 minutes at room temperature.
Tertiary detection was carried out using an avidin-biotin peroxidase complex
(Vectastain Elite, Vector Laboratories) for 60 minutes at room temperature and
visualization carried out with the substrate and chromagen 3,3'-diaminobenzidine
(Dako Cytomation, CA, USA). Sections were counterstained with haematoxin,
dehydrated in xylene and mounted.
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Scoring and analysis of immunoreactivity
The immunostaining intensity of the IP receptor epitope in all tissue sections
was assessed in a semi-quantitative manner on a 4-point scale: 0 = no
immunostaining, 1= mild immunostaining, 2 = moderate immunostaining, 3 = intense
immunostaining. All tissue sections were scored blind by two observers. This scoring
system has been previously validated in a subset of tissue sections in which
immunoreactivity was measured with a computerised image analysis system, a strong
correlation between quantitative data derived from the image analysis and subjective
scores by a trained observer was obtained (Wang et al., 1998).
Immunofluorescent confocal laser microscopy
Co-localisation of the site of expression of prostacyclin receptor (IP) with
epidermal growth factor receptor (EGFR) or the endothelial cell marker CD31 was
performed in human endometrium by dual immunofluorescence
immunohistochemistry and confocal laser microscopy. Human endometrial sections
(5 pm) were dewaxed, rehydrated and washed as described above. The
immunohistochemical methodology was repeated for antigen retrieval by pressure
cooking, quenching of hydrogen peroxidase activity and blocking of endogenous
streptavidin activity. Non-specific binding was further reduced by 20 minute
incubation with 5% non-immune rabbit serum diluted in PBS before overnight
incubation at 4°C with the polyclonal mouse anti-EGFR primary antibody (NCL-
EGFR-384, Nova-Castra, Newcastle-upon-Tyne, UK) at a dilution of 1 in 25. For co-
localization of the IP receptor with CD31, a monoclonal mouse anti CD31 antibody
(Dako Cytomation, CA, USA) was used at a dilution of 1 in 20. Control sections were
incubated with polyclonal goat anti-IP primary antibody at a dilution of 1 in 100 in
order to demonstrate specificity of the secondary antibody for the mouse primary
antibodies. The following day, sections were washed with PBS tween and incubated
with a 1 in 500 dilution of biotinylated rabbit anti-mouse IgG for one hour. A further
one-hour incubation with the fluorochrome streptavidin 488 Alexifluor (Molecular
Probes Inc. Cambridge Bioscience, Cambridge, UK) diluted at 1 in 200 in PBS was
performed. Next, sections were incubated for 20 minutes in a PBS solution containing
biotin in order to enhance fluorescent signal before re-blocking with 5% non-immune
rabbit serum. Incubation with the goat anti-IP antibody (Santa Cruz Inc.) at a 1 in 100
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dilution at 4°C overnight was then performed. A second control slide was incubated
with mouse anti-EGFR or mouse anti-CD31 primary antibody. Incubation with a 1 in
200 dilution of rabbit anti-goat peroxidase (Vector Laboratories, Peterborough, UK)
secondary antibody was performed for 30 minutes. Tertiary detection was performed
with an 8-minute incubation with Tyramide Cy3 solution (PerkinElmer Life Sciences,
Boston, USA) at a 1 in 50 dilution as per manufacture's instructions. Slides were
counterstained with To Pro (Molecular probes Inc.), at a 1 in 2000 dilution for 2
minutes and then mounted in permafluor.
Statistics
Unless otherwise stated and where appropriate, data were subjected to
statistical analysis with ANOVA and Fishers PLSD tests (Statview 4.0; Abacus
Concepts Inc., Piscataway, NJ, USA) and statistical significance accepted when
p<0.05. Semi-quantitative scoring results for immunohistochemical staining were
analysed by a non-parametric method, the Kruskall-Wallis test, followed by Dunn's
post-hoc multiple comparison test.
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4.3 Results
Prostacyclin receptor (IP) mRNA and protein expression within
human endometrium
The IP receptor mRNA expression in human endometrium across the
menstrual cycle was determined by Taqman quantitative RT-PCR analysis (figure
4.2). IP receptor mRNA was significantly upregulated during the menstrual stage of
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Figure 4.2
Relative mRNA expression of the IP receptor in the human endometrium across the
menstrual cycle as determined by real-time quantitative RT-PCR. Results are
expressed as the mean ± S.E.M. ofrelative mRNA expression levels, b is significantly
elevated from a (p<0.05). Tissue sample numbers are; n=7 proliferative (P); n=6
early secretory (ES); n=5 mid secretory (MS); n=6 late secretory (LS); n=4
menstrual (M).
This rise in RNA expression was found to precede the expression of the IP
receptor protein as detected by immunohistochemistry. The temporal spatial
expression of the IP receptor was examined in human endometrium across the
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menstrual cycle (figure 4.3). Subjective scoring of the IP receptor immunoreactivity
showed a significant variation of temporal-spatial expression across the menstrual
cycle within the glandular epithelium of the functional layer of human endometrium
(figure 4.4). IP receptor immunostaining was greatest during the proliferative (figure
4.3 i-iii) and early secretory (figure 4.3 iv) phases within the glandular compartment
of the functional layer and was observed to decrease during the late secretory stages
(figure 4.3 vi).
Figure 4.3 Immunohistochemical localization of the IP receptor within the human
endometrium across the menstrual cycle.
Variation in temporal/spatial localization of the IP receptor is demonstrated.
Glandular epithelial immunostaining (g) was present in both basal (b) andfunctional
(f) layers. Some stromal immunostaining was demonstrated in the functional layer
only. Prominent immunostaining of vessel endothelium (v) is seen throughout full
thickness of sections within endometrial and muscularis layers. Representative
sections from; (i) early proliferative; (ii) midproliferative; (Hi) late proliferative; (iv)
early secretory; (v) mid secretory (vi) late secretory, (vii) menstrual (insert shows
control staining with primary antibody after specific peptide pre-absorbtion) and








Box-plot demonstrating results of subjective scoring of IP receptor immunostaining
within the glandular epithelium of the functional layer of human endometrium.
Statistical analysis using the non-parametric ANOVA Kruskal-Wallis test indicated
that variation of immunostaining intensity was significantly different across the
menstrual cycle (p<0.05). The data are presented as box-and-whisker plots: box
represents the 25th and 75th percentiles and the heavy bar represents the median. The
whiskers are the 10lh and 90"' percentiles. Tissue sample numbers for each stage of
the cycle are presented.
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High magnification views (figure 4.5A) of a representative endometrial section show
the plasma membrane localisation of the IP receptor, with some cytoplasmic
immunoreactivity also present. Minimal basal layer stromal immunostaining was
observed in all tissue sections across the menstrual cycle in comparison to the
functional stroma.
In addition, IP receptor immunoreactivity appeared prominent in vessel
endothelium throughout the full thickness of endometrial tissue sections, involving
vessels within the endometrial and muscularis layers (figure 4.3 viii). To establish
this immunostaining as being vascular in location, dual confocal immunofluorescence
immunohistochemistry was used to co-localize the IP receptor with the endothelial
cell marker, CD 31 (figure 4.5B). IP receptor (red) was observed to co-localise
(yellow) with CD31 (green) in the blood vessels of all tissue sections investigated
indicating that IP receptor was present in the vascular compartment.
A B
Figure 4.5
(A) High magnification (xlOO) view ofimmunohistochemical stainingfor IP receptor
within epithelial gland and blood vessel of the functional layer of early secretory
endometrium (Scale bar =10pm).
(B) Endothelial staining is confirmed by confocal immunofluorescent colocalization
(merged; yellow) of the site ofexpression of IP receptor (red; figures ii and v) with
the endothelial cell marker, CD31 (green; figures i and iv) in early secretory
endometrium. Colocalization of IP receptor with CD31 (yellow; figures Hi and vi) is
demonstrated in vascular endothelium. (Scale bar = 10pm)
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Iloprost activation of the prostacyclin receptor in the Ishikawa Cell
To investigate the role of the IP receptor in endometrial epithelial cells, the
Ishikawa endometrial epithelial cell line was used. This cell line has previously been
shown to express functional IP receptors in our laboratory.
Treatment of Ishikawa cells with lOOnM Iloprost elicited a significant time-
dependent increase in phosphorylation of the ERK1/2 pathway with maximal
phosphorylation detected at 5 minutes (figure 4.6A; p<0.05). Previous studies in the
laboratory have demonstrated that prostanoid (including PGE2 and PGF2a) signalling
to downstream MAPK pathways involves transactivation of the EGFR (Sales et al.,
2005; Sales et al., 2004a; Sales et al., 2004b). To investigate the potential
involvement of the EGFR in transducing the PGI2-IP receptor signal to ERK1/2, the
selective EGFR tyrosine kinase inhibitor, AG 1478, was used. Pre-incubation of cells
for 1 hour with the EGFR kinase inhibitor (AG1478, lOOnM) or the inhibitor of
MAPK Kinase (MEK; PD98059, 50pM) abolished the phosphorylation of ERK1/2 in
response to a 5 minute lOOnM Iloprost treatment (figure 4.6B). No significant
alteration in basal levels of ERK phosphorylation was observed in cells treated with
chemical inhibitor on its own.
In order to further confirm a role for the EGFR in mediating the signalling of
the IP receptor to ERK 1/2, Ishikawa cells were co-transfected with a c-myc-tagged
ERK cDNA construct with either a dominant negative mutant cDNA isoform of the
epidermal growth factor receptor (DN-EGFR) or empty vector cDNA (pcDNA3).
Ishikawa cells were then treated with either vehicle or lOOnM Iloprost for 5 minutes.
The tagged ERK was immunoprecipitated with anti-c-myc antibody and ERK activity
of the tagged construct was determined by Western blotting as described in section
3.4.5. Iloprost treatment of Ishikawa cells resulted in a significant phosphorylation of
ERK1/2 in cells transfected with the empty vector (figure 4.6C, lane 2). This
elevation in ERK 1/2 phosphorylation by Iloprost was abolished by co-transfection of




























Figure 4.6 ERK1/2 phosphorylation following treatment of Ishikawa cells with
1 OOnM Iloprost.
(A) Western blot analysis of time course for ERK1/2 phosphorylation. Representative
blot demonstrates phosphorylated ERK1/2 (upper panel). Total ERK1/2 was
identified by re-probing the same blot with antibody directed against total ERK
protein (lower panel). Graph shows semi-quantitative analysis ofn=4 experiments as
described in the methods. Superscripts indicate significant differences (p<0.05').
(B) Western blot analysis of the effects of chemical inhibitors on ERK1/2
phosphorylation. PD98059 is a MEK inhibitor (inhibitor of ERK phosphorylation),
AG1478 is an inhibitor of EGFR tyrosine kinase. For each, a representative blot is
shown. Graph shows semi-quantitative analysis of n=3 experiments as described in
the methods, b is significantly differentfrom a (p<0.05).
(C) Ishikawa cells were co-transfected with a c-myc-tagged ERK cDNA construct,
together with either dominant negative cDNA isoform targeted against the EGFR
(lane 3) or empty vector pcDNA (lanes 1 and 2) and subsequently stimulated with
vehicle (lane 1) or 1 OOnM Iloprost (lanes 2 and 3) for 10 minutes. The tagged ERK
construct was immunoprecipitated (IP) and ERK phosphorylation of the tagged
construct determined by Western blot analysis (WB). Graph represents semi¬
quantitative analysis of n=4 experiments as described in the methods. (- denotes
absence of agent, + denotes presence of agent; b is significantly different from a
(p<0.05).
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PGI2-IP receptor signalling in Ishikawa cells promotes the
expression of pro-angiogenic genes
Recent studies have shown that COX enzymes and prostaglandins, such as
PGE2 and PGF2a can promote angiogenesis by up-regulating the expression of pro-
angiogenic genes (Sales et al., 2005; Sales et al., 2004a; Seno et al., 2002; Sonoshita
et al., 2001; Tsujii et al., 1998) and down regulating the expression of anti-
angiogenic genes (Perchick et al., 2003). Since the IP receptor is present in the
epithelial and vascular compartment of the human endometrium, the potential role of
IP receptor signalling on the expression of the pro-angiogenic genes, bFGF, Ang-1
and Ang-2, was investigated. These genes have been shown to be regulated by
prostanoids in other model systems (Sales et al., 2002; Tsujii et al., 1998). Iloprost
stimulation of Ishikawa cells caused a significant fold increase in the mRNA
expression of the pro-angiogenic factors; bFGF, Ang-1 and Ang-2 at 24 hours
compared to earlier time points (figure 4.7A). Co-treatment of the cells with the
EGFR kinase inhibitor (AG1478, lOOnM) significantly reduced the IP receptor
induced mRNA expression of all target genes (figure 4.7B; p<0.05).
Prostacyclin receptor signalling in Human Endometrium
To correlate these findings using the Ishikawa cell line to IP receptor
signalling in human endometrium in situ, human endometrial biopsy explants were
used. In order to investigate whether IP signalling in the human endometrium
involves cross talk with EGFR, co-localisation of IP receptor with EGFR by confocal
immunofluorescence microscopy was examined. Dual immunofluorescence
immunohistochemistry (figure 4.8) confirmed co-localization (merged; yellow) of the
IP receptor (red, 4.8A and 4.8D) with the epidermal growth factor receptor (green,
4.8B and 4.8E). Co-localisation was most evident within the glandular epithelial
compartments in both the basal (A, B and C) and functional (D, E and F) layers of the



























Iloprost Iloprost + AG1478
Figure 4.7
(A) Time course demonstrating basic fibroblast growth factor (bFGF), angiopoietin-1
(Ang-1) and angiopoietin-2 (Ang-2) gene expression in Ishikawa cells in response to
lOOnM Iloprost stimulation. Results are expressed as the mean + S.E.M. (n=4
experiments), b is significantly different from a (p<0.05).
(B) mRNA expression ofbFGF, Ang-1 and Ang-2 in Ishikawa cells following
stimulation with lOOnM Iloprostfor 24 hours in the absence or presence ofEGFR
tyrosine kinase inhibitor (AG1478, lOOnM) as determined by real-time quantitative
RT-PCR. Results are expressed as the mean + S.E.M. (n=2 experiments), b is
significantly differentfrom a (p<0.05).
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Figure 4.8
Confocal immunojluorescent localization ofthe site ofexpression of IP receptor (red;
A and D) with EGFR (green; B and E) and co-localization ofIP with EGFR (merged;
yellow; C and F). Expression is demonstrated in the epithelial cells ofthe basal (A, B
and C) and functional (D, E and F) human proliferative endometrium. Inserts are
shownfor negative control sections as described in the methods. (Scale bar =10pm).
Subsequently, we assessed the effect of PGI2-IP receptor signalling on
ERK1/2 phosphorylation and pro-angiogenic gene expression in human endometrial
tissue. Treatment of human endometrial tissue explants with lOOnM lloprost (figure
4.9) caused a significant phosphorylation of ERK.1/2 after 10 minutes. Pre-incubation
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Figure 4.9
Western blot analysis of ERK1/2 phosphorylation following stimulation of human
endometrial tissue explants with 100 nM lloprost for 10 minutes in the absence or
presence ofAG1478. Graph shows semi-quantitative analysis of n=3 experiments, b
is significantly different from a (p<0.05); - denotes absence of agent, + denotes
presence ofagent.
As observed in Ishikawa cells, treatment of human endometrial tissue with
lOOnM Iloprost for 24 hours resulted in a significant increase in bFGF mRNA
expression compared with vehicle control (p<0.05). Pre-incubation of the tissue with
lOOnM AG1478 for one hour abolished the Iloprost-induced elevation of bFGF.
(figure 4.10). A similar trend in expression of the two angiopoietin genes, Ang-1 and
Ang-2, was observed in response to treatment with 1 OOnM Iloprost. Pre-incubation of
endometrial tissue with 100 nM AG1478 reduced the Iloprost-mediated elevation of






























mRNA expression of bFGF (top panel), Ang-1 (middle panel) and Ang-2 (lower
panel) within normal human endometrial tissue following stimulation with lOOnM
Iloprost for 24 hours in the presence or absence of AG1478, as determined by
quantitative RT-PCR. Results are expressed as the mean ± S.E.M. (n=4 experiments),
b is significantly differentfrom a (p<0.05).
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4.4 Discussion
During the reproductive years, in the absence of pregnancy, the human
endometrium undergoes a series of cyclical changes culminating in the process of
menstruation. This process of physiological injury and repair requires continuous
remodelling of the superficial layers of the endometrium together with a concurrent
control of vessel remodelling and formation. Studies of angiogenesis in the
endometrium have confirmed continuous cycles of angiogenic activity with a number
of peaks of activity demonstrated throughout the menstrual cycle (Smith, S. K.,
2001). The role of COX enzymes, prostanoids and prostanoid receptors in the
reproductive tract has been well documented (Jabbour and Sales, 2004; Sales et al.,
2003; Smith, S. K. et al., 1981a; Smith, S. K. et al., 1981b) and the role for
prostaglandins in the endometrium reviewed in section 1.4.2 and 1.4.3. Menstrual
problems, such as painful periods (dysmenorrhoea), endometriosis and heavy
menstrual blood loss (menorrhagia), are linked to prostaglandin signalling. Indeed
first line treatment for such complaints involves the use of non-steroidal anti¬
inflammatory drugs (NSAIDs), which inhibit COX, the rate-limiting enzyme in
prostanoid production (Anderson et al., 1976; Cameron et al., 1990; Reid and
Virtanen-Kari, 2005).
The data presented in this chapter demonstrate the expression and localisation
of the IP receptor in epithelial, endothelial and stromal cells of the human
endometrium across the menstrual cycle. IP receptor mRNA is dramatically elevated
in human endometrium during the menstrual phase of the cycle and precedes the
glandular expression of IP receptor protein, which is highest in proliferative phase of
the menstrual cycle. Activation of prostanoid receptors such as EP and FP receptors
results in initiation of numerous effector signalling pathways, including the MAPK
pathway (Milne and Jabbour, 2003; Sales et al., 2004a; Sales et al., 2004b). The
MAPK pathway is a key signalling mechanism that regulates many cellular functions
such as growth, differentiation and transformation (Lewis et al., 1998; Naor et al.,
2000). The data presented herein also demonstrates that activation of the IP receptor
induces a rapid increase in p42 ERK phosphorylation in Ishikawa cells and p42/p44
ERK phosphorylation in endometrial tissue. Interestingly the differential
phosphorylation of ERK between Ishikawa cells and endometrial biopsy tissue may
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be due the presence of other cells types (stromal and endothelial) within the biopsy
tissue compared with the homogeneity of the Ishikawa cells line. This
phosphorylation of ERK in Ishikawa cells and endometrial tissues is inhibited with
the specific chemical inhibitor of EGFR kinase or by transfection of Ishikawa cells
with a dominant negative mutant isoform of the EGFR. Moreover the expression of
the EGFR co-localised with IP receptor in the glandular epithelial compartment of the
human endometrium. Thus, as observed with prostanoid receptor signalling to
downstream ERK 1/2 in other model systems (Buchanan et al., 2003; Pai et al., 2003;
Pai et al., 2002; Sales et al., 2005; Sales et al., 2004a), in the present study, the EGFR
is in close proximity with the IP receptor. EGFR transactivation is required for the
PGE-IP induced activation of the ERK 1/2 signalling pathway within human
endometrium. Whether the EGFR is held in a complex of protein-protein interactions
with the IP receptor in the glandular epithelial compartment, or whether
transactivation of the EGFR is mediated by intermediary scaffold adapter molecules
to facilitate ERK1/2 signalling, remains to be determined.
These data also demonstrate that IP receptor activation leads to an increase in
expression of several pro-angiogenic factors, including bFGF, Ang-1 and Ang-2 in
both the Ishikawa cell and normal human endometrium. bFGF is a potent growth
factor, which is known to promote growth and proliferation of numerous cell types by
activation of membrane FGF receptor tyrosine kinases. Moreover, bFGF is also
known to have potent pro-angiogenic effects in several model systems (Polnaszek et
al., 2003; Tsujii et al., 1998), and has been implicated in promoting tumour
angiogenesis (Bossard et al., 2004; Kwabi-Addo et al., 2004) and angiogenesis in
proliferative lesions of endometriosis (Mihalich et al., 2003). The angiopoietins are a
family of growth factors that act as ligands for the largely endothelial restricted Tie-2
receptor tyrosine kinase which is essential for vascular development. Ang-1 is a Tie-2
receptor agonist, which is required for recruitment of perivascular cells leading to the
formation and stabilisation of capillaries, vessel maturation and endothelial cell
survival (Jabbour et al., 2005). Ang-1 and other angiogenic factors such as VEGF and
bFGF may act synergistically to increase vascular sprouting and branching (Jabbour
et al., 2005). In addition Ang-1/Tie-2 interaction enhances the mitogenic effect of
angiogenic factors such as VEGF on endothelial cell growth (Jabbour et al., 2005).
By contrast, Ang-2 is a natural Tie-2 receptor antagonist, destabilising cell contacts
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and thus allowing access to angiogenic factors such as VEGF. The process of
angiogenesis is thus a fine balance between the expressions of numerous pro-
angiogenic factors, all of which may be present concurrently in the cell to regulate
vascularization in response to PGE-IP receptor interaction.
Furthermore, this chapter demonstrates that the action of PGf, via the IP
receptor, on target angiogenic gene expression is dependent upon the presence of the
EGFR. It is also possible that this up-regulation of angiogenic gene expression is
mediated by ERK1/2 phosphorylation. This mechanism of target gene regulation in
reproductive cells and tissues via prostanoid-receptor interaction is in agreement with
previous studies. Transactivation of the EGFR and ERK1/2 phosphorylation, leading
to increased expression of angiogenic genes including vascular endothelial growth
factor (VEGF) has previously been shown for PGE2-EP2 receptor (Sales et al.,
2004a) and PGF2a-FP receptor interaction (Sales et al., 2005), suggesting that EGFR
transactivation is a central theme for the promotion of vascular function in the human
endometrium by prostanoids. The present study focuses on the role of PGI2-IP
receptor signalling to angiogenic genes in epithelial cells, however it is possible that
PGI2-IP receptor signalling in stromal and endothelial cells may act in a synergistic
manner to favour angiogenesis in the endometrium, since the parallel studies on
whole tissue endometrial biopsy explants are in agreement with the data derived from
the Ishikawa cell line.
The precise role of PGI2 in human endometrium remains to be fully explored,
however, PGI2 has been implicated in menstruation (Baird et al., 1996) and menstrual
disturbances, where levels are elevated in endometrial pathologies such as heavy
menstrual blood loss (menorrhagia; (Smith, S. K. et al., 1981b). It is thus possible
that vascular disturbances in the endometrium of women with menstrual pathologies
such as heavy menstrual blood loss may be exacerbated by the elevation of pro-
angiogenic factors, such as bFGF, Ang-1 and Ang-2 brought about by enhanced
PGI2-IP receptor signalling. In other studies, an aberration of expression levels of
angiogenic growth factors have been demonstrated in endometrium taken from
women with heavy menstrual bleeding, such that a decrease in expression of Ang-1
mRNA (Hewett et al., 2002) and an increase of Ang-2 protein (Blumenthal et al.,
2002) are reported in endometrium collected from women with heavy menstrual
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blood loss compared to control endometrium. These alterations of angiopoietin
expression are coincident with an increase in expression of the bFGF receptor (FGF-
Rl) in the endometrium of women with excessive menstrual blood loss compared to
control endometrium (Sangha et al., 1997).
Taken together, these results demonstrate a potential role for PGI2-IP receptor
signalling in human endometrial glandular epithelial cells in regulating the expression
of several pro-angiogenic factors, which could influence angiogenesis by acting on
adjacent endothelial cells in an autocrine/paracrine manner, and have confirmed these
observations using whole tissue biopsy explants from human endometrium.
Moreover, these studies have demonstrated a role for IP-EGFR crosstalk in
promoting angiogenic factor expression in the endometrium. Blockade of EGFR
signalling with an orally active EGFR tyrosine kinase inhibitor has been used
successfully in inhibiting angiogenesis in nude mice (Baker et al., 2002).
Additionally, in a mouse model of colorectal cancer, studies have demonstrated that a
combinatorial approach using a non-selective COX-enzyme inhibitor in combination
with an inhibitor of EGFR kinase is of greater therapeutic benefit than either
compound on their own (Torrance et al., 2000). These observations of EGFR
inhibition and the data described in the present study suggest that targeted inhibition
of EGFR function with small molecule chemical inhibitors alone or in combination
with a COX enzyme inhibitor may modulate angiogenic activity in the endometrium
with possible benefits for menstrual complaints that are associated with aberrant
expression and signalling of prostanoids and altered angiogenesis or vascular function
(Guidi et al., 1996; Hickey et al., 2000; Kooy et al., 1996; Nap et al., 2004).
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Table 4.1 Sequences ofprimers and probes usedfor Taqman RT-PCR analysis.
Ang-1 Forward 5'-CTT GTG GCC CCT CCA ATC TA-3'
Reverse 5'-TAG TGC CAC TTT ATC CCA TTC AGT T-3'
Probe 5'-TGG TTT TGT CCC GCA GTA TAG AAC ATT
CCA T-3'
Ang-2 Forward 5'-GCC GCT CGA ATA CGA TGA CT-3'
Reverse 5'-ATT AGC CAC TTG CAG CCT CTG CA-3'
Probe 5'-TTC TCC AGC ACT TGC AGC CTC TGC A-3'
FGF Forward 5'-CCG ACG GCC GCG TTG AC-3'
Reverse 5'-GAC ACA ACT CCT CTC TCT T-3'




Forward 5'-GCC CTC CCC CTC TAC CAA-3'
Reverse 5'-TTT TCC AAT AAC TGT GGT TTT TGT G-3'
Probe 5'-CCA AGA GCC AGC CCC CTT TCT GC-3'
18S Forward 5'-CGT CTA CCA CAT CCA AGG AA-3'
Reverse 5'-GCT GGA ATT ACG GGG GCT-3'




expression in women with normal
and heavy menstrual blood loss.
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5.1 Introduction
Initial studies of menstrual fluid identified vasoactive substances with the
capabilities of inducing contractions in strips of ileal muscle (Pickles, 1957). These
were subsequently identified as the prostaglandins F2a (PGF2a) and E2 (PGE2), the
two most abundant prostaglandins found in the endometrium and menstrual fluid
(Lumsden et al., 1983). Evidence has since continued to mount, supporting a role for
prostaglandins in menstruation. This evidence is reviewed in section 1.4.
The prostaglandin synthesis pathway is described in detail in section 1.3.1.
Briefly, the cyclooxygenase (COX) enzymes generate PGH2 from arachidonic acid.
There are two main isoforms of the COX enzyme, COX-1 and COX-2, which
catalyse the rate-limiting step in prostanoid synthesis. COX-1 is traditionally thought
of as a constitutively expressed enzyme in many tissues and generates prostaglandins
for normal physiological function. Recent studies have however shown an up
regulation of COX-1 expression in various carcinomas (Hwang et al., 1998;
Kirschenbaum et al., 2000; Sales et al., 2002). COX-2 is rapidly induced in cells in
response to varied stimuli (Vane et al., 1998) such as growth factors, oncogenes and
carcinogens. A role has been ascertained for COX-2 in rheumatic diseases,
inflammation and tumorigenesis amongst other pathologies (Morita, 2002).
Once synthesised, PGH2 acts as an intermediary for a specific terminal
prostaglandin synthase enzymes. Synthesised prostaglandins mediate their actions via
seven-transmembrane G-protein coupled receptors (GPCRs). PGE2 can couple to four
subtypes of GPCRs, which have been pharmacologically classified as EP1, EP2, EP3
and EP4 (Coleman et al., 1994). These receptors are often co-expressed together in
the same cell and utilize alternate and in some cases opposing intracellular signalling
pathways (Ashby, 1998). EP2 and EP4 receptors, previously demonstrated in human
endometrium (Milne et al. 2001), are coupled to Gas and adenylyl cyclase, resulting
in increased formation of cyclic AMP (cAMP). PDE4 is a member of the
phosphodiesterase family of enzymes that has been previously demonstrated in
human endometrium (Bartsch et al., 2004) and is specific for hydrolysis of cAMP
(Sanz et al., 2005). The level of accumulation of the second messenger, cAMP, in
response to prostaglandin signalling may therefore, in part, be dependent upon the
level of PDE4 activity. The PGE2 pathway has previously been implicated in the
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problem of heavy MBL (Smith, S. K. et al., 1981a; Willman et al., 1976) although
specific signalling mechanisms have yet to be elucidated.
Previous investigations into the aetiology of heavy menstrual blood loss
(reviewed in section 1.4.2 and 1.4.3) have not been able to discover any differences in
circulating steroid hormone levels (Eldred and Thomas, 1994) or any specific
histological differences within the endometrium (Rees et al., 1984) of women with
heavy MBL compared to women with normal MBL. Additionally, there is no
difference in endometrial expression of oestrogen and progesterone receptors
(Critchley et al., 1994). However, evidence does exist implicating local mediators, in
particular prostaglandins (Sales et al., 2003). Increased levels of total prostaglandins
have been found in endometrium taken from women with heavy MBL (Smith, S. K.
et al., 1981a). furthermore, treatment using inhibitors of COX enzymes have
repeatedly been shown to reduce menstrual blood loss (Bonnar et al., 1996; Cameron
et al., 1990; Coulter et al., 1995) implicating disturbances of prostaglandin pathways
in the aetiology of heavy menstrual bleeding although the mechanisms underlying the
cause of heavy blood loss remain to be elucidated.
The aim of this chapter is to firstly, outline the expression of the
cyclooxygenase enzymes in human endometrium; secondly, determine the pattern of
expression of the various components of the COX-prostaglandin signalling pathways
present in the endometrium of women with both normal (<80ml) and heavy MBL
(>80ml); and thirdly, to examine the functional capabilities of the PGE2 signalling
pathways within endometrium taken from women with normal and heavy menstrual
blood loss. These aims are based upon the hypothesis that disturbances of local
mediator signalling, including prostaglandin signalling, are implicated in the
aetiology of heavy menstrual blood loss.
118
5.2 Methods
Tissue Collection and Measurement of Menstrual Blood Loss
Patients complaining of heavy menstruation were recruited from the
gynaecological outpatient setting. Ethical approval was obtained from Lothian
Research Ethics Committee and written informed consent was obtained from all
subjects before tissue collection. (The patient information sheet and ethical approval
are included in Appendices.) All subjects were aged 18 to 50 years of age (range 22
to 49; mean 40 years of age). All subjects reported regular menstrual cycles (cycle
length, 21-35 days) with no unscheduled, non menstrual, bleeding. No woman had
received hormonal preparation in the 3 months preceding biopsy collection. Patients
were clinically examined and clinical pelvic abnormalities, such as an enlarged
uterus, were further investigated by pelvic ultrasound imaging. Patients with known
uterine pathology such as fibroid disease and endometriosis were excluded from the
study.
Endometrial biopsies (n=26) were collected for research purposes at different
stages of the menstrual cycle with an endometrial suction curette (Pipelle, Laboratoire
CCD, Paris, France) from women with measured MBL. No suction curette biopsies
were taken during the menstrual phase of the cycle due to technical difficulties in
obtaining sufficient quantities of endometrium suitable for RNA analysis.
Table 5.1 Summary of endometrial biopsies collected from women with
measured menstrual blood loss.







Unclassifiable / Excluded 1 2
Immediately after collection, tissue was divided, transferred into RNA Later
(Ambion Inc, Huntingdon, UK) and stored at -70°C (for RNA extraction); fixed in
neutral buffered formalin for wax embedding (for immunohistochemical analysis and
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histological dating); and placed in RPMI 1640 medium (containing 2 mM L-
glutamine, 100 U penicillin and 100 pg/ml streptomycin) and transported to the
laboratory for in vitro culture.
In addition to consenting to provide an endometrial biopsy, patients agreed to
undergo measurement of menstrual blood loss (MBL) over one menstruation.
Measurement was based on a modified alkaline-haematin method as previously
described (Hallberg, Nilsson, 1964); see section 3.1.2). Briefly, used sanitary
products were added to a measured volume of 5% sodium hydroxide (between 2 to 4
litres). The contents were then left for 48 hours to allow conversion of haemoglobin
to haematin. During this same time period a 1 in 200 dilution of the patient's venous
blood in 5% sodium hydroxide was made and additionally stored. After 48 hours, an
aliquot of sodium hydroxide was removed from the volume soaking the sanitary
products and filtered through hardened filter paper (Whartman No 54, Maidstone,
UK). The optical density (OD) of menstrual blood loss solution and venous blood
sample were then measured using spectrophotometry at 546nm (A546).
MBL was then calculated as a quantity of patient's own venous blood using
the following equation (van Eijkeren et al., 1986);
(OD of Menstrual Blood Solution x Total Volume of added NaOH)
MBL =
(OD of Venous Blood x 200)
Validation work for this method of measuring menstrual blood loss has
previously been carried out by a collaborating research group based in Glasgow (data
not shown, see acknowledgements). The range of measured MBL was between 10ml
and 567ml with a median MBL of 42ml for the normal group (MBL <80ml) and a
median of 183ml for the heavy group (MBL >80ml). The quantification of menstrual
blood loss was not normally distributed (figure 5.1). All patients provided informed
consent for collection of an endometrial biopsy during the month proceeding or
immediately following collection of their menstrual loss.
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Measured menstrual blood loss (ml)
Figure 5.1 Distribution of measured menstrual blood loss plotted against patient
numbers
Graph demonstrates the range of measured menstrual blood loss plotted against the
patient numbers for each level ofmenstrual bleeding. Twenty-nine subjects provided
a menstrual collection for measurement with a range ofmenstrual blood loss between
10ml and 567ml.
In addition, full thickness endometrial biopsies at all stages of the menstrual
cycle (n=33), were previously collected from women undergoing hysterectomy for
benign gynaecological indications. These tissue sections were fixed in neutral
buffered formalin and wax embedded. Immunohistochemical analysis of the temporal
and spatial expression of the proteins involved in prostaglandin signalling (COX-1,
COX-2, FP, EP2, EP4 and IP) was then performed upon the tissue sections. Analysis
of expression within full thickness endometrial sections, allowed confirmation of
immunohistochemical staining techniques by comparison with previously published
work. In addition, carrying out immunohistochemistry on full thickness endometrial
tissue sections could provide a detailed immunostaining pattern for comparison with
the endometrial suction biopsies taken from women with measured MBL.
All biopsies were dated according to stated last menstrual period (LMP) and
dating was confirmed by histological assessment according to criteria of Noyes and
co-worker (Noyes, 1950). Furthermore, circulating oestradiol and progesterone serum
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levels were measured at the time of biopsy collection and were consistent for both
LMP and histological assignment of menstrual cycle stage. This is a robust method
for characterizing endometrial samples. Detailed gene microarray studies support this
method for characterizing endometrial samples with consistency across these three
parameters (Critchley et al., 2006; Talbi et al., 2006).
Inconsistencies between measured circulating hormone levels, stated day of last
menstrual period and/or histological assessment led to exclusion of three tissue
biopsies from the study.
Taqman quantitative Reverse Transcription Polymerase Chain Reaction (qRT-
PCR)
The expression of COX enzymes (COX 1&2) across the menstrual cycle and
expression of prostanoid receptors in endometrium characterised by MBL were
investigated by quantitative RT-PCR. Total RNA was extracted from endometrial
biopsies using the commercially available product RNeasy Midi Kit (Qiagen Ltd,
Sussex, UK) according to the manufacturer's instructions (see section 3.3.2). Each
tissue sample was able to provide sufficient quantities of RNA for complete analysis
of target genes. Samples were treated for DNA contamination by DNA digestion
during RNA purification. Following extraction, total RNA was eluted in 150pl of
nuclease free water and stored at -80°C. Quality of RNA was assessed using the
Agilent 2100 Bioanalyser system in combination with RNA6000nano chips (Agilent
Technologies, Cheshire, UK). Only RNA that displayed intact 18S and 28S peaks
was reverse transcribed to cDNA for real-time PCR analysis. Once extracted and
quantified, RNA samples were reverse transcribed as previously described in section
3.3.4. Thereafter, cDNA samples were stored at -20°C. A tube with no reverse
transcriptase was included to control for any DNA contamination.
Real time quantitative PCR was performed using an ABI 7700 Sequence
Detection System (Applied Biosystems, Warrington, UK) as previously described
(see section 3.3.5) using duplicate samples. A no template control (containing water)
was included. The inclusion of ribosomal 18S primers and probes was used to act as a
housekeeping gene for each reaction mix. cDNA obtained from a single sample of
endometrial tissue was included as a duplicate in all experiments to act as a relative
standard against which all expression levels are compared. All primers and probes
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were designed using the PRIMER express program (Applied Biosystems,
Warrington, UK) and their sequences can be found in table 5.2.
Data were analysed and processed using Sequence Detector version 1.6.3
(Applied Biosystems, Warrington, UK) according to manufacturer's instructions.
Expression of target genes were normalised to RNA loading for each sample using
18S ribosomal RNA as an internal standard. All results were expressed relative to the
standard cDNA obtained from a single sample of endometrial tissue and included in
all experiments.
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Table 5. 2 Sequences ofprimers and probes usedfor Taqman RT-PCR analysis.
COX-1 Forward 5'-TGT TCG GTG TCC AGT TCC AAT A-3'
Reverse 5'-ACC TTG AAG GAG TCA GGC ATG AG-3'
Probe 5'-CGC AAC CGC ATT GCC ATG GAG T-3'
COX-2 Forward 5'-CCT TCC TCC TGT GCC TGA TG-3'
Reverse 5'-ACA ATC TCA TTT GAA TCA GGA AGC T-3'
Probe 5'-TGC CCG ACT CCC TTG GGT GTC A-3'
PGES(MT) Forward 5'-CCT CAT CAG CAA GCG ACT-3'
Reverse 5'-CCA CTT GTC AGC AGC CTC A-3'
Probe 5'-AGC AGG CAC CGC CTC CAG-3'
EP1 Forward 5'-AGA TGG TGG GCC AGC TTG T-3'
Reverse 5'-GCC ACC AAC ACC AGC ATT G-3'
Probe 5'-CAG CAG ATG CAC GAC ACC ACC ATG-3'
EP2 Forward 5'-GAC CGC TTA CCT GCA GCT GTA C-3'
Reverse 5'-TGA AGT TGC AGG CGA GCA-3'
Probe 5'-CCA CCC TGC TGC TGC TTC TCA TTG TCT-3'
EP3 Forward 5'-GAC GGC CAT TCA GCT TAT GG-3'
Reverse 5'-TTG AAG ATC ATT TTC AAC ATC ATT ATC A-3'
Probe 5'-CTG TCG GTC TGC TGG TCT CCG CTC-3'
EP4 Forward 5'-ACG CCG CCT ACT CCT ACA TG-3'
Reverse 5'-AGA GGA CGG TGG CGA GAA T-3'
Probe 5'-ACG CGG GCT TCA GCT CCT TCC T-3'
PGFS Forward 5'-GGG ATC TCA ACG AGA CAA ACG-3'
Reverse 5'-AAA GGA CTG GGT CCT CCA AGA-3'
Probe 5'-TGG ACC CGA ACT CCC CGG TG-3'
FP Forward 5'-GCA GCT GCG CTT CTT TCA A-3'
Reverse 5'-CAC TGT CAT GAA GAT TAC TGA AAA AAA TAC-3'
Probe 5'-CAC AAC CTG CCA GAC GGA AAA CCG-3'
TBXS Forward 5'-CAG GTG TTG GTT GAG AAC TTC AGT A-3'
Reverse 5'-TGT CGG CTA CCG ACT TGA ACT-3'
Probe 5'-CAA ACC CGA CGC CAT TCT GTT GGT AAA G-3'
TBXR Forward 5'-TGG TGG TGG CCA GCG T-3'
Reverse 5'-CGG GTT TCG CAG CAC TGT-3'
Probe 5'-TGC CCC TTC TGG TCT TCA TCG CCC-3'
PGIS Forward 5'-ACG CAG ATG TGG AGA TCC CT-3'
Reverse 5'-GTC GTG TTC CGG CTG CA-3'
Probe 3'-CCT CAG CAG GTA CGG CTT CGG TCT G-5'
IP Forward 5'-GCC CTC CCC CTC TAC CAA-3'
Reverse 5'-TTT TCC AAT AAC TGT GGT TTT TGT G-3'
Probe 5'-CCA AGA GCC AGC CCC CTT TCT GC-3'
PDE4B Forward 5'-CCT TCA GTA GCA CCG GAA TCA-3'
Reverse 5'-CAA ACA AAC ACA CAG GCA TGT AGT T-3'
Probe 5'-AGC CTG CAG CCG CTC CAG CC-3'
18S Forward 5'-CGT CTA CCA CAT CCA AGG AA-3'
Reverse 5'-GCT GGA ATT ACG GGG GCT-3'
Probe 5'-TCG TGG CAC CAG ACT TGC CCT C-3'
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Immunohistochemical analysis of cyciooxygenase 1, cyclooxygenase 2 and
prostanoid receptors in human endometrium
To investigate the expression of the COX 1 and 2 enzymes and prostanoid
receptors in human endometrium, endometrial sections (5 pm) were dewaxed in
xylene and rehydrated using decreasing grades of ethanol. General
immunohistochemical protocols were carried out as described in section 3.2.2 after
preliminary optimization experiments had been performed to determine the best
protocol environment and antibody concentrations (see table within section 3.2.4 and
section 3.2.5 for experimental details). Sections were counterstained with
haematoxin, dehydrated in xylene and mounted.
Scoring and analysis of immunoreactivity
The immunostaining intensity of target epitopes in all tissue sections were
assessed in a semi-quantitative manner on a 4-point scale: 0 = no immunostaining, 1 =
mild immunostaining, 2 = moderate immunostaining, 3 = intense immunostaining.
All tissue sections were scored blind by two observers. This scoring system has been
previously validated in a subset of tissue sections in which immunoreactivity was
measured with a computerised image analysis system, a strong correlation between
quantitative data derived from the image analysis and subjective scores by a trained
observer was obtained (Wang et al, 1998).
Whole tissue cAMP Assay
Endometrial biopsies from proliferative and secretory phases of the menstrual
cycle were minced finely with scissors and incubated overnight in RPMI medium
containing 3pg/ml indomethacin (an inhibitor of COX-1 and COX-2 enzymes).
Following overnight treatment, approximately 1/3 of the tissue was removed and
stored at -20°C. The remaining tissue was incubated in the same medium containing
ImM l-methyl-3-isobutylxanthine (IBMX, Sigma, Poole, UK) for 30 minutes.
(IBMX inhibits the action of phosphodiesterases and prevents the rapid degradation
of cAMP.) It was then divided into two portions and treated with control medium or
lOOnM PGE2 for 10 minutes. Tissue was then lysed in 0.1M HC1 and frozen until
assayed. Cyclic AMP concentration was measured by ELISA (Biomol, Affiniti,
Exeter, UK) in accordance with manufacturer's instructions and normalised to protein
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concentration determined by protein assay according to manufactures instructions
(Bio-Rad, Hemel Hempstead, UK, see section 3.4.2 for more detailed methodology).
Statistical Analysis
Where data did not consistently fulfil the assumptions necessary for using
analysis of variance and t-test, the non-parametric Mann-Whitney test was used
(Graphpad InStat3) and statistical significance accepted when p<0.05.
Semi-quantitative scoring results (non-continuous data) for
immunohistochemical staining were analysed by a non-parametric method, the
Kruskall-Wallis test, followed by Dunn's post-hoc multiple comparison test.
Normally distributed data such as the cyclic AMP assay data were subjected
to statistical analysis with ANOVA and Fishers PLSD tests (Statview 4.0; Abacus





COX mRNA and protein expression within the human endometrium
across the menstrual cycle
The expression of COX1 and 2 mRNA in human endometrium was
determined by Taqman quantitative RT-PCR analysis (figure 5.2). No significant
differences in expression were discovered for COX-1. COX-2 mRNA was shown to
be significantly upregulated during the menstrual stage of the cycle when compared
to proliferative, mid-secretory and late secretory endometrium (p<0.05). A significant
increase of COX-2 mRNA expression was also noted in early secretory endometrium
(figure 5.2).
Standard immunohistochemical techniques successfully demonstrated spatio-
temporal expression of COX-1 and -2 proteins within the endometrium (figure 5.3A
and 5.4A). COX-1 immunostaining is demonstrated within glandular epithelial
compartment of both basal and functional layers. Some stromal immunostaining for
COX-1 was demonstrated in the functional layer only. Vascular endothelial,
perivascular cell and strong white blood cell immunostaining is also noted for COX-
1. COX-2 immunostaining is also found within the glandular epithelial compartment
of both basal and functional layers. The stromal compartment demonstrates
immunostaining within the functional layer only. Very little vascular endothelium or
perivascular cell immunostaining is noted for COX-2. Subjective scoring of both
COX isoform's immunostaining demonstrates a significant variation of temporal
spatial expression across the menstrual cycle within normal endometrium (figure
5.3B and 5.4B). There is a significant variation in protein expression levels within the
stroma of the function layer of the endometrium for COX-1 across the menstrual
cycle. Variation of temporal spatial COX-2 protein expression is significant within
the glandular and stromal compartments of the functional layer of the endometrium
and also within the glandular compartment of the basal layer.
Similar localisation of COX-1 and COX-2 is noted within the endometrium,
however additional COX-1 staining is prominently seen within white blood cells of
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Figure 5.2
Relative mRNA expression of COX 1 and 2 in the human endometrium across the
menstrual cycle as determined by real-time quantitative RT-PCR. Results are
expressed as the mean ± S.E.M. of relative mRNA expression levels. Note the
magnitude ofchange for COX-2 is greater than COX-1, hence the difference ofscales
for y-axis. b is significantly elevated from a (p<0.05). Tissue sample numbers are;
n=7 proliferative (P); n=5 early secretory (ES); n=5 mid secretory (MS); n=6 late
secretory (LS); n=4 menstrual (M).
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Figure 5.3 Cyclooxygenase 1 Immunohistochemistry
(A) Immunohistochemical localization of COX-1 within the human endometrium
across the menstrual cycle. Variation in temporal/spatial localization of COX-1 is
demonstrated. Glandular epithelial immunostaining (g) was present in both basal (b)
and functional (f) layers. Some stromal immunostaining was demonstrated in the
functional layer only. Representative sections from; (i) proliferative (insert shows
control staining with primary antibody after specific peptide pre-absorbtion); (ii)
early secretory; (Hi) mid secretory; (iv) late secretory; (v) menstrual are shown, (vi)
High magnification view of the functional layer of late secretory endometrium
demonstrating immunohistochemical staining for COX-1 within epithelial gland and
spiral arterial blood vessel endothelial and perivascular cells (v). Note the strong
immunostaining ofwhite blood cells distributed around the spiral arteriole vessel (v).
(B) Box-plots demonstrating results of subjective scoring of COX-1 immunostaining
within the cellular compartments of human endometrium. Statistical analysis using
the non-parametric ANOVA Kruskal-Wallis test indicated that variation of
immunostaining intensity was significantly different across the menstrual cycle
(p<0.05) for COX-1 within the stroma of the functional layer. The data are presented
as box-and-whisker plots: box represents the 25th and 75th percentiles and the heavy
bar represents the median. The whiskers are the 10th and 90th percentiles. P,
proliferative (n=16); ES, early secretory (n=6); MS, mid secretory (n=5); LS, late
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Figure 5.4 Cyclooxygenase 2 Immunohistochemistry
(A) Immunohistochemical localization of COX-2 within the human endometrium
across the menstrual cycle. Variation in temporal/spatial localization of COX-2 is
demonstrated. Glandular epithelial immunostaining (g) was present in both basal (b)
and functional (f) layers. Some stromal immunostaining was demonstrated in the
functional layer only. No vessel staining was detected in the vessel endothelium
within the basal layer. Representative sections from; (i) proliferative; (ii) early
secretory (insert shows control staining with primary antibody after specific peptide
pre-absorbtion); (Hi) mid secretory; (iv) late secretory; (v) menstrual are shown, (vi)
High magnification view of immunohistochemical staining for COX-2 within the
functional layer of late secretory endometrium. Note the reduced immunostaining
within vessel endothelium and perivascular cells compared to figure 5.3 vi. There is
also an absence of immunostainingfor white blood cells.
(B) Box-plots demonstrating results of subjective scoring of COX-2 immunostaining
within the cellular compartments of human endometrium. Statistical analysis using
the non-parametric ANOVA Kruskal-Wallis test indicated that variation of
immunostaining intensity was significantly different across the menstrual cycle
(p<0.05) for COX-2 within the epithelial glands and stroma of the functional layer
and also within the epithelial glands of the basal layer. The data are presented as
box-cind-whisker plots: box represents the 25th and 75th percentiles and the heavy bar
represents the median. The whiskers are the 10th and 90th percentiles. P, proliferative
(n=16); ES, early secretory (n=6); MS, mid secretory (n=5); LS, late secretory
(n=5); M, menstrual (n=2).
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Cyclooxygenase mRNA and protein expression within endometrium
obtained from women with measured menstrual blood loss.
Quantitative RT-PCR analysis
Analysis of mRNA expression for a variety of genes associated with
prostanoid signalling within the endometrium by quantitative RT-PCR was
performed. Analysis of COX-1 and COX-2 mRNA expression demonstrated a
significant increase in secretory endometrium of women with MBL in excess of 80ml
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Figure 5.5
Box-plot demonstrating relative cyclooxygenase-1 (COX-1) and cyclooxygenase-2
(COX-2) mRNA expression in proliferative and secretory endometrium of women
with normal and heavy measured menstrual blood loss (normal MBL <80ml, heavy
MBL >80ml). The data are presented as box-and-whisker plots: box represents the
25th and 75th percentiles and the heavy bar represents the median. The whiskers are
the 10th and 90th percentiles. NP, normal proliferative (n=7); HP, heavy proliferative




Immunohistochemical staining was performed upon the suction curette
endometrial biopsies obtained from women with measured menstrual blood loss for
the inducible form of the cyclooxygenase enzyme-COX2. Immunostaining intensities
were analysed and subjectively scored using a semi quantitative scoring system
(section 3.2.3). No differences in protein expression were detected in the different
endometrial cellular compartments between women with normal and heavy MBL. An
explanation for the lack of detection of differences in protein expression to support
mRNA data is proposed in this chapter's discussion.
Prostanoid receptor and synthase expression within endometrium
obtained from women with measured menstrual blood loss
Quantitative RT-PCR analysis
Analysis of synthase enzymes and respective prostanoid receptors
downstream of COX action within prostaglandin signalling was performed. There
were no significant differences in mRNA expression detected for the prostanoid
synthase enzymes - prostacyclin, thromboxane, PGE2 and PGF2tt synthases.
No significant differences in endometrial expression were detected for
prostacyclin or thromboxane receptors. PGE2 has four known receptors for its ligand
action. No significant differences in expression were detected between the two groups
of endometrial samples for EP2, EP3 and EP4. The mRNA expression of the PGE2
receptor, EP1, was significantly increased in secretory endometrium of women with
heavy MBL compared with normal MBL. Finally, mRNA expression of the receptor
for PGF2cc (FP) was significantly reduced in proliferative endometrium of women
with heavy MBL compared to normal MBL (figure 5.6).
ImmunohistochemicaI analysis
In addition to immunohistochemistry for COX2, staining was performed upon
the suction curette biopsies collected from women with measured MBL for PGE2
receptors EP2 and EP4 together with the IP receptor (chapter 4). Using a semi
quantitative scoring system to measure scoring intensity, no differences were noted
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between endometrial groups classified according to menstrual blood loss. An
explanation for the lack of detection of differences in protein expression to support
mRNA data is proposed in this chapter's discussion.
Functional PGE2 receptor signalling in endometrium of women with
measured MBL
The PGE2 pathway has previously been implicated in the problem of heavy
MBL (Smith, S. K. et al., 1981a; Willman et al., 1976). The PGE2 receptors, EP2 and
EP4, are known to activate the cAMP / protein kinase A pathway within the human
endometrium (Milne et al., 2001; Regan, 2003). To investigate potential differences
in PGE2 receptor function between endometrial samples of women with measured
MBL, we therefore looked at cAMP production as an endpoint for receptor function.
Cyclic AMP production in response to treatment with lOOnM PGE2 was
higher in endometrial tissue explants collected from women with heavy MBL
compared to endometrium from women with normal MBL (figure 5.1A).
As described, analysis of prostanoid receptor mRNA expression did not detect
any significant differences for EP2 or EP4 in endometrium of women with measured
MBL. Therefore, in order to investigate whether effects at the post-receptor level
could explain this enhanced functionality of the EP receptor, we investigated the
expression of phosphodiesterase isotype 4B (PDE4B) in the same endometrial
samples. PDE4 is a member of the phosphodiesterase family of enzymes that has
been previously demonstrated in human endometrium (Bartsch et al., 2004) and is
specific for hydrolysis of cAMP (Sanz et al., 2005). Quantitative RT-PCR analysis
demonstrated a significant reduction in expression of PDE4B in secretory
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Composite figure of box-plot graphs demonstrating relative mRNA expression for
prostanoid receptors in proliferative and secretory endometrium of women with
normal and heavy measured menstrual blood loss (normal MBL <80ml, heavy MBL
>80ml). The data are presented as box-and-whisker plots: box represents the 25th
and 75th percentiles and the heavy bar represents the median. The whiskers are the
10th and 90th percentiles. NP, normal proliferative (n=7); HP, heavy proliferative
(n=5); NS, normal secretory (n=6); HS, heavy secretory (n=5). EP1 to EP4 are the
receptors for prostaglandin E2; FP is the receptor for prostaglandin F2a; TBXR is
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Figure 5.7
A) Cyclic AMP (cAMP) production by endometrial tissue explants in response to a 10
minute stimulation with lOOnM PGE2 or vehicle. Graph shows average fold increase
in cAMP production by endometrium from women with normal and heavy menstrual
blood loss (normal MBL <80ml, heavy MBL >80ml). * indicates significant elevated
cAMP production (p<0.05).
B) Phophodiesterase 4B (PDE4B) mRNA expression in endometrium from women
with normal and heavy menstrual blood loss (normal MBL <80ml, heavy MBL
>80ml) as determined by real time quantitative RT-PCR. The data are presented as
box-and-whisker plots: box represents the 25th and 75th percentiles and the heavy bar
represents the median. The whiskers are the 10th and 90th percentiles. NP, normal
proliferative (n = 7'); HP, heavy proliferative (n-5); NS, normal secretory (n=6); HS,
heavy secretory (n-5). * indicates significant difference (p<0.05).
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5.4 Discussion
This study demonstrates a significant variation in temporal and spatial protein
expression for COX-1 in the endometrial stroma of the functional layer. Otherwise,
very little change in expression of either mRNA or protein is noted for COX-1 in the
endometrial compartments across the menstrual cycle. However, COX-2
demonstrates marked changes in mRNA expression across the menstrual cycle with
co-ordinating differences in protein expression noted, particularly within the
endometrial functional layer. These observations are consistent with current thinking
that, in the normal physiological state, cells responsible for prostaglandin production
constitutively express COX-1 and that COX-2 is the inducible form of the enzyme.
However, it is important to note that previous studies have demonstrated an up
regulation of COX-1 in various carcinomas (Sales et al., 2002). This present study
also demonstrates significantly elevated levels in mRNA expression of both COX-1
and COX-2 in endometrium obtained from women with measured heavy MBL,
thereby adding heavy menstrual blood loss to the list of gynaecological complaints
demonstrating an alteration in expression of both COX enzymes. Clinically, these
data suggest that it is important to use a general inhibitor of both COX-1 and COX-2
enzyme action for treatment of the complaint of heavy menstruation. Mefenamic
acid, a COX inhibitor and member of the Fenamate family of drugs, is routinely used
as a first line treatment for heavy menstrual bleeding (Reid and Virtanen-Kari, 2005).
As well as inhibiting prostaglandin synthesis, fenamates have been shown to inhibit
binding of PGE2 to its receptors (Rees et al., 1988). In keeping with this dual mode of
action, the PGE2 pathway has previously been implicated in the problem of heavy
menstrual blood loss. Elevated levels of PGE2 have been found in endometrium of
women complaining of heavy periods (Willman et al., 1976) and further experiments
confirmed an apparent shift in synthesis in favour of PGE2 over PGF2a in the
endometrium of women with heavy MBL (Smith, S. K. et al., 1981a).
These current data demonstrate an enhanced PGE2-EP induced cAMP
production in endometrium obtained from women with heavy MBL, however the
expression of mRNA for EP2 and EP4 receptors, which are known to couple to
cAMP production, does not display any significant correlation with measured MBL
in the present studies. Previous published data have demonstrated an increase in
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PGE2 binding sites in uterine tissue associated with the complaint of heavy MBL
(Adelantado et al., 1988) although specific receptor subtypes were not identified.
Indeed, it is plausible that EP2 and EP4 receptor numbers could be regulated at the
post-transcriptional level resulting in increased PGE2 receptor binding sites. However,
in this study, no differences in expression of protein levels for EP2 and EP4 were
detected using immunohistochemical techniques. Analysis of protein expression
would have been best performed using western blot techniques, however not enough
tissue quantity was available to perform these experiments.
PGF20C and PGE2are two prominent prostaglandins found in human
endometrium (Lumsden et al., 1986b). In the endometrium, PGF2« receptor (FP) and
PGE2 receptors EP2 and EP4 are responsible for their respective ligand action. Whilst
there was a reduction in expression of FP mRNA in the endometrium taken from
women with heavy MBL, no changes in the expression of EP2 and EP4 mRNA were
found. Therefore, a shift of endometrial prostaglandin signalling in favour of the
PGE2 pathway over the PGF2a pathway may exist in the endometrium of women with
heavy MBL. Previous work has shown a decrease in the PGF2a / PGE2 ratio in the
endometrium of women with measured heavy MBL compared to women with normal
MBL (Smith, S. K. et al., 1981a).
Immunohistochemistry confirmed the cellular localization of expression for
COX-2 and the prostanoid receptors. These immunostaining patterns are consistent
with previous published studies (Battersby et al., 2004b; Jones et al., 1997; Milne et
al., 2001). Using a semi quantitative analysis of staining intensity, no differences in
protein expression could be detected in endometrium from women with heavy
menstrual blood loss compared to normal MBL. It is expected that protein expression
is temporally and spatially regulated within human endometrium (Battersby et al.,
2004a; Nayak et al., 2000). However, in order to demonstrate this variation, analysis
of full thickness endometrial biopsies, collected at the time of hysterectomy, is
preferable. Our endometrial samples were collected by suction curette from,
predominantly, the superficial layers of the endometrium. Unfortunately, this
mechanism of tissue collection only samples a small portion of the endometrium and
tissue architecture is disrupted during the collection process. As patients were not
undergoing a hysterectomy, we did not have the benefit of access to full thickness
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endometrial biopsies to detect the subtle differences of protein expression expected to
exist.
Although it would have been preferable to have quantified protein expression
using immunohistochemical staining techniques we feel it is more important that we
were able to demonstrate a significant difference in the functional endpoint of the
PGE2 signalling pathway between endometrium taken from women with both normal
and heavy menstrual blood loss (figure 5.7A).
The COX2-PGE2-EP pathway has previously been shown to influence
angiogenic factors such as vascular endothelial growth factor (VEGF) through a
mechanism mediated by cAMP (Sonoshita et al., 2001). Therefore, the enhanced
ability for cAMP production by endometrium taken from women with heavy
menstrual blood loss may have important effects on the expression of angiogenic
factors. Altered endothelial function as a result of disturbances to angiogenic factors
has previously been implicated in heavy menstrual blood loss (Kooy et al., 1996).
Thromboxane and prostacyclin are implicated in platelet function and
vascular haemostasis (Grosser et al., 2006) and there is strong expression of their
respective receptors in the endometrial vascular compartment (Chapter 4, Figure 4.4;
Battersby, unpublished data). However, no differences in expression of the genes
involved in their signalling pathways downstream of COX enzymes were detected
between the two groups of endometrium from women with heavy and normal MBL.
Phosphodiesterases (PDE) are a large family of enzymes that are responsible
for the hydrolysis of cyclic nucleotides (Sanz et al., 2005). PDE4B is an isoenzyme
that is found in the human endometrium (Bartsch et al., 2001; Bartsch et al., 2004)
and shows specificity for hydrolysis of cAMP. We have shown that in addition to an
enhanced ability to produce cAMP in response to PGE2, endometrium taken from
women with heavy MBL expresses a significantly reduced level of PDE4B isoform
mRNA.
In summary, increased expression of the rate limiting COX enzymes in
endometrium from women with heavy MBL will lead to an increase in prostaglandin
production and signalling. In addition, enhanced functionality of the EP receptors
coupled to cAMP production could in part be explained by a reduction in PDE4B
expression within endometrium of women with heavy MBL. These data therefore
present a novel mechanism of endometrial prostaglandin signalling that may lead to
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the complaint of heavy menstruation. Enhanced COX-PGE2 signalling and reduced
PDE4B expression in endometrium from women with heavy MBL presents us with
new therapeutic opportunities in the treatment of heavy menstrual bleeding.
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Chapter 6
The effect of the Selective Progesterone
Receptor Modulators (SPRM;
asoprisnil) upon prostaglandin




The following chapter includes work supported by TAP Pharmaceuticals
Products Inc., Lake Forest, IL 60045, USA.
Progesterone plays a crucial role in controlling various reproductive functions.
The isolation of progesterone in 1934 (Allen WM, 1934) led to the search for
synthetic, orally active progestins (PR agonists) that have found broad applications in
fertility control and hormone therapy. Since the discovery of mifepristone (Baulieu,
1989), several progesterone antagonists (PAs) became available for potential clinical
use. More recently, selective progesterone receptor modulators (SPRMs) have been
synthesised and biologically characterised.
SPRMs represent a new class of PR ligands that exert clinically relevant
tissue-selective progesterone agonist, antagonist, partial, or mixed agonist/antagonist
effects on various progesterone target tissues in an in vivo situation depending on the
biological action studied (Chwalisz et al., 2005)). Asoprisnil (J867) is a novel
steroidal compound that belongs to the class of 1 ip-benzaldoxime-substituted
estratrienes (Chwalisz et al., 2005). Asoprisnil demonstrates a high degree of receptor
and tissue selectivity, with high-binding affinity for PR, moderate affinity for
glucocorticoid receptor (GR), low affinity for androgen receptor (AR), and no
binding affinity for oestrogen or mineralocorticoid receptors (DeManno et al., 2003).
Primate studies first provided evidence that the use of SPRM may induce
amenorrhoea by directly targeting the endometrium and have direct endometrial
antiproliferative effects at all times in the menstrual cycle (Chwalisz et al., 2006).
Similar effects have since been confirmed in women (Chwalisz et al., 2004). In
addition to inducing amenorrhoea, asoprisnil has been shown to shrink fibroid
volumes, improve symptoms associated with fibroids and reduce endometriosis-
associated pain (Chwalisz et al., 2007; Chwalisz et al., 2005; DeManno et al., 2003).
SPRMs are ranked according to their progesterone agonist / antagonist activity
(figure 6.1). Asoprinil (J867) has been shown to have a pronounced progesterone
agonist activity with endometrial antiproliferative effects and has an absence of
abortifact or labour inducing activity (Chwalisz et al., 2005). As such, it is currently
undergoing drug trials to assess its suitability as a treatment for fibroid associated
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Figure 6.1
Diagram represents spectrum of progesterone agonist and antagonist activity.
Asoprisnil (J867) has predominantly progesterone agonist activity with some
antagonist activity. (ONA, onapristone; SPRMs, selective progesterone receptor
modulators; RU486, mifepristone; adaptedfrom (Schubert et al. Semin Reprod Med
2005 23: 58-73)).
Although the mechanism of asoprisnil-induced amenorrhea is still not
completely understood, the current evidence suggests that asoprisnil may have a
direct or indirect inhibitory effect on endometrial spiral arteries.
Interestingly, asoprisnil-induced morphological changes in spiral arteries,
characterized by thickening of the wall, clearly differ from those commonly observed
in women using long-acting progestins or levonorgestrel-containing intrauterine
systems. These treatments are associated with the formation of "thin-walled"
microvessels that are very fragile, and frequently lead to breakthrough bleeding
(Smith, O.P. and Critchley, 2005; Williams et al., 2007).
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Disturbances of prostaglandin receptor signalling have previously been
implicated in vascular function (Jabbour et al., 2006). This chapter sets out to explore
the effect of asoprisnil upon the expression of cyclooxygenase en2ymes and
components of prostanoid signalling within the endometrium obtained from women




This was a Phase 2 multi-centre randomized double-blind placebo-controlled
study of asoprisnil administered for 12 weeks. Dose selection was based upon data
from Phase I and Phase II studies (Williams et al., 2007; Chwalisz et al., 2007) which
showed asoprisnil at doses of 5 mg, 10 mg, and 25 mg to be safe in subjects treated
for 12-weeks. Asoprisnil 10 mg and 25 mg doses and the 12-week duration of
treatment were chosen because they were effective for treatment of excessive
bleeding, in reducing leiomyoma and uterine volumes, and in decreasing mass effect
symptoms, such as pelvic pressure and bloating, over a 3-month treatment period.
At baseline, screening procedures (performed within 45 days of study
commencement) included pelvic and breast examination, complete physical
examination, Pap test [ThinPrep® Pap Test, Cytyc Corp], ECG, transvaginal
ultrasound (TVU), endometrial biopsy [Unimar Pipelle® Endometrial Suction
Curette, Medscand], contraception counselling and clinical laboratory investigations -
chemistry, haematology, urinalysis, endocrine panel, lipid profile, coagulation screen
and serum and urine pregnancy tests. After successful enrolment based on inclusion
and exclusion criteria, women were sequentially assigned subject numbers in
ascending numerical order that encoded the assignment of the woman, via a
randomization schedule, to one of the three treatment arms of the study. Patients were
randomized to one of three parallel dose groups in a 1:1:1 ratio to receive daily doses
of asoprisnil 10 mg, 25 mg or placebo. Patients and all study personnel were blinded
to treatment groups. Asoprisnil or placebo tablets were supplied in blister cards of
identical appearance, supplied to the site packaged in sealed kits. Drug was self-
administered as an oral dose taken once daily. Treatment was initiated no later than
the fifth day of the subject's menstrual cycle, and continued for 12 weeks, when
subjects were to undergo hysterectomy within 24 hours of the final dose of drug. The
patients returned all used and unused study medication blister cards at eight-week and
final visits so that verification of medication compliance could be monitored.
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Patients studied
The study group was composed of patients with symptomatic
leiomyomata from four centres (Edinburgh, Southampton, Glasgow, Liverpool) in
good general health with a menstrual cycle between 17 and 42 days, and symptoms
related to overall fibroid size, pressure and/or heavy uterine bleeding, who were
scheduled for hysterectomy. Each patient had at least one intramural non-
pedunculated, submucosal or subserosal fibroid with a diameter of at least 2 cm or
multiple small fibroids with uterine volume > 200 cm on ultrasonography. Other
inclusion criteria included age over 18 years; negative pregnancy test; a washout
period of 4 months for hormonal therapies; serum FSE1 of <30mIU/mL at
commencement; agreement to use double barrier method of contraception
(condom/diaphragm/sponge plus spermicide) throughout the study until
hysterectomy, unless surgically sterile by bilateral tubal ligation or vasectomy of
partner; and normal Papanicolaou (Pap) test. Patients were not permitted to enter the
study without a normal endometrial biopsy report based on an adequate specimen
taken within 3 months of commencement. Screening data were collected in the clinic
by study nurses or gynaecologists. All patients voluntarily signed a full Informed
Consent Form. The study was performed according to the ethical principles of the
Declaration of Flelsinki (1989 revision) and the protocol approved by the Institutional
Review Board (Multicentre Research Ethics Committee).
Hysterectomy and processing of uterine samples
The following description of tissue sample processing and histological
assessment is provided by Dr Alistair Williams, consultant pathologist supervising
tissue processing.
After removal of the uterus, the unfixed specimen was placed on ice
immediately and taken without delay to the local pathology laboratory, where the
study pathologist or deputy was on hand to open and sample the specimen. The
specimen was oriented and a probe inserted through the external os of the cervix to
define the position of the cavity. The uterus was opened using a long-bladed knife
along the plane of the probe. Endometrial tissue samples were collected from the
fundus, the body and the isthmus of the uterus and placed in RNA Later (Ambion Inc,
Huntingdon, UK) and stored at -70°C (for RNA extraction). The remaining opened
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specimen was then placed in an adequate volume of 10% buffered formaldehyde and
allowed to fix overnight. For large specimens, parallel parasagittal slices 2 cm in
thickness were made to permit adequate fixation overnight. The following day, the
pathologist sampled the specimen for routine diagnostic reporting, and took
additional blocks for study assessment. Endometrial samples were taken from areas
away from leiomyomata wherever possible. All specimens were processed by routine
methods to paraffin wax, and 3 pm haematoxylin-eosin sections were prepared by
microtomy and mounted on glass slides. Histological sections of endometrium were
considered unsuitable for assessment if a leiomyoma was present within 10 mm of
the endometrium.
During Phase I studies with asoprisnil, it became clear that SPRMs including
asoprisnil induce unique changes in the endometrium that cannot be assessed by
currently used criteria of endometrial dating (i.e. the Noyes criteria) (Noyes et al.,
1950), because of differential effects on glands and stroma. As a result, TAP
Pharmaceutical Products Inc, Lake Forest, IL, Diagnostic Cytology Laboratories,
Indianapolis, IN and a group of expert gynaecological pathologists developed a list of
diagnostic criteria that allows for classification of changes induced by SPRMs
("Dictionary of Endometrial Biopsy Diagnoses for Clinical Trials with SPRMs" -
data on file). This system supplements the conventional descriptive criteria of the
normal menstrual cycle as described by Noyes (Noyes et al., 1950). Endometrium,
without pathology, is usually defined histologically as being proliferative, secretory,
menstrual, inactive or unsatisfactory for classification. The majority of asoprisnil-
treated subjects showed endometrial morphology that was consistently recognisable
as showing a "non-physiologic secretory effect". This appearance is unfamiliar to
histopathologists, as it is not seen in normal cycling endometrium or in any described
condition, and is believed to reflect the partial agonist/antagonist effect of asoprisnil
described in animal studies (DeManno et al., 2003). The histological features
defining the effect are endometrial glands showing tortuosity similar to the
architecture of the secretory phase, but with a rarity of secretory activity or
cytoplasmic vacuolation. Glands frequently showed cystic dilatation however, and
although nuclear stratification was present, there was a paucity of mitotic activity.
Appearances of cystic glandular dilatation are frequently associated in the minds of
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histopathologists with simple hyperplasia of endometrium, but the non-physiologic
secretory effect differed in that glandular crowding was absent, cystic change was
often focal involving one or two glands in a field of non-dilated glands, and mitotic
activity was very sparse or absent. Gland dilatation is a feature commonly seen in the
inactive, non-secretory endometrium of the perimenopausal and postmenopausal
woman, and is not considered indicative of glandular secretory activity. It may in fact
represent glands in which the opening to the surface has become occluded, perhaps as
a consequence of the lack of secretory activity.
With asoprisnil, the endometrial stroma showed increasing compactness
without decidual change, but the most characteristic stromal effect involved vessels.
Aggregations of thin-walled vessels were seen in endometrial stroma more frequently
in asoprisnil-treated patients than in placebo-treated patients. Additionally, vessels
with thickened muscularised walls were seen with greater frequency in asoprisnil
patients than in controls.
Taqman quantitative Reverse Transcription Polymerase Chain Reaction (qRT-
PCR)
The endometrial expression of COX enzymes (COX 1&2) and the expression
of genes involved in prostanoid signalling were investigated by quantitative RT-PCR.
Total RNA was extracted from endometrial biopsies using Trizol reagent (Invitrogen
Life technologies, Paisley, UK) followed by the commercially available product
RNeasy Midi Kit (Qiagen Ltd, Sussex, UK) according to the manufacturer's
instructions (see section 3.3.2). Each tissue sample was able to provide sufficient
quantities of RNA for complete analysis of target genes. Samples were treated for
DNA contamination by DNA digestion during RNA purification. Following
extraction, total RNA was eluted in 150pl of nuclease free water and stored at -80°C.
Quality of RNA was assessed using the Agilent 2100 Bioanalyser system in
combination with RNA6000nano chips (Agilent Technologies, Cheshire, UK). Only
RNA that displayed intact 18S and 28S peaks was reverse transcribed to cDNA for
real-time PCR analysis. Once extracted and quantified, RNA samples were reverse
transcribed as previously described in section 3.3.4. Thereafter, cDNA samples were
149
stored at -20°C. A tube with no reverse transcriptase was included to control for any
DNA contamination.
Real time quantitative PCR was performed using an ABI 7700 Sequence
Detection System (Applied Biosystems, Warrington, UK) as previously described
(see section 3.3.5) using duplicate samples. A no template control (containing water)
was included. The inclusion of ribosomal 18S primers and probes was used to act as a
housekeeping gene for each reaction mix. cDNA obtained from a single sample of
endometrial tissue was included as a duplicate in all experiments to act as a relative
standard against which all expression levels are compared. All primers and probes
were designed using the PRIMER express program (Applied Biosystems,
Warrington, UK) and their sequences can be found in table 5.2, chapter 5.
The PCR data is analysed by calculating the threshold cycle or Cj for each
sample. This is the cycle number (range 0-40) at which the accumulation of PCR
product shows exponential growth and crosses a threshold. The higher the initial
product sequence of interest, the lower the Cj value, as the product accumulates
earlier in the PCR run. This value is then related to the amount of total cDNA loaded
by comparing it to the Ct value for the housekeeping gene, 18S. The difference
between the two (the aCt) is then related to the value for the standard cDNA,
included in all experiments, giving a aaCt value for each sample. Finally the formula
2 "AACT is applied. This formula means that the final results will then be comparative
to the standard sample and will be normalised for differences in initial cDNA loading.
The standard sample always has a figure of 1 and a sample with a final result of 10
has ten times more sequence of interest than the standard sample. If the sequence of
interest is not detected after 40 cycles, the CT value is treated as right-censored at 40,
and the delta CT values is treated as right-censored at 40-threshold cycle for 18s.
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Immunohistochemical analysis of cyclooxygenase 1 and cyclooxygenase 2
To investigate the expression of the COX 1 and COX 2, endometrial sections
(5 pm) were dewaxed in xylene and rehydrated using decreasing grades of ethanol.
The use of the Bond automated IHC machine was carried out as described in section
3.2.5 after preliminary optimization experiments had been performed to determine the
best protocol environment and antibody concentrations (see table within section
3.2.4). Sections were counterstained with haematoxin, dehydrated in xylene and
mounted.
Semi-quantitative analysis
Immunohistochemical staining was semi-quantitatively assessed using the
histoscore method by two separate observers ranking the intensity of immunostaining
on a scale of 0 to 3 (0=no staining to 3=intense staining). The amount of tissue in
each slide, with specific immunostaining intensity, was estimated as a percentage in
graduations of 10%. The final histoscore is an integer between 0 and 300.
Once the slides had been independently scored the values were tabulated and
an overall score for each section determined following consultation between the two
observers.
Data analysis and statistical methods
The SAS System 8.2 is used by TAP appointed statisticians to perform the
statistical analysis. All subjects with evaluable data for a specific imunohistochemical
variable are included for analysis of that variable. Based on morphological
assessment by consultant pathologist, a placebo subject was classified into
proliferative phase or secretory phase by a pre-agreed histological algorithm. There
were only 2 samples obtained which were placebo-treated and allocated a
proliferative categorisation. Meaningful comparison of asoprisnil treatment
endometrium with proliferative endometrium is therefore difficult and differences
should be interpreted with caution. Wilcoxon rank sum tests were performed to
compare each asoprisnil group with the placebo subjects in the secretory phase.
Hochberg's multiple comparison procedure was used to control the familywise Type




Results of mRNA expression for COX-1, COX-2 and various prostanoid
signalling genes is summarised in table 6.1 and figure 6.2
Data showed a trend for down regulation of COX-1 mRNA expression in the
asoprisnil treated group but statistical significance was not reached. In contrast, the
trend in expression of COX-2 is up regulated in the asoprisnil treated groups,
approaching significance for the lOmg Asoprisnil group when compared against
expression in placebo/secretory tissue.
There is a significant up-regulation of prostaglandin dehydrogenase (PGDH)
mRNA in both asoprisnil groups when compared with the placebo/secretory
treatment groups. When the prostaglandin E2 and F2 series receptors are examined, a
dramatic upregulation of FP expression is noted in both asoprisnil treatment groups
when compared against the placebo/secretory treatment groups. No differences are
noted in the expression of EP4. A significant decrease of mRNA expression is noted
for the EP2 receptor in the asoprisnil lOmg group when compared with
placebo/secretory endometrium.
Immunohistochemistry Analysis for Cyclooxygenase enzymes
The box plots of figure 6.3 and 6.4 represent the results of the histoscoring for
each tissue compartment; surface epithelium, endometrial glands, endometrial stroma
and endothelium. There is a significant increase in COX-1 in the glands for both
asoprisnil doses when compared against placebo/secretory treatment groups. This
effect alters in the surface epithelium where a reduction in expression for COX-1 is
noted in the high dose asoprisnil treatment group.
No significant difference for COX-2 expression is detected when analysing
immunohistochemical scoring intensity by this method.
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Variable Treatment Group N Median Ratio P-Value
COX-1 Placebo/Proliferative 2 17.2 - -
Placebo/Secretory 8 15.5 1 -
Asoprisnil lOmg 12 17.3 0.27 0.09
Asoprisnil 25mg 10 17.3 0.28 0.07
COX-2 Placebo/Proliferative 2 17.0 - -
Placebo/Secretory 8 16.9 1 -
Asoprisnil lOmg 12 14.8 4.2 0.048
Asoprisnil 25mg 10 15.2 3.2 0.10
PGDH Placebo/Proliferative 2 18.6 - -
Placebo/Secretory 8 20.2 1 -
Asoprisnil lOmg 12 18.4 3.3 0.004
Asoprisnil 25mg 10 19.0 2.2 0.02
EP2 Placebo/Proliferative 2 22.3 - -
Placebo/Secretory 8 18.5 1 -
Asoprisnil lOmg 12 20.6 0.24 0.004
Asoprisnil 25mg 10 19.7 0.43 0.08
EP4 Placebo/Proliferative 2 21.4 - -
Placebo/Secretory 8 18.3 1.0 -
Asoprisnil lOmg 12 18.2 1.09 0.99
Asoprisnil 25mg 10 17.8 1.41 0.48
FP Placebo/Proliferative 2 27.7 - -
Placebo/Secretory 8 26.8 1.0 -
Asoprisnil lOmg 12 22.5 18.4 0.004
Asoprisnil 25mg 10 21.6 35.8 0.001
Table 6.1 Q-RT-PCR Resultsfor prostanoid signalling pathway mediators
The median represents the difference between the threshold cycles for the target and
the reference 18s included in the reaction mix. P values are for each asoprisnil group
compared with the placebo/ secretory group using Wilcoxon's rank sum test. The
ratio is taken as the amount of target normalised to the reference and relative to the























































Figure 6.2 Asoprisnil effects on prostanoid signalling gene expression
Graph demonstrates mRNA expression as determined by quantitative RT-PCR
analysis. Expression is relative to the placebo/secretory treatment endometrium,
which is represented by the x-axis on this logarithmic graph. * represents significant
difference in expression from base line (p<0.05; COX, cyclooxygenase; PGDH,




Box-plot demonstrating results of subjective scoring of COX-1 immunostaining
within the human endometrium. Statistical analysis using the non-parametric
Hochberg's multiple comparison procedure indicated that immunostaining intensity
was significantly increased within the glandular epithelium for both asoprisnil doses
and a decrease in immunostaining within the surface epithelial cell for 25mg
asoprisnil treated group (p<0.05). The data are presented as box-and-whisker plots:
box represents the 25th and 75th percentiles and the heavy bar represents the median.
The whiskers are the 10th and 90th percentiles. There were only 2 samples obtained
which were placebo-treated and allocated a proliferative categorisation. Meaningful
comparison of asoprisnil treatment endometrium with proliferative endometrium is
therefore difficult and differences should be interpreted with caution.
Figure 6.4
Box-plot demonstrating results of subjective scoring of COX-2 immunostaining
within the human endometrium. Statistical analysis using Hochberg's multiple
comparison procedure did not indicated any significant differences in
immunostaining intensity within different tissue compartments. The data are
presented as box-and-whisker plots: box represents the 25th and 75th percentiles and
the heavy bar represents the median. The whiskers are the 10th and 90th percentiles.
There were only 2 samples obtained which were placebo-treated and allocated a
proliferative categorisation. Meaningful comparison of asoprisnil treatment
endometrium with proliferative endometrium is therefore difficult and differences
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6.4 Discussion
Many genes are regulated by the progesterone receptor (section 1.2.5).
Progesterone is the natural ligand for this receptor and can influence many biological
functions by gene regulation. Progesterone withdrawal is a key physiological event
complied in the mechanism of menstruation (section 1.4.1) and is known to influence
the expression of genes at many levels of prostanoid signalling. Both in vitro and in
vivo studies indicate that PR-A and PR-B can profoundly effect the biological
response to progesterone and synthetic progestins (Chwalisz et al., 2005). Progestins
are widely used for treating many gynaecological disorders but they are often
associated with side effects such as depression, bloating and break through bleeding
thereby interfering with drug compliance (Smith, O.P. and Critchley, 2005). The
effectiveness and side effects of progestins are dependent upon the type of progestin
used, the dose of drug and indeed the mode of delivery e.g oral, subdermal,
intramuscular. Progesterone antagonists such as mifepristone (RU486) also show
potential for use in many studies of gynaecological disorders, however they are
principally therapeutically used for their abortifact properties (Baird et al., 2003).
Selective progesterone receptor modulators (SPRMs) are able to provide the benefits
of both progesterone agonist and antagonist actions whilst avoiding many of their
drawbacks (Chwalisz et al., 2005).
Asoprisnil produced a trend to upregulation of COX-2 mRNA in
endometrium as compared with placebo/secretory endometrium. Previous studies
have demonstrated an up regulation of COX-2 in the late secretory stage of the
menstrual cycle in response to physiological or pharmacological progesterone
withdrawal (Hapangama et al., 2002; Jones et al., 1997; Ota et al., 2001). This
suggests that with regard to COX-2 transcription, asoprisnil is demonstrating a
progesterone antagonist action. The picture for COX-1 mRNA expression is for a
trend in down- regulation although again, significance is not reached. The results of
immunohistochemical staining for the COX enzymes provide more information. As
for COX-2 mRNA expression, there is a similar trend for an increase in expression
for COX-2 within the glandular compartment of the asoprisnil treated endometrium
but a downtrend noted in the endometrial stroma. This difference of expression
within endometrial tissue compartments may explain why true significance is not
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obtained after Hochberg's multiple comparison. Differences in effect upon protein
expression within tissue compartments is also seen for COX-1 immunostaining where
a significant upregulation found in glandular cells is opposed by a down regulation
within the surface epithelium. This makes meaningful analysis of mRNA expression
difficult, as isolation of the various cellular compartments for mRNA analysis would
be technically challenging and not possible within the boundaries of this study.
The mode of action of SPRMs upon COX transcription is therefore complex.
Asoprisnil's ligand action upon the PR may be dependent upon the tissue
compartment of action, local concentrations of drug and ratio of PR-A and PR-B
isotypes. Additionally PR ligand binding induces a conformational change to the
receptor altering the interaction with coregulators of transcriptional activity
(Chwalisz et al., 2005). The effect of a SPRM upon transcription of a particular gene
is therefore difficult to predict.
In the endometrium, prostaglandins are not stored but are immediately
synthesized and released and metabolized to inactive metabolites by PG 15
dehydrogenase (PGDH) enzyme (Casey et al., 1980). Previous work has
demonstrated a down-regulation of expression of endometrial PGDH in response to
pharmacological progesterone withdrawal (Hapangama et al., 2002). Asoprisnil
significantly upregulated endometrial PGDH expression as compared to
placebo/secretory endometrium thereby demonstrating a progesterone agonist action
in contrast to its effects upon COX-2 mRNA expression.
PGF2a and PGE2 are two prominent prostaglandins found in human
endometrium (Lumsden et al., 1986b). In the endometrium, PGF2a receptor (FP) and
PGE2 receptors EP2 and EP4 are responsible for their respective ligand action. The
effects of asoprisnil upon endometrial mRNA expression for these receptors are
examined. There is a significant upregulation of FP mRNA endometrial expression in
women taking both doses of asoprisnil. EP2 mRNA expression is however down
regulated in endometrium obtained from women taking lOmg asoprisnil compared to
placebo/secretory treatment subjects.
The effects of asoprisnil upon prostaglandin signalling within human
endometrium are therefore varied and complex. A reduction in menstrual blood loss
has been demonstrated as a possible clinical benefit of asoprisnil and the mechanisms
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of action for this effect have been postulated to involve changes to endometrial
vasculature (Chwalisz et al., 2004; DeManno et al., 2003; Chwalisz et al., 2007).
Prostaglandins have additionally been implicated in disorders of menstruation (see
section 1.4.3). Chapter 5 explores the role of these prostaglandin signalling in the
aetiology of heavy menstrual bleeding and concludes that a shift in prostanoid
signalling in favour of the PGE2 pathway over PGF2a may have a role in this
pathology, thereby supporting earlier studies (Smith, S. K. et al., 1981a). In contrast,
the use of the SPRM asoprisnil, which leads to a cessation of menstrual bleeding,
may cause a shift in signalling in favour of PGF2oc over PGE2 pathways.
Whether asoprisnil associated changes in prostaglandin signalling within the
endometrium participate in vascular and cellular changes that lead to a reduction of
menstrual blood loss has however not yet been proven. The exact mechanism of
action of the SPRM, asoprisnil, is currently being researched. Clinical studies with
asoprisnil demonstrated that this SPRM effectively controls leiomyoma-associated
symptoms, including heavy uterine bleeding and pressure-related symptoms, and
reduces leiomyoma volume. Furthermore, studies with this SPRM showed its efficacy
in controlling pain symptoms associated with endometriosis. Further studies, in a
larger study population, are needed to determine the optimal treatment regimens with






It has been postulated that the increasing incidence in menstrual disorders are
due to changes in life style in the second half of the twentieth century. The
development of the contraceptive pill, reduction in family size and /or the incidence
of lactational amenorrhoea has meant that today a woman would experience a much
greater number of menstrual cycles (approximately 400) compared to her ancestors
(30-40 cycles).
Twenty years ago, 60% of women referred to secondary care with a complaint
of heavy menstrual bleeding had a hysterectomy within 5 years. In 2005, 50% of
these women had a hysterectomy within 2 years (Reid and Virtanen-Kari, 2005).
Disorders of the menstrual cycle place a considerable burden on general practice and
specialist health service resources and are the most common indication for
hysterectomy (Vessey et al., 1992). It is this health burden, which drives intense
research into the exact mechanisms of the menstrual process despite the gross
physiological aspects being well established. It has become clear that the cellular
mechanisms involved in the aetiology of abnormal uterine bleeding are complex and
involve a number of different molecular systems.
Menstrual dysfunction encompasses benign pathologies such as heavy
menstrual blood loss (menorrhagia), painful periods (dysmenorrhoea), endometriosis
and disorders of menstrual timing such as; frequent periods, infrequent or scanty
periods (oligomenorrhoea), and amenorrhea (absent menstrual periods). Disorders of
timing such as oligomenorrhoea and amenorrhoea are closely associated with
disturbances in the hypothalamic-pituitary-ovarian axis and morphological changes
within the uterus. These changes are not precipitated by local disturbances within the
endometrial environment and therefore fall out with the remit of this thesis, which
discusses prostaglandin signalling in the endometrium.
The molecular mechanism of menstruation in response to progesterone
withdrawal is a complex cascade of events that have yet to be fully elucidated. It in
part involves the production of prostaglandins that are able to induce vasoconstriction
leading to a reduced blood flow to the endometrium. Subsequently there is increased
expression of a range of locally acting mediators including cytokines, angiogenic
factors, protease enzymes and further prostaglandins. The cumulative endpoint of
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these changes in local mediators, together with an influx of migratory leukocytes is
the process of menstruation (Brenner et al., 2002; Critchley et al., 2001b; Jabbour et
al., 2005) section 1.4; figure 1.5).
Evidence has since continued to mount, supporting a role for local
disturbances of prostaglandin synthesis, secretion and metabolism in several
pathologies of the endometrium. Endometrial pathologies, in which prostaglandins
appear to have an aetiological role, are those in which the clinical symptoms of pain
or bleeding disturbances are prominent. A role for COX enzymes and prostaglandins
has been ascertained in reproductive tract pathology, including painful menstruation
(dysmenorrhoea), heavy menstrual bleeding (menorrhagia) and endometriosis
(Lundstrom et al., 1976; Morita, 2002; Ota et al., 2001; Smith, S. K. et al., 1981a&b).
Indeed first line treatment for such complaints involves the use of non-steroidal anti¬
inflammatory drugs (NSAIDs), which inhibit COX, the rate-limiting enzyme in
prostanoid production (Cameron et al., 1990; Reid and Virtanen-Kari, 2005). Non¬
selective NSAID use has, however, been associated with gastrointestinal toxicity,
ulceration, platelet dysfunction and kidney damage in at least 1% of users (Fosslien,
1998). In addition, well-publicised and unforeseen cardiovascular problems have
arisen with selective COX-2 inhibitors (Krumholz et al., 2007) that dramatically
highlight the need for a further understanding of these enzymes, metabolites and their
receptors.
It has traditionally been thought that in the normal physiological state, cells
responsible for prostaglandin production, constitutively express COX-1 and are
induced to express COX-2 in response to external stimulation. This present study
demonstrates significantly elevated levels in mRNA expression of both COX-1 and
COX-2 in endometrium obtained from women with measured heavy MBL (chapter 5,
figure 5.5), thereby adding heavy menstrual blood loss to the list of gynaecological
complaints demonstrating an alteration in expression of both COX enzymes.
Clinically, these data suggest that it is important to use a general inhibitor of both
COX-1 and COX-2 enzyme action for treatment of the complaint of heavy
menstruation. Increased expression of the rate limiting COX enzymes in
endometrium from women with heavy menstrual blood loss will lead to an increase in
prostaglandin production and signalling. Of the two main prostaglandins in the
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endometrium, PGE2 and PGF2a, a shift in balance of signalling towards the PGE2
pathway has previously been suggested (Smith, S. K. et al., 1981a). A reduction in
PGF2a receptor mRNA in this study supports this finding. Furthermore, enhanced
functionality of the PGE2 receptors coupled to cAMP production has also been
demonstrated in endometrium from women with heavy MBL as compared to normal
(chapter 5, figure 5.7). The effect of this increased cAMP production was not studied.
However, prostanoid coupled cAMP signalling has previously been linked to
angiogenic influences (Sales et al., 2004a) in the Ishikawa endometrial epithelial cell
line.
Emerging evidence supports a role for COX enzymes, prostaglandins and
prostaglandin receptor signalling pathways in a multitude of phenotypic changes
within reproductive tissues including the promotion of angiogenesis and vascular
function (Sales et al., 2005; Tsujii et al., 1998). The remodelling of the human
endometrium required during the menstrual cycle requires tight control of angiogenic
growth factors to coordinate the growth of new vessel formation.
By investigating the molecular signalling mechanism within both human
endometrium and an endometrial epithelial cell line, this thesis demonstrates a
potential role for PGI2-IP receptor signalling in human endometrial glandular
epithelial cells in regulating the expression of several pro-angiogenic factors. Such
prostanoid signalling could influence angiogenesis by acting on adjacent endothelial
cells in an autocrine/paracrine manner. Moreover, these studies have demonstrated a
role for IP-EGFR crosstalk in promoting angiogenic factor expression in the
endometrium. Prostanoid receptor crosstalk with EGFR, linked to angiogenic
alterations, has previously been demonstrated for both PGE2 and PGF2a prostaglandin
signalling within endometrial epithelial cell lines (Sales et al., 2005; Sales et al.,
2004a).
A comparative study, which investigated endometrial tissue from women with
heavy and normal blood loss, has demonstrated increased endothelial cell
proliferation in women with heavy menstrual blood loss (Kooy et al., 1996).
Additionally, the proliferation and differentiation pattern of the vascular smooth
muscle cells around spiral arterioles of the endometrium of women with heavy
menstrual bleeding is significantly reduced compared to that of women with normal
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blood loss (Abberton et al., 1996; Abberton et al., 1999). These data implicate
disturbances of endometrial angiogenesis in the endometrial pathology leading to
heavy menstrual blood loss. Whether these angiogenic alterations effect vascular
development, composition and structural integrity or permeability is more difficult to
ascertain. Heavy MBL has previously been reviewed as a defect of vasoconstriction,
leading to reduced control of blood volume loss (Livingstone and Fraser, 2002).
Ultimately, vascular permeability and leakage at the time of menstruation will be
determined by a milieu of pro and anti-angiogenic factors. The demonstrated over-
expression of COX enzymes in heavy MBL and the established role of COX enzymes
in regulation of angiogenic factors would suggest a disturbance in the balance of
these factors in heavy compared with normal menstruation. This is further
exacerbated by the effect of COX enzymes upon decreasing anti-angiogenic factors.
A reduction in expression of cathepsin D (an anti-angiogenic factor) mRNA and
protein has previously been demonstrated in Ishikawa endometrial epithelial cells
over-expressing COX-2 (Perchick et al., 2003).
Early studies into the effects of the selective progesterone receptor modulators
(SPRMs; see section 6) have provided hope for advancements in the treatments of
abnormal menstruation, endometriosis associated pelvic pain and also fibroid disease.
Phase II trials have shown that asoprisnil, a SPRM, produces a dose dependent
amenorrhoea, reduces endometriosis associated pain and shrinks the volume of
fibroid uteri (Chwalisz et al., 2005). The mechanism of action for this family of
compounds is complex, exerting a tissue-selective agonist, antagonist or partial
agonist/antagonist effect on the progesterone receptor. Interestingly, evidence
demonstrates that asoprisnil causes the formation of unusual, thick-walled arterioles
in the endometrium when compared to progesterone agonist or antagonists. Overall,
early trials suggest that asoprisnil induces its therapeutic benefits such as suppression
of menstruation via an endometrial specific vascular effect. The exact mechanisms of
action are however poorly understood. The effect of asoprisnil upon prostanoid
signalling has been examined within this thesis. The effects of asoprisnil upon
expression of genes involved in prostanoid signalling are complex with alterations
both in keeping with progesterone agonist and antagonist actions. Whether
prostanoids are indirectly involved in the action of asoprisnil upon endometrial
vasculature has not yet been ascertained.
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Studies are advancing to elucidate the mechanism of action for this compound
but research in to endometrial function is generally hampered by the absence of good
animal models.
This thesis is based on the hypothesis that menstrual dysfunction, including
heavy menstrual blood loss is due to (a) up-regulated expression/synthesis of
cyclooxygenase enzymes and prostaglandin receptors, and (b) initiation of enhanced
intracellular signalling pathways in response to prostaglandins. By identifying the
prostanoids responsible for these effects and the specific receptors/signalling
pathways that are associated with their function, we hope to establish information that
may result in the development of novel therapeutic targets for menstrual pathology.
Although data published within this thesis further implicate the COX enzymes in
heavy MBL and also demonstrate an enhanced functional capability of endometrium
in response to stimulation with PGE2, specific receptor differences in endometrium
taken form women with heavy as compared to normal MBL, have been more difficult
to demonstrate. It would appear sensible to suggest that defects of prostaglandin
signalling within endometrial pathologies are not attributable to a defective
expression of just one receptor. Instead, that signalling defects are the end result of
subtle alterations at any and probably many stages of prostanoid signalling. The
concept of multi-gene activation patterns is now being explored to explain these
complex molecular differences that lead to menstrual pathologies, principally with
the use of gene microarray technologies.
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7.2 For the future
This thesis has outlined the close relationship between prostaglandin
signalling and angiogenic alterations. The signalling pathways linking prostanoid
receptor activation and angiogenic endpoint appear to necessitate a "cross
communication" with the epidermal growth factor receptor (EGFR). Blockade of
EGFR signalling with an orally active EGFR tyrosine kinase inhibitor has been used
successfully in inhibiting angiogenesis in nude mice (Baker et al., 2002). Targeted
inhibition of EGFR function with small molecule chemical inhibitors alone or in
combination with a COX enzyme inhibitor may modulate angiogenic activity in the
endometrium with possible benefits for menstrual complaints that are associated with
aberrant expression and signalling of prostanoids and altered angiogenesis or vascular
function.
The challenge in the future is to unravel the signalling pathways that
precipitate menstrual disorders. In order to accomplish this, the exact nature of the
molecules, the cross-talk that may exist between them and their role in signalling
needs to be established. It is important to accurately assess whether these pathways
function independently, or converge to amplify specific signals that are crucial for the
progression of the studied pathology. Only with this knowledge will we be able to
apply novel therapeutic intervention strategies.
Our knowledge of the factors regulating menstrual function/dysfunction has
historically relied on candidate gene approaches with a requirement for knowledge of
the gene structure and sequence. This approach has been applied to investigate the
variation in expression of the candidate genes in the human endometrium across the
menstrual cycle. It is also important to bear in mind that menstrual disorders may
result from multiple aetiologies with different aetiologies occasionally found to be
responsible for the same clinical complaint.
The advent of global mining of genes, using approaches such as genomics and
proteomics, will greatly enhance our knowledge on the aberrations in gene expression
in menstrual disorders. They offer a powerful approach of exploring the global
transcriptional and signalling effects of drugs such as SPRMs upon the endometrium,
thereby offering insight into their mode of action. Previous research has applied
genomic array technology within human endometrial function (Giudice, 2004; Kao et
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al., 2003; Kao et al., 2002; Talbi et al., 2006). These global approaches can give a
great insight into the various genetic and molecular pathways when applied in context
of specific endometrial pathologies. The application of such genomic approaches to
menstrual disorders will greatly advance our knowledge of the library of genes that
may be altered in these complaints. Moreover, they will outline a molecular
"signature" that is the characteristic of the aetiology behind each of the menstrual
complaints being investigated. With the advancement of these signatures, with time it
may become possible to "tailor" the therapeutic option most appropriate to the
individual patient from the variety of options available to the physician.
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BACKGROUND: Although the mechanisms underlying the causes of heavy menstrual blood loss (MBL) remain to be
elucidated, prostaglandins have been previously implicated. This study was initiated to elucidate a pattern of
expression of the various components of the cyclooxygenase (COX)-prostaglandin signalling pathways present in
the endometrium of women with normal and heavy MBLs. METHODS: Endometrial biopsies were collected at differ¬
ent stages of the menstrual cycle from women who underwent measurement of MBL. Tissue was divided for either
examination of gene expression by quantitative RT-PCR analysis or in vitro culture experimentation. RESULTS:
Analysis of gene expression demonstrated a significant elevation in expression of COX-1 and COX-2 mRNA in endo¬
metrium obtained from women with heavy MBL when compared with endometrium obtained from women with
normal MBL. Tissue culture with PGE2 stimulation caused a significantly elevated production of cyclic AMP
(cAMP) by endometrium of women with heavy MBL when compared with normal MBL. Expression of phosphodi¬
esterase 4B, an enzyme involved in cAMP breakdown, was reduced in these same endometrial samples obtained
from women with heavy MBL. CONCLUSIONS: These data identify the E series prostaglandin receptors and
their signalling pathways as potential therapeutic targets in the treatment of heavy menstruation.
Key words: cyclooxygenase/heavy menstruation/menorrhagia/prostaglandin receptors
Introduction
Initial studies of menstrual fluid identified vasoactive sub¬
stances with the capabilities of inducing contractions in strips
of ileal muscle (Pickles, 1957). These were subsequently ident¬
ified as prostaglandins F2a (PGF2cl) and E2 (PGE2), the two
most abundant prostaglandins found in the endometrium and
menstrual fluid (Lumsden et al., 1983). Evidence has since
continued to mount, supporting a role for prostaglandins in
menstruation (Baird et al., 1996).
In the prostaglandin synthesis pathway, the cyclooxygenase
(COX) enzymes generate PGH2 from arachidonic acid. There
are two main isoforms of the COX enzyme: COX-1 and
COX-2. COX-1 is constitutively expressed in many tissues
and generates prostaglandins for normal physiological function,
whereas COX-2 is rapidly induced in cells in response to varied
stimuli (Vane et al., 1998). Once synthesized, PGH2 acts as an
intermediary for a specific terminal prostaglandin synthase
enzyme. Synthesized prostaglandins mediate their actions via
seven-transmembrane G-protein coupled receptors (GPCRs).
PGE2 can couple to four subtypes of GPCRs, which have
been pharmacologically classified as EP1, EP2, EP3 and EP4
(Coleman et al., 1994). These receptors are often co-expressed
together in the same cell and, utilize alternate and, in some
cases, opposing intracellular signalling pathways (Ashby,
1998). EP2 and EP4 receptors, previously demonstrated in
human endometrium (Milne et al., 2001), are coupled to G pro¬
teins (Gas) and adenylyl cyclase, resulting in the increased for¬
mation of cyclic AMP (cAMP). PDE4 is a member of the
phosphodiesterase family of enzymes, which has been pre¬
viously demonstrated in human endometrium (Bartsch et al.,
2004), and is specific for the hydrolysis of cAMP (Sanz et al.,
2005). The level of accumulation of the second messenger,
cAMP, in response to prostaglandin signalling may therefore
be dependent on the level of PDE4 activity. The PGE2
pathway has previously been implicated in the problem of
heavy menstrual blood loss (MBL) (Willman et al., 1976;
Smith et al., 1981; Adelantado et al., 1988), although specific
signalling mechanisms have yet to be elucidated. Additional
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prostaglandins include prostacyclin and thromboxane, which
act upon their respective receptors (IP and TBXR). Prostacyclin
and thromboxane are best known for their effects on the vascu¬
lar endothelium, where their synthesis is well noted (Ullrich
et al., 2001). Menstruation is an active process whereby the
upper two-thirds of the endometrium, the functional layer, are
shed and regenerated on a cyclical basis. Menstrual problems
account for much of the morbidity that occurs in women of
reproductive age. Thirty percentage of women consider their
menstruation to be excessive, rising to 50% in perimenopausal
women (Prentice, 1999, 2000). Management typically involves
invasive surgery. In 2002-3, over 13 000 surgical procedures
(hysterectomy and endometrial ablation) were performed in
UK for complaints of heavy bleeding (Reid and Mukri,
2005). An estimated 3.5 million workdays are lost annually
(Weeks et al., 2000).
The objective definition of heavy MBL is often based on the
measurement of menstrual haemoglobin content. This method
of measurement was first described in Scandinavian studies,
which demonstrated the mean MBL to be 40 ml. Regular
MBL in excess of 63 ml was associated with iron deficiency
anaemia (Hallberg, 1964; Hallberg et al., 1966). The 90th
centile for measured blood loss was 80 ml and this has tra¬
ditionally been accepted as the upper limit of normal in clinical
evaluation of MBL.
Previous investigations into the aetiology of heavy MBL
have not been able to discover any differences in circulating
steroid hormone levels (Eldred and Thomas, 1994) or
any specific histological differences within the endometrium
(Rees et al., 1984) of women with heavy MBL when compared
with women with normal MBL. Additionally, there is no differ¬
ence in endometrial expression of estrogen and progesterone
receptors (Critchley et al., 1994). However, evidence does
exist implicating local mediators, in particular, prostaglandins
(Sales and Jabbour, 2003). Increased levels of total prostaglan¬
dins have been found in endometrium taken from women with
heavy MBL (Smith et al., 1981). Furthermore, treatment using
inhibitors of COX enzymes has repeatedly been shown to
reduce MBL (Cameron et al., 1990; Coulter et al., 1995;
Bonnar and Sheppard, 1996), implicating disturbances of
prostaglandin pathways in the aetiology of excessive menstrual
bleeding, although the mechanisms underlying the cause of
heavy blood loss remain to be elucidated.
This study was initiated to determine a pattern of expression
of the various components of the COX-prostaglandin signal¬
ling pathways present in the endometrium of women with
normal and heavy MBLs (>80 ml). This is based on the
hypothesis that disturbances of local mediator signalling,
including prostaglandin signalling, are implicated in the
aetiology of heavy MBL.
Materials and methods
Tissue collection and measurement of MBL
Patients complaining of heavy menstruation were recruited
from the gynaecological outpatient setting. Ethical approval
was obtained from the Lothian Research Ethics Committee
and written informed consent was obtained from all subjects
before tissue collection. All subjects were aged 18-50 (range
22-49; mean 40 years of age). All subjects reported
regular menstrual cycles (cycle length 21-35 days), with no
unscheduled, non-menstrual bleeding. No woman had received
hormonal preparation in the 3 months preceding biopsy
collection. Patients were clinically examined and clinical
pelvic abnormalities, such as an enlarged uterus, were further
investigated by pelvic ultrasound imaging. Patients with
known uterine pathology such as fibroid disease and endome¬
triosis were excluded from the study.
Endometrial biopsies (n = 26) were collected for research
purposes at different stages of the menstrual cycle with an
endometrial suction curette (Pipelle, Laboratoire CCD, Paris,
France). No biopsies were taken during the menstrual phase
of the cycle because of technical difficulties in obtaining
sufficient quantities of endometrium suitable for RNA analysis.
Biopsies were dated according to stated last menstrual period
(LMP) and dating was confirmed by histological assessment
according to criteria of Noyes et al. (1950). Furthermore,
circulating estradiol and progesterone serum levels were
measured at the time of biopsy collection and were consistent
for both LMP and histological assessment of the menstrual
cycle stage. This is a robust method for characterizing endo¬
metrial samples. Detailed gene microarray studies support
this method for characterizing endometrial samples with
consistency across these three parameters (Critchley et al.,
2006; Talbi et al., 2006).
Inconsistencies between measured circulating hormone
levels, stated day of LMP and/or histological assessment,
led to exclusion of three tissue biopsies from the study.
Table I provides a summary of the biopsies (n — 23) used
within this work.
Immediately after collection, tissue was divided, transferred
into RNA Later (Ambion Inc., Huntingdon, UK) and stored
at — 70°C (for RNA extraction), fixed in neutral-buffered
formalin for wax embedding (for histological dating) and
placed in Rosewell Park Memorial Institute (RPMI) 1640
medium (containing 2mM L-glutamine, 100 U penicillin and
100 |xg ml-1 streptomycin) and transported to the laboratory
for in vitro culture.
In addition to consenting to provide an endometrial biopsy,
patients agreed to undergo measurement of MBL over one
menstruation. Measurement was based on a modified
alkaline-haematin method as previously described (Hallberg,
1964). Briefly, used sanitary products were added to a
measured volume of 5% sodium hydroxide (between 2 and
4 1). The contents were then left for 48 h to allow conversion
of haemoglobin to haematin. During this same time period,
Table I. Summary of collected endometrial biopsies
Stage of menstrual cycle Number of biopsies
Menstrual blood MBL >80 ml
loss (MBL) <80 ml
Proliferative 7 5
Secretory 6 5
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a 1 in 200 dilution of the patient's venous blood in 5% sodium
hydroxide was made and additionally stored. After 48 h, an
aliquot of sodium hydroxide was removed from the volume
soaking the sanitary products and filtered through hardened
filter paper (Whartman No. 54, Maidstone, UK). The optical
density (OD) of MBL solution and venous blood sample
were then measured using spectrophotometry at 546 nm (As46).
MBL was then calculated as a quantity of patient's own
venous blood using the following equation (van Eijkeren
et al., 1986):
(OD of menstrual blood solution
x total volume of added NaOH)
MBL = -
(OD of venous blood x 200)
Validation work for this method of measuring MBL has pre¬
viously been carried out (data not shown).
The range of measured MBL was between 10 and 567 ml
with a median MBL of 42 ml for the normal group (MBL
>80 ml) and a median MBL of 183 ml for the heavy group
(MBL >80 ml). All patients provided informed consent for
collection of an endometrial biopsy during the month proceed¬
ing or immediately following collection of their menstrual loss.
Whole tissue cAMP assay
Endometrial biopsies from proliferative and secretory phases
of the menstrual cycle were minced finely with scissors and
incubated overnight in RPMI medium containing 3 pgrnl-1
indomethacin (an inhibitor of COX-1 and COX-2 enzymes).
Following overnight treatment, approximately one-third of
the tissue was removed and stored at — 20°C. The remaining
tissue was incubated in the same medium containing 1 mM
l-methyl-3-isobutylxanthine (IBMX, Sigma, Poole, UK) for
30 min. (IBMX inhibits the action of phosphodiesterases and
prevents the rapid degradation of cAMP.) It was then divided
into two portions and treated with control medium or 100 nM
PGE2 for 10 min. Tissue was then lysed in 0.1 M HC1 and
frozen until assayed. Cyclic AMP concentration was measured
by enzyme-linked immunosorbent assay (Biomol, Affiniti,
Exeter, UK) in accordance with the manufacturer's instructions
and normalized to protein concentration determined by protein
assay according to the manufacturer's instructions (Bio-Rad,
Hemel Hempstead, UK).
Taqman quantitative reverse transcriptase-polymerase
chain reaction
The expression of COX enzymes across the menstrual cycle
and the expression of prostanoid receptors in endometrium
characterized by MBL were investigated by quantitative RT-
PCR. Total RNA was extracted from endometrial biopsies
using the commercially available product RNeasy Midi Kit
(Qiagen Ltd, Sussex, UK), according to the manufacturer's
instructions. Each tissue sample was able to provide sufficient
quantities of RNA for the complete analysis of our target genes.
Samples were treated for DNA contamination by DNA diges¬
tion during RNA purification. Following extraction, total
RNA was eluted in 150 p.1 of nuclease-free water and stored
at — 80°C. Quality of RNA was assessed using the Agilent
2100 Bioanalyser system in combination with RNA6000nano
chips (Agilent Technologies, Cheshire, UK). Only RNA that
displayed intact 18S and 28S peaks was reverse transcribed
to cDNA for real-time PCR analysis.
Once extracted and quantified, RNA samples were reverse
transcribed as previously described (Milne et al., 2001; Sales
et al., 2004). Thereafter, cDNA samples were stored at
— 20"C. A tube with no reverse transcriptase was included to
control for any DNA contamination.
Real-time quantitative PCR was performed using an ABI
7700 Sequence Detection System (Applied Biosystems,
Warrington, UK) as previously described (Milne et al., 2001;
Sales et al., 2004) using duplicate samples. A no-template
control (containing water) was included. The inclusion of ribo-
somal 18S primers and probes was used to act as a housekeep¬
ing gene for each reaction mix. All primers and probes were
designed using the PRIMER express programme (Applied
Biosystems) and their sequences can be found in Table II.
Data were analysed and processed using Sequence Detector
version 1.6.3 (Applied Biosystems) according to manufac¬
turer's instructions. Expression of target genes was normalized
to RNA loading for each sample using 18S ribosomal RNA as
an internal standard. All results were expressed relative to a
control standard (cDNA obtained from a single sample of
endometrial tissue and included in all experiments).
Statistical analysis
The quantitative RT-PCR data did not consistently fulfil the
assumptions necessary for using analysis of variance
(ANOVA) and t-test; therefore, the non-parametric Mann-
Whitney test was used (Graphpad InStat3) and statistical signifi¬
cance accepted when P < 0.05. Cyclic AMP assay data were
subjected to statistical analysis with ANOVA and Fishers
PLSD tests (Statview 4.0; Abacus Concepts Inc., Piscataway,
NJ, USA) and statistical significance accepted when P < 0.05.
Results
Quantitative RT-PCR analysis of genes involved with
prostaglandin signalling
Analysis of mRNA expression for a variety of genes associated
with prostanoid signalling within the endometrium by quanti¬
tative RT-PCR was performed. Analysis of COX-1 and
COX-2 mRNA expressions demonstrated a significant increase
in secretory endometrium of women with MBL in excess of
80 ml when compared with endometrium of women with
MBL <80 ml (Figure 1).
No significant differences in endometrial expression were
detected for prostacyclin or thromboxane receptors. Regarding
the receptors for PGE2, no significant differences in expression
were detected between the two groups of endometrial samples
for EP2, EP3 and EP4. The mRNA expression of EP1 was sig¬
nificantly increased in secretory endometrium of women with
heavy MBL when compared with normal MBL. Finally,
mRNA expression of the receptor for PGF2a (FP) was signifi¬
cantly reduced in proliferative endometrium of women with
heavy MBL when compared with normal MBL (Figure 2).
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5'-TGT TCG GTG TCC AGT TCC AAT A-3'
5'-ACC TTG AAG GAG TCA GGC ATG AG-3'




5'-CCT TCC TCC TGT GCC TGA TG-3'
5'-ACA ATC TCA TTT GAA TCA GGA AGC T-3'
5'-TGC CCG ACT CCC TTG GGT GTC A-3'
Prostaglandin E2 receptor type 1 (EP1) Forward
Reverse
Probe
5'-AGA TGG TGG GCC AGC TTG T-3'
5'-GCC ACC AAC ACC AGC ATT G-3'
5'-CAG CAG ATG CAC GAC ACC ACC ATG-3'
Prostaglandin E2 receptor type 2 (EP2) Forward
Reverse
Probe
5'-GAC CGC TTA CCT GCA GCT GTA C-3'
5'-TGA AGT TGC AGG CGA GCA-3'
5'-CCA CCC TGC TGC TGC TTC TCA TTG TCT-3'
Prostaglandin E2 receptor type 3 (EP3) Forward
Reverse
Probe
5'-GAC GGC CAT TCA GCT TAT GG-3'
5'-TTG AAG ATC ATT TTC AAC ATC ATT ATC A-3'
5'-CTG TCG GTC TGC TGG TCT CCG CTC-3'
Prostaglandin E2 receptor type 4 (EP4) Forward
Reverse
Probe
5'-ACG CCG CCT ACT CCT ACA TG-3'
5'-AGA GGA CGG TGG CGA GAA T-3'
5'-ACG CGG GCT TCA GCT CCT TCC T-3'
Prostaglandin F2o[ receptor (FP) Forward
Reverse
Probe
5'-GCA GCT GCG CTT CTT TCA A-3'
5'-CAC TGT CAT GAA GAT TAC TGA AAA AAA TAC-3'
5'-CAC AAC CTG CCA GAC GGA AAA CCG-3'
Thromboxane receptor (TBXR) Forward
Reverse
Probe
5'-TGG TGG TGG CCA GCG T-3'
5'-CGG GTT TCG CAG CAC TGT-3'













5'-GCC CTC CCC CTC TAC CAA-3'
5'-TTT TCC AAT AAC TGT GGT TTT TGT G-3'
5'-CCA AGA GCC AGC CCC CTT TCT GC-3'
5'-CCT TCA GTA GCA CCG GAA TCA-3'
5'-CAA ACA AAC ACA CAG GCA TGT AGT T-3'
5'-AGC CTG CAG CCG CTC CAG CC-3'
5'-CGT CTA CCA CAT CCA AGG AA-3'
5'-GCT GGA ATT ACG GGG GCT-3'
5'-TCG TGG CAC CAG ACT TGC CCT C-3'
Functional PGE2 receptor signalling in endometrium
of women with measured MBL
The PGE2 receptors, EP2 and EP4, are known to activate the
cAMP/protein kinase A pathway within the human endometrium
(Milne et al., 2001; Regan, 2003). To investigate the potential
differences in PGE2 receptor function between endometrial
samples of women with measured MBL, we therefore looked
at cAMP production as an end-point for receptor function.
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Figure 1. Box plot demonstrating relative cyclooxygenase-1 (COX-1) and COX-2 mRNA expression in proliferative and secretory endometrium
of women with normal and heavy measured menstrual blood losses (MBLs) (normal MBL <80 ml and heavy MBL >80 ml). The data are pre¬
sented as box-and-whisker plots: box represents the 25th and 75th percentiles and the heavy bar represents the median. The whiskers are the 10th
and 90th percentiles. NP, normal proliferative (n = 7); HP, heavy proliferative (n = 5); NS, normal secretory (n = 6); HS, heavy secretory
{n = 5). Asterisk indicates significant difference (P < 0.05).
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Figure 2. Composite figure of box plot graphs demonstrating relative mRNA expression for prostanoid receptors in proliferative and secretory
endometrium of women with normal and heavy measured menstrual blood losses (MBLs) (normal MBL <80 ml and heavy MBL >80 ml). The
data are presented as box-and-whisker plots: box represents the 25th and 75th percentiles and the heavy bar represents the median. The whiskers
are the 10th and 90th percentiles. NP, normal proliferative (n = 7); HP, heavy proliferative (n = 5); NS, normal secretory (n = 6); HS, heavy
secretory (n = 5). EP1 to EP4 are the receptors for prostaglandin E2; FP is the receptor for prostaglandin F2u; TBXR is the receptor for thrombox¬
ane and IP is the receptor for prostacyclin. Asterisk indicates significant difference (P < 0.05).
Cyclic AMP production in response to treatment with
100 nM PGE2 was higher in endometrial tissue explants col¬
lected from women with heavy MBL when compared with
endometrium of women with normal MBL (Figure 3A).
As described earlier, the analysis of prostanoid receptor
mRNA expression did not detect any significant differences
for EP2 or EP4 in endometrium of women with measured
MBL. Therefore, in order to investigate whether effects at
the post-receptor level could explain this enhanced functional¬
ity of the EP receptor, we investigated the expression of phos¬
phodiesterase isotype 4B (PDE4B) in the same endometrial
samples. Quantitative RT-PCR analysis demonstrated a sig¬
nificant reduction in the expression of PDE4B in secretory
endometrium of women with heavy MBL, compared with
normal MBL (Figure 3B).
Discussion
This study demonstrates significantly elevated levels in mRNA
expression of both COX-1 and COX-2 enzymes in endome¬
trium obtained from women with measured heavy MBL.
These data suggest that it is important to use a general inhibi¬
tor of both COX-1 and COX-2 enzyme action in treating the
complaint of heavy menstruation. Mefenamic acid, a COX
inhibitor and a member of the Fenamate family of drugs, is
routinely used as a first-line treatment for menorrhagia. As
well as inhibiting prostaglandin synthesis, it has been shown
to inhibit binding of PGE2 to its receptors (Rees et al.,
1988). In keeping with this dual mode of action, the PGE2
pathway has previously been implicated in the problem of
heavy MBL. Elevated levels of PGE2 have been found in
the endometrium of women complaining of heavy periods
Page 5 of 7
O.P.Milling Smith, H.N.Jabbour and H.O.D.Critchly
<80
MBL (ml)
>80 NP HP NS HS
Figure 3. (A) Cyclic AMP (cAMP) production by endometrial tissue explants in response to a 10 min stimulation with 100 nM PGE2 or vehicle.
Graph shows average fold increase in cAMP production by endometrium of women with normal and heavy menstrual blood losses (MBLs)
(normal MBL <80 ml and heavy MBL >80 ml). Asterisk indicates significant elevated cAMP production (P < 0.05). (B) Phosphodiesterase
4B (PDE4B) mRNA expression in endometrium of women with normal and heavy MBLs (normal MBL <80 ml and heavy MBL >80 ml) as
determined by real-time quantitative RT-PCR. The data are presented as box-and-whisker plots: box represents the 25th and 75th percentiles
and the heavy bar represents the median. The whiskers are the 10th and 90th percentiles. NP, normal proliferative (n = 7); HP, heavy proliferative
(n = 5); NS, normal secretory (n = 6); HS, heavy secretory (n = 5). Asterisk indicates significant difference (P < 0.05).
(Willman et al., 1976) and further experiments confirmed an
apparent shift in synthesis in favour of PGE2 over PGF2tt in
the endometrium of women with heavy MBL (Smith et al.,
1981).
Additionally, our data demonstrate an enhanced PGE2-
EP-induced cAMP production in the endometrium obtained
from women with heavy MBL; however, the expression of
EP2 and EP4 receptors, which are known to couple to
cAMP production, does not display any significant correlation
with measured MBL in our studies. Previous data have
demonstrated an increase in PGE2 binding sites in uterine
tissue associated with the complaint of heavy MBL
(Adelantado et al., 1988), although specific receptor subtypes
were not identified. Indeed, it is plausible that EP2 and
EP4 receptor numbers could be regulated at the post-
transcriptional level, resulting in increased PGE2 receptor
binding sites. PGF2a and PGE2 are two prominent prostaglan¬
dins found in human endometrium (Lumsden et al., 1986). In
the endometrium, PGF2a receptor (FP) and PGE2 receptors,
EP2 and EP4, are responsible for their respective ligand
action. Although there was a reduction in the expression of
FP in the endometrium taken from women with heavy
MBL, no changes in the expression of EP2 and EP4 were
found. Therefore, a shift of endometrial prostaglandin signal¬
ling in favour of the PGE2 pathway over the PGF2ct pathway
may exist in the endometrium of women with heavy MBL.
Previous work has shown a decrease in the PGF2c(/PGE2
ratio in the endometrium of women with measured heavy
MBL when compared with women with normal MBL
(Smith et al., 1981).
The COX-2-PGE2-EP pathway has previously been
shown to influence angiogenic factors such as vascular endo¬
thelial growth factor through a mechanism mediated by
cAMP (Sonoshita et al., 2001). Therefore, the enhanced
ability for cAMP production by endometrium taken from
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women with heavy MBL may have important effects on
the expression of angiogenic factors. Altered endothelial
function as a result of disturbances to angiogenic factors
has previously been implicated in excessive MBL (Kooy
et al., 1996).
Thromboxane and prostacyclin are implicated in platelet
function and vascular haemostasis (Grosser et al., 2006) and
there is a strong expression of their respective receptors in
the endometrial vascular compartment (Milling Smith et al.,
2006; Battersby, unpublished data). However, no differences
in the expression of the genes involved in their signalling path¬
ways downstream of COX enzymes were detected between the
two groups of the endometrium of women with heavy and
normal MBLs.
PDEs are a large family of enzymes that are responsible for
the hydrolysis of cyclic nucleotides (Sanz et al., 2005). PDE4B
is an isoenzyme that is found in the human endometrium
(Bartsch et al. 2001, 2004) and shows specificity for hydrolysis
of cAMP. We have shown that in addition to an enhanced
ability to produce cAMP in response to PGE2, endometrium
taken from women with heavy MBL expresses a significantly
reduced level of PDE4B isoform mRNA.
In summary, increased expression of the rate-limiting COX
enzymes in the endometrium of women with heavy MBL will
lead to an increase in prostaglandin production and signalling.
In addition, enhanced functionality of the EP receptors coupled
to cAMP production could in part be explained by a reduction
in PDE4B expression within endometrium of women with
heavy MBL.
Our data, therefore, present a novel mechanism of endo¬
metrial prostaglandin signalling that may lead to the complaint
of heavy menstruation. Enhanced COX-PGE2 signalling and
reduced PDE4B expression in the endometrium of women
with heavy MBL present us with new therapeutic opportunities
in the treatment of heavy menstrual bleeding.
Prostaglandin signalling in heavy menses
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Prostacyclin Receptor Up-Regulates the Expression of
Angiogenic Genes in Human Endometrium via Cross
Talk with Epidermal Growth Factor Receptor and the
Extracellular Signaling Receptor Kinase 1/2 Pathway
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Medical Research Council Human Reproductive Science Unit (O.P.M.S., S.B., K.J.S., H.N.J.) and Department of
Reproductive and Developmental Sciences (O.P.M.S., H.O.D.C.), University of Edinburgh, Center for Reproductive Biology,
Queen's Medical Research Institute, Edinburgh EH16 4TJ, Scotland, United Kingdom
Prostacyclin (PGI) is a member of the prostanoid family of
lipid mediators that mediates its effects through a seven-
transmembrane G protein-coupled receptor (IP receptor). Re¬
cent studies have ascertained a role for prostanoid-receptor
signaling in angiogenesis. In this study we examined the tem¬
poral-spatial expression of the IP receptor within normal hu¬
man endometrium and additionally explored the signaling
pathways mediating the role of IP receptor in activation of
target angiogenic genes. Quantitative RT-PCR analysis dem¬
onstrated the highest endometrial expression of the IP recep¬
tor during the menstrual phase compared with all other
stages of the menstrual cycle. Immunohistochemical analysis
localized the site of IP receptor expression to the glandular
epithelial compartment with stromal and perivascular cell
immunoreactivity. Expression of the immunoreactive IP re¬
ceptor protein was greatest during the proliferative and early
secretory phases of the menstrual cycle. To explore the role of
the IP receptor in glandular epithelial cells, we used the Ish-
ikawa endometrial epithelial cell line. Stimulation of Ish-
ikawa cells and human endometrial biopsy explants with 100
nM iloprost (a PGI analog) rapidly activated ERK1/2 signaling
and induced the expression of proangiogenic genes, basic fi¬
broblast growth factor, angiopoietin-1, and angiopoietin-2, in
an epidermal growth factor receptor (EGFR)-dependent man¬
ner. Furthermore, EGFR colocalized with IP receptor in the
glandular epithelial compartment. These data suggest that
PGI-IP interaction within glandular epithelial cells can pro¬
mote the expression of proangiogenic genes in human endo¬
metrium via cross talk with the EGFR. (Endocrinology 147:
1697-1705, 2006)
ARACHIDONIC ACID (AA) is released from plasmamembrane phospholipids and is cyclized, oxygen¬
ated, and reduced to the unstable intermediary prostaglan¬
din (PG), prostaglandin H2 (PGH2) by cyclooxygenase (COX)
enzymes (1, 2). This intermediary serves as a substrate for
terminal PG synthase enzymes, such as prostacyclin (PGI)
synthase (PGIS), which completes the synthesis of PGI. PGI
is a member of the PG family and has a mode of action via
coupling to the heptahelical G protein-coupled PGI receptor
(IP receptor) (3, 4). PGI is best known for its effect on the
vascular endothelium, where its expression is found in abun¬
dance (5).
The IP receptor is known to mediate a cAMP rise and has
been termed a relaxant receptor (1), with routine activation
of the IP receptor activating adenylate cyclase via the Gs
subunit in a dose-dependent manner. Knockout studies dis¬
rupting the IP gene in mice have demonstrated thrombotic
tendencies and decreased inflammatory responses (6,7). The
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Abbreviations: AA, Arachidonic acid; Ang-1, angiopoetin-1; bFGF,
basic fibroblast growth factor; COX, cyclooxygenase; DN, dominant
negative; EGFR, epidermal growth factor receptor; IP receptor, G pro¬
tein-coupled PGI receptor; MEK, MAPK kinase; PG, prostaglandin; PGI,
prostacyclin; PGIS, PGI synthase; VEGF, vascular endothelial growth
factor.
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cyclical regeneration and repair undergone by the human
endometrium during the menstrual cycle necessarily in¬
volves physiological processes involving clotting and in¬
flammation. Uterine PGI production may be involved in
myometrial smooth muscle relaxation, vasodilation, and pre¬
vention of clot formation. These physiological actions are all
involved in the process of menstruation, and a role for PGI
in menstruation and menstrual disturbances is likely. In¬
deed, endometrium collected from women with excessive
menstrual blood loss has a greater capability of enhancing
myometrial PGI production than endometrium collected
from women with normal menstrual blood loss (8). Previous
studies have also demonstrated an increase in the expression
of PGIS and IP receptor mRNA during the menstrual stage
compared with the proliferative and secretory stages of the
cycle (4).
The cyclical remodeling of the human endometrium re¬
quires tight control of angiogenic growth factors to coordi¬
nate the growth of new vessel formation. Previous studies
have demonstrated that COX enzymes, in particular COX-2
(9), and PGs such as PGE2 (10) and PGF2„ (11) can modulate
the expression of target angiogenic genes within the human
endometrium.
This study was designed to investigate the expression of
the IP receptor and its role within the human endometrium.
Using an endometrial epithelial cell line (Ishikawa) and hu¬
man endometrial tissue, we investigated the intracellular
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signaling transduction pathways activated after PGI-IP li-
gand-receptor interaction. We found that the IP receptor is
spatio-temporally regulated within the glandular epithelial
compartment of human endometrium and is colocalized
with the epidermal growth factor receptor (EGFR) in human
endometrial glandular epithelial cells. Investigation of IP
receptor signal transduction pathways using Ishikawa cells
and human endometrial tissue showed rapid activation of
the ERK1/2 signaling pathway in an EGFR-dependent man¬
ner. Moreover, activation of the IP receptor was shown to
promote changes in the expression of proangiogenic genes,
basic fibroblast growth factor (bFGF), angiopoietin-1 (Ang-
1), and Ang-2.
Materials and Methods
Patients and tissue collection
Endometrial biopsies were collected at different stages of the men¬
strual cycle with an endometrial suction curette (Pipelle, Laboratoire
CCD, Paris, France) from women attending the gynecological outpatient
setting. In addition, full-thickness endometrial biopsies at all stages of
the menstrual cycle were collected from women undergoing hysterec¬
tomy for benign gynecological indications. Immediately after collection,
tissue was divided, transferred into RNA Later (Ambion, Inc., Hunt¬
ingdon, UK), stored at —70 C (for RNA extraction), fixed in neutral
buffered formalin, wax embedded (for immunohistochemical analysis)
or placed in RPMI 1640 medium (containing 2 mM L-glutamine, 100 U
penicillin, and 100 pg/ml streptomycin), and transported to the labo¬
ratory for in vitro culture. All subjects were 18-50 yr of age and reported
regular menstrual cycles (cycle length, 21-35 d). No woman had received
hormonal preparation in the 3 months preceding biopsy collection.
Biopsies were dated according to stated last menstrual period and were
confirmed by histological assessment according to criteria of Noyes and
co-workers (12). Furthermore, circulating estradiol and progesterone
serum levels were measured at the time of biopsy collection and were
consistent for both last menstrual period and histological assignment of
menstrual cycle stage. Ethical approval was obtained from Lothian
research ethics committee, and written informed consent was obtained
from all subjects before tissue collection.
Tissue culture
Tissue samples were finely minced using sterile forceps and scissors
before overnight incubation in serum-free RPMI medium (as described
above) and 3 pg/ml indomethacin (a dual COX enzyme inhibitor to
inhibit endogenous prostanoid production). The next day, tissue was
pretreated with a specific chemical inhibitor of EGFR kinase (AG1478;
100 nM) for 1 h before stimulation with 100 nM iloprost for the time
period stated in the figure legends. After stimulation, tissue was either
snap-frozen in dry ice and stored at —20 C for subsequent protein
extraction or stored at —70 C for RNA extraction. Protein was harvested
by homogenization of tissue in protein lysis buffer. Protein content was
determined using a protein assay kit (Bio-Rad Laboratories, Inc., Hemel
Hempstead, UK).
Cell culture
Ishikawa human endometrial epithelial cells (European Collection of
Cell Culture, Wiltshire, UK) were maintained as previously described
(10,13). The cells were grown on monolayer in 6-cm dishes to 60—80%
confluence, after which the culture medium was replaced with serum-
free DMEM containing 3 p-g/ml indomethacin for overnight incubation.
The next day, cells were pretreated with specific inhibitors of EGFR
kinase (AG1478; 100 nM) or MAPK kinase (MEK; PD98059; 50 /xm) for
1 h before stimulation with 100 nM iloprost or 100% (vol/vol) ethanol
as a vehicle control for the time period specified in the figure legends.
After stimulation with iloprost, proteins were harvested and extracted
as described previously (10), and the protein content in the supernatant
fraction was determined using a protein assay kit (Bio-Rad Laboratories,
Inc.).
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TaqMan quantitative RT-PCR
The expression of IP receptor across the menstrual cycle and the
effects of iloprost on proangiogenic gene expression in Ishikawa cells or
endometrial tissue were investigated by TaqMan quantitative RT-PCR
analysis. Total RNA was extracted from endometrial biopsies using an
RNeasy Midi Kit (Qiagen, Sussex, UK) according to the manufacturer's
instructions. Samples were treated for DNA contamination by DNA
digestion during RNA purification. RNA was extracted from Ishikawa
cells as described previously (10, 13). Once extracted and quantified,
RNA samples were reverse transcribed and subjected to real-time quan¬
titative PCR using an ABI PRISM 7700 Sequence Detection System
(Applied Biosystems, Warrington, UK) as previously described (10,13).
All primers and probes were designed using the PRIMER express pro¬
gram (Applied Biosystems; Table 1); IP primers and probes have been
previously described (4).
Data were analyzed and processed using Sequence Detector version
1.6.3 (Applied Biosystems) according to the manufacturer's instructions.
The expression of IP receptor and proangiogenic genes was normalized
to RNA loading for each sample using 18S RNA as an internal standard.
Results were expressed relative to an internal positive standard of
pooled human endometrial cDNA, which was included in all reactions.
The fold increase was determined by dividing the relative expression in
PGI-treated cells/tissues by the relative expression of the vehicle control.
Transient transfections and immunoprecipitation
To confirm the role of EGFR in iloprost-mediated ERK1 /2 phosphor¬
ylation, we used a dominant negative (DN) mutant EGFR. Ishikawa cells
were seeded to a density of 5 X 105/well in 6-cm dishes, then transfected
with a c-Myc-tagged ERK1/2 cDNA construct together with either
empty vector cDNA (pcDNA3; Invitrogen Life Technologies, Inc., de
Schelp, The Netherlands) or DN-EGFR cDNA using Superfect (Qiagen,
Crawley, UK) according to the manufacturer's protocol (DN-EGFR and
c-Myc tagged ERK constructs were gifts from Dr. Zvi Naor, Tel-Aviv
University, Tel-Aviv, Israel). Optimal concentrations of cDNA for trans-
fection were determined by titration, and the transfection efficiency of
the Ishikawa cell line was determined by transfection with a pcDNA6/
V5/His/lacZ cDNA construct (Invitrogen Life Technologies, Inc.) and
a /3-galactosidase assay. Transfection efficiency, as reported previously
for this cell line using standard procedures according to the manufac¬
turer protocol, is 45 ± 5% (11). The following day, cells were starved by
overnight incubation in serum-free medium containing 3 /ag/ml indo¬
methacin, then treated with 100 nM iloprost or vehicle for 10 min. Cells
were lysed, and protein was quantified as described above. The tagged
ERKl/2 was immunoprecipitated from whole-cell lysate. For immuno¬
precipitation, equal amounts of protein were incubated with specific
c-Myc antibody preconjugated to protein A Sepharose overnight at 4 C
with gentle rotation. Beads were washed extensively with lysis buffer,
and immune complexes were eluted and solubilized in Laemmli buffer
[125 mM Tris-HCl (pH 6.8), 4% sodium dodecyl sulfate, 5% 2-mercap-



















GTG GCC CCT CCA ATC TA
TGC CAC TTT ATC CCA TTC AGT T
TTT TGT CCC GCA GTA TAG AAC ATT CCA T
GCT CGA ATA CGA TGA CT
AGC CAC TTG CAG CCT CTG CA
TCC AGC ACT TGC AGC CTC TGC A
ACG GCC GCG TTG AC
ACA ACT CCT CTC TCT T
AGA GCG ACC CTC ACA
CTA CCA CAT CCA AGG AA
GGA ATT ACG GGG GCT
TGG CAC CAG ACT TGC CCT
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toethanol, 20% glycerol, and 0.05% bromophenol blue], boiled for 5 min,
and subjected to Western blot analysis.
Western blot analysis
Western blot analysis was conducted to investigate ERK1/2 expres¬
sion in Ishikawa cells and human endometrial tissue. A total of 50 /ng
protein from whole-cell lysate was resuspended in 20 pi Laemmli buffer.
Proteins were resolved on 4-20% Tris-glycine gels (NOVEX, Invitrogen
Life Technologies, Inc.), transferred onto a polyvinylidene difluoride
membrane (Millipore Corp., Watford, UK), and subjected to immuno-
blot analysis as previously described (14). Blots were incubated with
anti-phospho-p42/p44 ERK (9101, Cell Signaling Technologies/New
England Biolabs, Hertfordshire, UK) and alkaline-phosphatase conju¬
gated secondary antibodies (Sigma-Aldrich Corp., Ayrshire, UK). Im-
munoblots were stripped and reprobed with antibody recognizing total
ERK (sc-93, Santa Cruz Biotechnology/Autogen-Bioclear, Wiltshire,
UK). Immunoreactive proteins were visualized by the enhanced chemi-
luminescence system according to the manufacturer's instructions (Am-
ersham Biosciences, Little Chalfont, UK). Proteins were revealed and
quantified by Phosphorlmager analysis using a Typhoon 9400 Phos-
phorlmager (Molecular Dynamics, part of Amersham Biosciences). Rel¬
ative density in immunoblots was calculated by dividing the value
obtained from the phosphorylated immunoblots by the value obtained
from the total immunoblots in the same experiment and was expressed
as the fold increase above the vehicle control value.
Immunohistochemistry
To investigate the expression of the IP receptor in human endome¬
trium, endometrial sections (5 /am) from across the menstrual cycle were
dewaxed in xylene and rehydrated using decreasing grades of ethanol,
followed by water. All washes were carried out in 0.01 M PBS (Sigma-
Aldrich Corp.). Antigen retrieval was performed by pressure-cooking in
0.01 M sodium citrate (pH 6.0) for 5 min. Thereafter, slides were se¬
quentially incubated with 3% hydrogen peroxide (VWR, Inc., Poole, UK)
in distilled water for 10 min (to quench endogenous peroxidase activity),
followed by a 15-min incubation with avidin and biotin solutions (Vector
Laboratories, Inc., Peterborough, UK) to block endogenous streptavidin
activity. Nonspecific binding was further reduced by 20-min incubation
with nonimmune horse serum (Vector Laboratories, Inc.) in a humidi¬
fied chamber at room temperature before overnight incubation with the
primary antibody at 4 C. For localization of IP receptor, slides were
incubated with a goat polyclonal antibody raised against a peptide
mapping near the carboxyl terminus of IP receptor of human origin
(sc-20436, Santa Cruz Biotechnology, Inc.) at a 1:30 dilution in normal
horse serum. Preabsorption of the antibody with a specific blocking
peptide (Santa Cruz Biotechnology, Inc.) was used as the negative con¬
trol in addition to a control goat IgG antibody at a matched protein
concentration to the IP antibody. After a wash in PBS with 0.01% Tween
20, the slides were incubated in biotinylated horse antigoat secondary
antibody (Vector Laboratories, Inc.) in normal horse serum at a 1:200
dilution for 60 min at room temperature. Tertiary detection was carried
out using an avidin-biotin-peroxidase complex (Vectastain Elite, Vector
Laboratories, Inc.) for 60 min at room temperature, and visualization
was carried out with the substrate and chromagen 3,3'-diaminobenzi-
dine (DakoCytomation, Carpinteria, CA). Sections were counterstained
with hematoxylin, dehydrated in xylene, and mounted.
Scoring and analysis of immunoreactivity
The immunostaining intensity of the IP receptor epitope in all tissue
sections was assessed in a semiquantitative manner on a 4-point scale:
0, no immunostaining; 1, mild immunostaining; 2, moderate immuno¬
staining; and 3, intense immunostaining. All tissue sections were scored
blind by two observers. This scoring system has been previously vali¬
dated in a subset of tissue sections in which immunoreactivity was
measured with a computerized image analysis system; a strong corre¬
lation between quantitative data derived from the image analysis and
subjective scores determined by a trained observer was obtained (15).
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Immunofluorescent confocal laser microscopy
Colocalization of the site of expression of the IP receptor with EGFR or
the endothelial cell marker CD31 was performed in human endometrium
by dual-immunofluorescence immunohistochemistry and confocal laser
microscopy. Human endometrial sections (5 ^m) were dewaxed, rehy¬
drated, and washed as described above. The immunohistochemical meth¬
odology was repeated for antigen retrieval by pressure cooking, quenching
of hydrogen peroxidase activity, and blocking of endogenous streptavidin
activity. Nonspecific binding was further reduced by 20-min incubation
with 5% nonimmune rabbit serum diluted in PBS before overnight incu¬
bation at 4 C with the polyclonal mouse anti-EGFR primary antibody
(NCL-EGFR-384; Nova-Castra, Newcastle-upon-Tyne, UK) at a dilution of
1:25. For colocalization of the IP receptor with CD31, a monoclonal mouse
anti-CD31 antibody (DakoCytomation) was used at a dilution of 1:20.
Control sections were incubated with polyclonal goat anti-IP primary an¬
tibody at a dilution of 1:100 to demonstrate the specificity of the secondary
antibody for the mouse primary antibodies. The following day, sections
were washed with PBS Tween 20 and incubated with a 1:500 dilution of
biotinylated rabbit antimouse IgG for 1 h. An additional 1-h incubation with
the fluorochrome streptavidin AlexiFluor 488 (Molecular Probes, Inc., Cam¬
bridge Bioscience, Cambridge, UK) diluted at 1:200 in PBS was performed.
Next, sections were incubated for 20 min in a PBS solution containing biotin
to enhance fluorescent signal before reblocking with 5% nonimmune rabbit
serum. Incubation with the goat anti-IP antibody (Santa Cruz Biotechnol¬
ogy, Inc.) at a 1:100 dilution at 4 C overnight was then performed. A second
control slide was incubated with mouse anti-EGFR or mouse anti-CD31
primary antibody. Incubation with a 1:200 dilution of rabbit antigoat per¬
oxidase (Vector Laboratories, Inc.) secondary antibody was performed for
30 min. Tertiary detection was performed with an 8-min incubation with
tyramide Cy3 solution (PerkinElmer Life Sciences, Boston, MA) at a 1:50
dilution according to the manufacturer's instructions. Slides were coun¬
terstained with To Pro (Molecular Probes, Inc.) at a 1:2000 dilution for 2 min,
then mounted in Permafluor (Immunotech-Coulter, Buckinghamshire,
UK).
Statistics
Unless otherwise stated and where appropriate, data were subjected
to statistical analysis with ANOVA and Fisher's protected least signif¬
icant difference tests (StatView 4.0; Abacus Concepts, Inc., Piscataway,
NJ), and statistical significance was accepted at P < 0.05. Semiquanti¬
tative scoring results for immunohistochemical staining were analyzed
by a nonparametric method, the Kruskal-Wallis test, followed by Dunn's
post hoc multiple comparison test.
Results
IP receptor mRNA and protein expression within human
endometrium
IP receptor mRNA expression in human endometrium
across the menstrual cycle was determined by TaqMan quan¬
titative RT-PCR analysis (Fig. 1). IP receptor mRNA was
significantly up-regulated during the menstrual stage of the
cycle compared with all other stages in the cycle (P < 0.05).
This rise in RNA expression was found to precede the
expression of the IP receptor protein, as detected by immu¬
nohistochemistry. The temporal spatial expression of the IP
receptor was examined in human endometrium across the
menstrual cycle (Fig. 2A). Subjective scoring of IP receptor
immunoreactivity showed a significant variation of tempo¬
ral-spatial expression across the menstrual cycle within the
glandular epithelium of the functional layer of human en¬
dometrium (Fig. 3; P < 0.05). IP receptor immunostaining
was greatest during the proliferative (Fig. 2Ai) and early
secretory (Fig. 2Aii) phases within the glandular compart¬
ment of the functional layer and was observed to decrease
during the late secretory stages (Fig. 2Aiii). Fligh magnifi¬
cation views (Fig. 2B) of a representative endometrial section
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Fig, 1. Relative mRNA expression of the IP receptor in the human
endometrium across the menstrual cycle as determined by real-time
quantitative RT-PCR. Results are expressed as the mean ± sem rel¬
ative mRNA expression levels, b is significantly elevated from a (P <
0.05). Tissue sample numbers are: n = 7 proliferative, n = 6 early
secretory, n = 5 midsecretory, n = 6 late secretory, and n = 4 men¬
strual.
show the plasma membrane localization of the IP receptor,
with some cytoplasmic immunoreactivity also present. Min¬
imal basal layer stromal immunostaining was observed in all
tissue sections across the menstrual cycle compared with the
functional stroma.
In addition, IP receptor immunoreactivity appeared prom¬
inent in vessel endothelium throughout the full thickness of
A
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endometrial tissue sections, involving vessels within the en¬
dometrial and muscularis layers. To establish this immuno¬
staining as being vascular in location, dual-confocal immu¬
nofluorescence immunohistochemistry was used to
colocalize the IP receptor with the endothelial cell marker,
CD 31 (Fig. 2C). IP receptor (red) was observed to colocalize
(yellow) with CD31 (green) in the blood vessels of all tissue
sections investigated, indicating that IP receptor was present
in the vascular compartment.
Iloprost activation of the IP receptor in Ishikawa cells
Treatment of Ishikawa cells with 100 nM iloprost elicited
a significant time-dependent increase in phosphorylation of
the ERK1/2 pathway, with maximal phosphorylation de¬
tected at 5 min (Fig. 4A; P < 0.05). Previous studies in our
laboratory have demonstrated that prostanoid (including
PGE2 and PGF2a) signaling to downstream MAPK pathways
involves transactivation of the EGFR (10, 11, 13). To inves¬
tigate the potential involvement of the EGFR in transducing
the PGI-IP receptor signal to ERK1/2, we used the selective
EGFR tyrosine kinase inhibitor, AG1478. Preincubation of
cells for 1 h with the EGFR kinase inhibitor (AG1478; 100 nM)
or inhibitor of MEK (PD98059; 50 /am) abolished the phos¬
phorylation of ERK1/2 in response to a 5-min 100-nM ilo¬
prost treatment (Fig. 4B). No significant alteration in basal
levels of ERK phosphorylation was observed in cells treated
with chemical inhibitor alone (data not shown).

























Fig. 2. A, Immunohistochemical localization of the IP re¬
ceptor within the human endometrium across the men¬
strual cycle. Variation in temporal/spatial localization of
the IP receptor is demonstrated. Glandular epithelial im¬
munostaining (g) was present in both basal (b) and func¬
tional (f) layers. Some stromal immunostaining was dem¬
onstrated in the functional layer only. Representative
sections from i) proliferative, ii) early secretory, iii) late
secretory, and iv) menstrual (inset shows control staining
with primary antibody after specific peptide preabsorption)
stages are shown. Scale bar, 10 pm. B, High magnification
(X100) view of immunohistochemical staining for IP recep¬
tor within epithelial gland and blood vessel of the functional
layer of early secretory endometrium. Scale bar, 10 pm. C,
Endothelial staining is confirmed by confocal immunoflu-
orescent colocalization (merged; yellow) of the site of ex¬
pression of IP receptor (red; ii and v) with the endothelial
cell marker, CD31 (green; i and iv) in early secretory en¬
dometrium. Colocalization of IP receptor with CD31 (yellow;
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Fig. 3. Box plot demonstrating results of subjective scoring of IP
receptor immunostaining within the glandular epithelium ofthe func¬
tional layer of human endometrium. Statistical analysis using the
nonparametric ANOVA Kruskal-Wallis test indicated that variation
in immunostaining intensity was significantly different across the
menstrual cycle (P < 0.05). The data are presented as box and whisker
plots; the box represents the 25th and 75th percentiles, and the heavy
bar represents the median. The whiskers are the 10th and 90th per¬
centiles. Tissue sample numbers for each stage of the cycle are pre¬
sented.
of IP receptor with EGFR by confocal immunofluorescence
microscopy. Dual-immunofluorescence immunohistochem-
istry (Fig. 6) confirmed colocalization (merged; yellow) of the
IP receptor (Fig. 6, A and D, red) with the EGFR (Fig. 6, B and
E, green). Colocalization was most evident within the glan¬
dular epithelial compartments in both basal (Fig. 6, A-C) and
functional (Fig. 6, D-F) layers of the endometrium, with
minimal stromal cell colocalization.
Subsequently, we assessed the effect of PGI-IP receptor
signaling on ERK1/2 phosphorylation and proangiogenic
gene expression in human endometrial tissue. Treatment of
human endometrial tissue explants with 100 nM iloprost (Fig.
7A) caused a significant phosphorylation of ERK1/2 after 10
min. Preincubation of the tissue with 100 nM AG1478 for 1 h
abolished the iloprost-induced phosphorylation of ERK1/2.
As observed in Ishikawa cells, treatment of human endo¬
metrial tissue with 100 nM iloprost for 24 h resulted in a
significant increase in bFGF mRNA expression compared
with vehicle control (P < 0.05). Preincubation of the tissue
with 100 nM AG1478 for 1 h abolished the iloprost-induced
elevation of bFGF (Fig. 7B). A similar trend in expression of
the two angiopoietin genes, Ang-1 and Ang-2, was observed
in response to treatment with 100 nM iloprost. Preincubation
of endometrial tissue with 100 nM AG1478 reduced the ilo-
prost-mediated elevation of Ang-1 and Ang-2 expression;
however, the reduction was not statistically significant (Fig.
7B).
of the IP receptor to ERK1/2, we cotransfected Ishikawa cells
with a c-Myc-tagged ERK cDNA construct with either a DN
mutant cDNA isoform of the epidermal growth factor re¬
ceptor (DN-EGFR) or empty vector cDNA (pcDNA3). Ish¬
ikawa cells were then treated with either vehicle or 100 nM
iloprost for 5 min. The tagged ERK was immunoprecipitated
with anti-c-Myc antibody, and the ERK activity of the tagged
construct was determined by Western blotting as described
in Materials and Methods. Iloprost treatment of Ishikawa cells
resulted in a significant phosphorylation of ERK1/2 in cells
transfected with the empty vector (Fig. 4C, lane 2). This
elevation in ERK1/2 phosphorylation by iloprost was abol¬
ished by cotransfection of cells with the DN-EGFR cDNA
(Fig. 4C, lane 3).
PGI-IP receptor signaling in Ishikawa cells promotes the
expression ofproangiogenic genes
Iloprost stimulation of Ishikawa cells caused a significant
fold increase in mRNA expression of the proangiogenic
genes, bFGF, Ang-1, and Ang-2, at 24 h compared with earlier
time points (Fig. 5A). Cotreatment of the cells with the EGFR
kinase inhibitor (AG1478; 100 nM) significantly reduced IP
receptor-induced mRNA expression of all target genes (Fig.
5B; P < 0.05).
IP receptor signaling in human endometrium
To correlate our findings using the Ishikawa cell line to IP
receptor signaling in human endometrium in situ, we used
human endometrial biopsy explants. Initially we investi¬
gated whether IP signaling in the human endometrium in¬
volves cross talk with EGFR and examined the colocalization
Discussion
During the reproductive years, in the absence of preg¬
nancy, the human endometrium undergoes a series of cy¬
clical changes, culminating in the process of menstruation.
This process of physiological injury and repair requires con¬
tinuous remodeling of the superficial layers of the endome¬
trium together with a concurrent control of vessel remodel¬
ing and formation. Studies of angiogenesis in the endometrium
have confirmed continuous cycles of angiogenic activity,
with a number of peaks of activity demonstrated throughout
the menstrual cycle (reviewed in Ref. 16). The roles of COX
enzymes, prostanoids, and prostanoid receptors in the re¬
productive tract have been well documented (8, 14, 17, 18).
In particular, menstrual problems, such as excessive blood
loss, are linked to PG signaling. Indeed, first-line treatment
for such complaints involves the use of nonsteroidal antiin¬
flammatory drugs, which inhibit COX, the rate-limiting en¬
zyme in prostanoid production (19, 20).
The data presented in this manuscript demonstrate the
expression and localization of the IP receptor in epithelial,
endothelial, and stromal cells of the human endometrium
across the menstrual cycle. IP receptor mRNA is dramatically
elevated in human endometrium during the menstrual phase
of the cycle and precedes the glandular expression of IP
receptor protein, which is highest in the proliferative phase
of the menstrual cycle. The IP receptor is a Gs-coupled hep-
tahelical transmembrane receptor that has been shown to
activate the protein kinase A pathway, resulting in the pro¬
duction of cAMP (4). Activation of prostanoid receptors,
such as E- and F-series prostanoid receptors, results in ini¬
tiation of numerous effector signaling pathways, including
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Fig. 5. (A) Time course demonstrating bFGF, Ang-1 and Ang-2 gene
expression in Ishikawa cells in response to 100 nM Iloprost stimula¬
tion. Results are expressed as the mean + sem (n = 4 experiments),
b is significantly different from a (P < 0.05). B, mRNA expression of
bFGF, Ang-1 and Ang-2 in Ishikawa cells following stimulation with
100 nM Iloprost for 24 h in the absence or presence of EGFR tyrosine
kinase inhibitor (AG1478, 100 nM) as determined by real-time quan¬
titative RT-PCR. Results are expressed as the mean + sem (n = 3
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Fig. 4. ERK1/2 phosphorylation after treatment of Ishikawa cells
with 100 nM iloprost. A, Western blot analysis of time course for
ERK1/2 phosphorylation. A representative blot demonstrates phos-
phorylated ERK1/2 (upper panel). Total ERK1/2 was identified by
reprobing the same blot with antibody directed against total ERK
protein (lower panel). Graph shows semiquantitative analysis of four
experiments, as described in Materials and Methods. Superscripts
the MAPK pathway (10,13,21). The MAPK pathway is a key
signaling mechanism that regulates many cellular functions,
such as growth, differentiation, and transformation (22, 23).
The data presented in this report also demonstrate that ac¬
tivation of the IP receptor induces a rapid increase inp42 ERK
phosphorylation in Ishikawa cells and of p42/p44 ERK phos¬
phorylation in endometrial tissue. Interestingly, the differ¬
ential phosphorylation of ERK between Ishikawa cells and
indicate significant differences (P < 0.05). B, Western blot analysis of
the effects of chemical inhibitors on ERK1/2 phosphorylation.
PD98059 is a MEK inhibitor (inhibitor of ERK phosphorylation);
AG1478 is an inhibitor of EGFR tyrosine kinase. For each, a repre¬
sentative blot is shown. The graph shows semiquantitative analysis
of three experiments as described in Materials and Methods, b is
significantly different from a (P < 0.05). C, Ishikawa cells were co-
transfected with a c-Myc-tagged ERK cDNA construct together with
either a DN cDNA isoform targeted against the EGFR (lane 3) or
empty vector pcDNA (lanes 1 and 2) and subsequently stimulated
with vehicle (lane 1) or 100 nM iloprost (lanes 2 and 3) for 10 min. The
tagged ERK construct was immunoprecipitated (IP) and ERK phos¬
phorylation of the tagged construct determined by Western blot anal¬
ysis (WB). The graph represents semiquantitative analysis of four
experiments, as described in Materials and Methods. —, Absence of
agent; +, presence of agent, b is significantly different from a (P <
0.05).
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Fig. 6. Confocal immunofluorescent localization of the
Site ot expression oi IF receptor (red; A and L>) with
EGFR (green; B and E) and colocalization of IP with
F.GFR (merged; yellow; C and F). Expression is demon
strated in the epithelial cells of the basal (A-C) and
functional (D-F) human proliferative endometrium. In¬
serts aie shown fui negative cuntiul sections as de¬
scribed in the methods (Srnlp hnr, Ifl /im )
endometrial biopsy tissue may be due to the presence of
other cells types (stromal and endothelial) within the biopsy
tissue compared with the homogeneity of the Ishikawa cell
line. Alternatively, Ishikawa cells originate from an endo¬
metrial carcinoma and may respond differently from normal
endometrial epithelial cells. This phosphorylation of ERK in
Ishikawa cells and endometrial tissues is inhibited with the
specific chemical inhibitor of EGFR kinase or by transfection
of Ishikawa cells with a DN mutant isoform of the EGFR.
Moreover the expression of EGFR colocalized with IP recep¬
tor in the glandular epithelial compartment of the human
endometrium. Thus, as observed with prostanoid receptor
signaling to downstream ERK1/2 in other model systems
(10, 11, 24-26), in the present study, EGFR is in close prox¬
imity with the IP receptor, and EGFR transactivation is re¬
quired for the PGI-IP-induced activation of the ERK1/2 sig¬
naling pathway within human endometrium. Whether the
EGFR is held in a complex of protein-protein interactions
with the IP receptor in the glandular epithelial compartment,
or transactivation of the EGFR is mediated by intermediary
scaffold adapter molecules to facilitate ERK1/2 signaling
remains to be determined.
Our data also demonstrate that IP receptor activation by
PGI leads to an increase in mRNA expression of several
proangiogenic genes, including bFGF, Ang-1, and Ang-2, in
both Ishikawa cells and normal human endometrium. bFGF
is potent growth factor, which is known to promote the
growth and proliferation of numerous cell types by activa¬
tion of membrane FGF receptor tyrosine kinases. Moreover,
bFGF is known to have potent proangiogenic effects in sev¬
eral model systems (27, 28) and has been implicated in pro¬
moting tumor angiogenesis (29,30) and angiogenesis in pro¬
liferative lesions of endometriosis (31). The angiopoietins are
a family of growth factors that act as ligands for the largely
endothelial-restricted Tie-2 receptor tyrosine kinase, which is
essential for vascular development. Ang-1 is a Tie-2 receptor
agonist that is required for recruitment of perivascular cells,
leading to the formation and stabilization of capillaries, ves¬
sel maturation, and endothelial cell survival. Ang-1 and
other angiogenic factors, such as vascular endothelial growth
factor (VEGF) and bFGF, may act synergistically to increase
vascular sprouting and branching. In addition, the Ang-1/
Tie-2 interaction enhances the mitogenic effect of angiogenic
factors, such as VEGF, on endothelial cell growth (reviewed
in Ref. 32). By contrast, Ang-2 is a natural Tie-2 receptor
antagonist, destabilizing cell contacts and thus allowing ac¬
cess to angiogenic factors, such as VEGF. The process of
angiogenesis is thus a fine balance among the expressions of
numerous proangiogenic factors, all of which may be present
concurrently in the cell to regulate vascularization in re¬
sponse to PGI-IP receptor interaction.
Furthermore, in the present study we have demonstrated
that the actions of PGI, via the IP receptor, on target angio¬
genic gene expression are dependent upon the presence of
the EGFR. It is also possible that this up-regulation of ex¬
pression is mediated by ERK1/2 phosphorylation. This
mechanism of target gene regulation in reproductive cells
and tissues via prostanoid-receptor interaction is in agree¬
ment with previous studies. Transactivation of EGFR and
ERK1/2 phosphorylation, leading to increased expression of
angiogenic genes, including VEGF, have previously been
shown for PGE2-E-series prostanoid receptor 2 (10) and
PGF2(1-F-series prostanoid receptor interaction (11), suggest¬
ing that EGFR transactivation is a central theme for the pro¬
motion of vascular function in the human endometrium by
prostanoids. In the present study we have focused on the role
of PGI-IP receptor signaling to angiogenic genes using the
Ishikawa endometrial epithelial cell line as a model system;
however, it is possible that PGI-IP receptor signaling in stro¬
mal and endothelial cells may act in a synergistic manner
with epithelial cells in the endometrium to favor angiogen¬
esis, because our parallel studies of whole tissue endometrial
biopsy explants are in agreement with our data derived from
the Ishikawa cell line.
The precise role of PGI in human endometrium remains to
be fully explored; however, PGI has been implicated in men¬
struation (33) and menstrual disturbances, where levels are
elevated in endometrial pathologies such as menorrhagia
(excessive menstrual blood loss) (8). It is thus possible that
vascular disturbances in the endometrium of women with
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Fig. 7. ERK1/2 phosphorylation after treatment of endometrial tis¬
sue explants with 100 nM iloprost. A, Western blot analysis of ERK1/2
phosphorylation after stimulation with 100 nM iloprost for 10 min in
the absence or presence of AG1478. The graph shows semiquantita¬
tive analysis of three experiments determined as described in Mate¬
rials and Methods, b is significantly different from a (P < 0.05).
-, Absence of agent; +, presence of agent. B, mRNA expression of
bFGF (top panel), Ang-1 (middle panel), and Ang-2 (lower panel)
within normal human endometrial tissue after stimulation with 100
nM iloprost for 24 h in the presence or absence of AG1478, as deter¬
mined by quantitative RT-PCR. Results are expressed as the mean ±
SEM (n = 4 experiments), b is significantly different from a (P < 0.05).
menstrual pathologies such as menorrhagia may be exacer¬
bated by the elevation of proangiogenic genes, such as bFGF,
Ang-1, and Ang-2, brought about by enhanced PGI-IP re¬
ceptor signaling. In other studies, an aberration of expression
levels of angiogenic growth factors has been demonstrated in
endometrium from women with menorrhagia, such that a
decrease in the expression of Ang-1 mRNA (34) and an in¬
crease in Ang-2 protein (35) were reported in endometrium
collected from women with heavy menstrual blood loss com¬
pared with control endometrium. These alterations in Ang
expression are coincident with an increase in the expression
of bFGF receptor in the endometrium of women with ex¬
cessive menstrual blood loss compared with control endo¬
metrium (36).
Taken together, we have demonstrated a potential role for
PGI-IP receptor signaling in the Ishikawa endometrial epi¬
thelial cell line and whole human endometrial biopsy ex-
plants in regulating the mRNA expression of several proan¬
giogenic genes. These genes can influence angiogenesis by
acting on adjacent endothelial cells in an autocrine/paracrine
manner. Moreover, these studies have demonstrated a role
for PGI-EGFR cross talk in promoting angiogenic gene ex¬
pression in the endometrium. Blockade of EGFR signaling
with an orally active EGFR tyrosine kinase inhibitor has been
used successfully in inhibiting angiogenesis in nude mice
(37). Additionally, in a mouse model of colorectal cancer,
studies have demonstrated that a combinatorial approach
using a nonselective COX enzyme inhibitor in combination
with an inhibitor of EGFR kinase is of greater therapeutic
benefit than either compound alone (38). These observations
of EGFR inhibition and ours reported in the present study
suggest that targeted inhibition of EGFR function with small
molecule chemical inhibitors alone or in combination with a
COX enzyme inhibitor may modulate angiogenic activity in
the endometrium, with possible benefits for menstrual pa¬
thologies that are associated with aberrant expression and
signaling of prostanoids and altered angiogenesis or vascular
function (39-42).
Acknowledgments
Received August 23, 2005. Accepted December 13, 2005.
Address all correspondence and requests for reprints to: Dr. Henry
N. Jabbour, Medical Research Council Human Reproductive Science
Unit, Centre for Reproductive Biology, Queen's Medical Research In¬
stitute, 47 Little France Crescent, Edinburgh EH16 4TJ, Scotland, United
Kingdom. E-mail: h.jabbour@hrsu.mrc.ac.uk.
This work was supported by the Medical Research Council. A Clinical
Research Fellowship Grant was awarded to O.M.S. from University of
Edinburgh College of Medicine and Veterinary Medicine.
O.P.M.S., S.B., K.J.S., and H.N.J, have nothing to declare. H.O.D.C. has
received support for invited presentations at scientific meetings on the
management of menstrual bleeding problems from Schering, but not on
the context or topic of the scientific content of this manuscript.
References
1. Narumiya S, FitzGerald GA 2001 Genetic and pharmacological analysis of
prostanoid receptor function. J Clin Invest 108:25-30
2. Marnett LJ 1992 Aspirin and the potential role of prostaglandins in colon
cancer. Cancer Res 52:5575-5589
3. Narumiya S, Sugimoto Y, Ushikubi F 1999 Prostanoid receptors: structures,
properties, and functions. Physiol Rev 79:1193-1226
4. Battersby S, Critchley HO, de Brum-Fernandes AJ, Jabbour HN 2004 Tem-
Downloaded from endo.endojournals.org by on July 29, 2007
Milling Smith et al. • IP Receptor Signaling to Angiogenic Genes Endocrinology, April 2006, 147(4): 1697-1705 1705
poral expression and signalling of prostacyclin receptor in the human endo¬
metrium across the menstrual cycle. Reproduction 127:79 -86
5. Smyth EM, FitzGerald GA 2002 Human prostacyclin receptor. Vitam Horm
65:149-165
6. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y,
Ichikawa A, Aze Y, Tanaka T, Yoshida N, Ueno A, Oh-ishi S, Narumiya S
1997 Altered pain perception and inflammatory response in mice lacking
prostacyclin receptor. Nature 388:678 -682
7. Ueno A, Naraba H, Ikeda Y, Ushikubi F, Murata T, Narumiya S, Oh-ishi S
2000 Intrinsic prostacyclin contributes to exudation induced by bradykinin or
carrageenin: a study on the paw edema induced in IP-receptor-deficient mice.
Life Sci 66:155-160
8. Smith SK, Abel MH, Kelly RW, Baird DT 1981 A role for prostacyclin (PGI2)
in excessive menstrual bleeding. Lancet 1:522-524
9. Gately S, Li WW 2004 Multiple roles of COX-2 in tumor angiogenesis: a target
for antiangiogenic therapy. Semin Oncol 31:2-11
10. Sales KJ, Maudsley S, Jabbour HN 2004 Elevated prostaglandin EP2 receptor
in endometrial adenocarcinoma cells promotes vascular endothelial growth
factor expression via cyclic 3',5'-adenosine monophosphate-mediated trans-
activation of the epidermal growth factor receptor and extracellular signal-
regulated kinase 1/2 signaling pathways. Mol Endocrinol 18:1533-1545
11. Sales KJ, List T, Boddy SC, Williams AR, Anderson RA, Naor Z, Jabbour HN
2005 A novel angiogenic role for prostaglandin F2ra-FP receptor interaction in
human endometrial adenocarcinomas. Cancer Res 65:7707-7716
12. Noyes RW, Hertig AT, Rock J 1950 Dating the endometrial biopsy. Fertil Steril
1:3-25
13. Sales KJ, Milne SA, Williams AR, Anderson RA, Jabbour HN 2004 Expres¬
sion, localization, and signaling of prostaglandin F2a receptor in human en¬
dometrial adenocarcinoma: regulation of proliferation by activation of the
epidermal growth factor receptor and mitogen-activated protein kinase sig¬
naling pathways. J Clin Endocrinol Metab 89:986-993
14. Jabbour HN, Sales KJ 2004 Prostaglandin receptor signalling and function in
human endometrial pathology. Trends Endocrinol Metab 15:398-404
15. Wang H, Critchley HO, Kelly RW, Shen D, Baird DT 1998 Progesterone
receptor subtype B is differentially regulated in human endometrial stroma.
Mol Hum Reprod 4:407-412
16. Smith SK 2001 Regulation of angiogenesis in the endometrium. Trends En¬
docrinol Metab 12:147-151
17. Smith SK, Abel MH, Kelly RW, Baird DT 1981 Prostaglandin synthesis in the
endometrium of women with ovular dysfunctional uterine bleeding. Br J
Obstet Gynaecol 88:434-442
18. Sales KJ, Jabbour HN 2003 Cyclooxygenase enzymes and prostaglandins in
reproductive tract physiology and pathology. Prostaglandins Other Lipid Me-
diat 71:97-117
19. Anderson AB, Haynes PJ, Guillebaud J, Turnbull AC 1976 Reduction of
menstrual blood-loss by prostaglandin-synthetase inhibitors. Lancet 1:774-776
20. Cameron IT, Haining R, Lumsden MA, Thomas VR, Smith SK 1990 The
effects of mefenamic acid and norethisterone on measured menstrual blood
loss. Obstet Gynecol 76:85-88
21. Milne SA, Jabbour HN 2003 Prostaglandin (PG) F2„ receptor expression and
signaling in human endometrium: role of PGF2a in epithelial cell proliferation.
J Clin Endocrinol Metab 88:1825-1832
22. Lewis TS, Shapiro PS, Ahn NG 1998 Signal transduction through MAP kinase
cascades. Adv Cancer Res 74:49-139
23. Naor Z, Benard O, Seger R 2000 Activation of MAPK cascades by G-protein-
coupled receptors: the case of gonadotropin-releasing hormone receptor.
Trends Endocrinol Metab 11:91-99
24. Buchanan FG, Wang D, Bargiacchi F, DuBois RN 2003 Prostaglandin E2
regulates cell migration via the intracellular activation of the epidermal growth
factor receptor. J Biol Chem 278:35451-35457
Endocrinology is published monthly by The Endocrine
25. Pai R, Nakamura T, Moon WS, Tarnawski AS 2003 Prostaglandins promote
colon cancer cell invasion; signaling by cross-talk between two distinct growth
factor receptors. FASEB J 17:1640-1647
26. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS 2002
Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promot¬
ing colon cancer growth and gastrointestinal hypertrophy. Nat Med 8:289-293
27. Polnaszek N, Kwabi-Addo B, Peterson LE, Ozen M, Greenberg NM, Ortega
S, Basilico C, Ittmann M 2003 Fibroblast growth factor 2 promotes tumor
progression in an autochthonous mouse model of prostate cancer. Cancer Res
63:5754-5760
28. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN 1998 Cyclo¬
oxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705-
716
29. Kwabi-Addo B, Ozen M, Ittmann M 2004 The role of fibroblast growth factors
and their receptors in prostate cancer. Endocr Relat Cancer 11:709-724
30. Bossard C, Van den Berghe L, Laurell H, Castano C, Cerutti M, Prats AC,
Prats H 2004 Antiangiogenic properties of fibstatin, an extracellular FGF-2-
binding polypeptide. Cancer Res 64:7507-7512
31. Mihalich A, Reina M, Mangioni S, Ponti E, Alberti L, Vigano P, Vignali M,
Di Blasio AM 2003 Different basic fibroblast growth factor and fibroblast
growth factor-antisense expression in eutopic endometrial stromal cells de¬
rived from women with and without endometriosis. J Clin Endocrinol Metab
88:2853-2859
32. Jabbour HN, Kelly RW, Fraser HM, Critchley HOD 2006 Endocrine regu¬
lation of menstruation. Endocr Rev 27:17-46
33. Baird DT, Cameron ST, Critchley HO, Drudy TA, Howe A, Jones RL, Lea RG,
Kelly RW 1996 Prostaglandins and menstruation. Eur J Obstet Gynecol Reprod
Biol 70:15-17
34. Hewett P, Nijjar S, Shams M, Morgan S, Gupta J, Ahmed A 2002 Down-
regulation of angiopoietin-1 expression in menorrhagia. Am J Pathol 160:773-
780
35. Blumenthal RD, Taylor AP, Goldman L, Brown G, Goldenberg DM 2002
Abnormal expression of the angiopoietins and Tie receptors in menorrhagic
endometrium. Fertil Steril 78:1294-1300
36. Sangha RK, Li XF, Shams M, Ahmed A 1997 Fibroblast growth factor recep-
tor-1 is a critical component for endometrial remodeling: localization and
expression of basic fibroblast growth factor and FGF-R1 in human endome¬
trium during the menstrual cycle and decreased FGF-R1 expression in men¬
orrhagia. Lab Invest 77:389-402
37. Baker CH, Kedar D, McCarty MF, Tsan R, Weber KL, Bucana CD, Fidler IJ
2002 Blockade of epidermal growth factor receptor signaling on tumor cells
and tumor-associated endothelial cells for therapy of human carcinomas. Am J
Pathol 161:929-938
38. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner
A, Nunes M, Frost P, Discafani CM 2000 Combinatorial chemoprevention of
intestinal neoplasia. Nat Med 6:1024-1028
39. Kooy J, Taylor NH, Healy DL, Rogers PA 1996 Endothelial cell proliferation
in the endometrium of women with menorrhagia and in women following
endometrial ablation. Hum Reprod 11:1067-1072
40. Hickey M, Fraser IS 2000 Clinical implications of disturbances of uterine
vascular morphology and function. Baillieres Best Pract Res Clin Obstet Gynae¬
col 14:937-951
41. Nap AW, Griffioen AW, Dunselman GA, Bouma-Ter Steege JC, Thijssen VL,
Evers JL, Groothuis PG 2004 Antiangiogenesis therapy for endometriosis.
J Clin Endocrinol Metab 89:1089-1095
42. Guidi AJ, Abu-Jawdeh G, Tognazzi K, Dvorak HF, Brown LF1996 Expression
of vascular permeability factor (vascular endothelial growth factor) and its
receptors in endometrial carcinoma. Cancer 78:454-460
the foremost professional society serving theSociety (http://www.endo-society.org),
endocrine community.
Downloaded from endo.endojournals.org by on July 29, 2007
MCE
ELSEVIER Molecular and Cellular Endocrinology 252 (2006) 191-200
Molecular and Cellular Endocrinology
www.elsevier.com/locate/mce
Prostaglandin receptors are mediators of vascular function in
endometrial pathologies
Henry N. Jabbour*, Kurt J. Sales, Oliver P. Milling Smith,
Sharon Battersby, Sheila C. Boddy
MRC Human Reproductive Sciences Unit, Centre for Reproductive Biology, The Queen's Medical Research Institute,
47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom
Abstract
Prostaglandins are bioactive lipids produced from arachidonic acid by cyclooxygenase enzymes and specific terminal prostanoid synthase
enzymes. Following biosynthesis, prostaglandins exert an autocrine/paracrine function by coupling to specific prostanoid G protein-coupled
receptors to activate intracellular signaling and gene transcription. For many years prostaglandins have been recognised as key molecules in
reproductive biology by regulating ovulation, endometrial physiology and proliferation of endometrial glands and menstruation. More recently a
role for COX enzymes and prostaglandins has been ascertained in reproductive tract pathology, including dysmenorrhea, endometriosis, menorrhagia
and cancer. Emerging evidence supports a role for COX enzymes, prostaglandins and prostaglandin receptor signaling pathways in a multitude of
phenotypic changes in reproductive tissues including the promotion of angiogenesis and vascular function. Here we provide an overview of some
of the findings from these studies with specific emphasis on the role of cyclooxygenase enzymes, prostaglandins and their receptors in benign and
neoplastic pathologies of the human endometrium.
© 2006 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
The uterus plays a crucial role in survival of the species in all
viviparous animals. Implantation of the fertilized egg is a critical
event common to all species. Humans and old-world primates
differ from most other animals in that they shed a significant
proportion of their endometrium if pregnancy is not established
at the opportune time. Human endometrium is thus a dynamic
tissue which, in order to prepare for implantation, undergoes
well-defined cycles of proliferation, differentiation and degra¬
dation (menstruation) in response to the prevailing endocrine
and paracrine environment.
It is essential to have a detailed knowledge of the local mech¬
anisms regulating local endometrial events involved in implan¬
tation and menstruation if we are to understand the mechanisms
responsible for aberrations in endometrial function. This ever
expanding knowledge base has the potential to contribute to far
reaching applications in the medical management of benign and
neoplastic pathologies of the endometrium such as unaccept¬
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able heavy menstrual bleeding, painful periods, endometriosis
and cancer.
Cyclooxygenase (COX) enzymes and prostaglandins are
known as important regulators of reproductive function and
more recent data has implicated a role for these molecules in
various pathologies including those of the endometrium. In this
short review we will focus on the role of prostaglandins and
their receptors in pathologies of the endometrium with special
reference to their potential effects on angiogenic and vascular
function.
2. Cyclooxygenase enzymes, prostaglandins and their
receptors
Prostaglandins, thromboxanes and leukotrienes, collectively
referred to as eicosanoids, are the COX and lipooxygenase
(LOX) metabolites of arachidonic acid (AA). Following activa¬
tion of phospholipase A2 (PLA2), AA is released from plasma
membrane phospholipids or dietary fats and is cyclized, oxy¬
genated and reduced to the intermediary prostaglandin H2
(PGH2) by COX enzymes. This intermediate serves as the
substrate for terminal prostanoid synthase enzymes. These
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are named according to the prostaglandin they produce such
that prostaglandin D2 is synthesised by prostaglandin-D-
synthase (PGDS), prostaglandin E2 (PGE2) by prostaglandin-
E-synthase (PGES), prostaglandin F2a by prostaglandin-F-
synthase (PGFS), prostacyclin by prostaglandin-I-synthase
(PGIS) and thromboxane (TXA2) by thromboxane synthase
(TXS) (Narumiya et al., 1999).
Three isoforms of COX enzyme (COX-1, COX-2 and
COX-3) have been reported to catalyze the committed step
in prostanoid (prostaglandins and thromboxanes) biosynthesis
(Morita, 2002; Chandrasekharan et al., 2002). COX-1 is long
thought of as a constitutive enzyme involved in performing
normal physiological functions, but has now been shown by
us and others to be up-regulated in various carcinomas (Sales
et al., 2002a; Hwang et al., 1998; Kirschenbaum et al., 2000;
Maldve et al., 2000) and to play a central role in tumorigenesis
(Narko et al., 1997; Chulada et al., 2000; Kitamura et al., 2002).
COX-2 is an immediate early gene that is rapidly induced by
growth factors, oncogenes, carcinogens and tumor-promoting
phorbol esters and a role has been ascertained for COX-2 in
rheumatic disease, inflammation and tumorigenesis (Morita,
2002).
The roles played by COX enzymes in reproductive biology
have been demonstrated using COX-deficient mice. Studies in
COX-1-deficient mice have shown that the gestation period is
prolonged and parturition is reduced coincident with a reduc¬
tion in the number of viable offspring. Interestingly, conception
and fetal development are unaltered suggesting that prostanoids
produced by COX-1 are not critical for ovulation, fertilization or
implantation, but are essential for bringing on normal labour at
term. This is confirmed by observations between wild type mice
giving natural birth and COX-1 deficient females having their
young delivered by cesarean section, where there are no notice¬
able differences in the number or size of the offspring delivered
(Langenbach et al., 1995; Gross et al., 1998).
By contrast, ablation of the COX-2 gene in mice results in
multiple reproductive failures, including ovulation, fertilization,
implantation and decidualization confirming that prostaglandins
produced by COX-2 play a crucial role in these processes
(Langenbach et al., 1999a,b; Dinchuk et al., 1995; Lim et al.,
1997). Prior to ovulation, pituitary gonadotropins trigger the
expression of COX-2 and synthesis of PGE2 to promote follicle
expansion and ovulation. In COX-2 deficient mice, absence of
PGE2 in preovulatory follicles disrupts follicle expansion and
results in anovulation. Under these conditions administration of
exogenous PGE2 has been shown to rescue ovulation (Davis et
al., 1999). Thus, although both COX isoforms essentially cat¬
alyze the same reaction, in the reproductive tract there are clear
differences in the prostanoid profile and functions of the two
COX enzymes.
Following biosynthesis, prostanoids are rapidly transported
out of the cell by means of a prostaglandin transporter (PGT) and
act in an autocrine/paracrine manner on their cognate heptaheli-
cal transmembrane G-protein-coupled receptors (GPCRs) in the
vicinity of their sites of production. PGD2, PGE2, PGF2a, PGI2
and TXA2 exert their biological function through interactions
with DP, EP, FP, IP and TP GPCRs respectively. There are four
subtypes of EP receptors, termed EP1, EP2, EP3 and EP4, which
are encoded by four separate genes (Narumiya et al., 1999). In
addition, there are several splice variants of the EP3, FP and TP
receptors, which differ only in their C-terminal tails. Generally,
prostanoid receptor isoforms exhibit similar ligand binding but
differ in their signaling pathways, their sensitivity to agonist-
induced desensitisation, and their tendency toward constitutive
activity. Phylogenetic analyses indicate that receptors sharing a
common signal pathway have higher sequence homology than
receptors sharing a common prostanoid as their preferential lig¬
and. Among the different receptors, the IP, DP, EP2 and EP4
receptors elevate intracellular cAMP accumulation via Gas and
have been termed "relaxant" receptors since they induce smooth
muscle relaxation. TP, FP and EP1 receptors induce calcium
mobilisation via Gaq and constitute a "contractile" receptor
group since they cause smooth muscle contractions. The remain¬
ing receptor, EP3, is generally associated with a decline in cAMP
levels and has been termed the "inhibitory" receptor and usually
stimulates smooth muscle contraction, however depending on
the splice variant and cell type, the EP3 receptor can also ele¬
vate intracellular cAMP and mobilise calcium (Narumiya et al.,
1999).
The specific roles played by prostanoids, especially PGE2
and PGF2a in modulating reproductive physiology, have been
demonstrated using mice deficient for each of the prostanoid
receptors (Narumiya et al., 1999). The most startling observa¬
tions have been derived from the EP2 and FP receptor knockouts.
Recent studies have shown that the EP2 and FP receptors are
indispensible in female reproduction (Kennedy et al., 1999;
Hizakietal., 1999; Tilley et al., 1999; Narumiya and FitzGerald,
2001). Loss of EP2 receptor function in murine model systems
by gene ablation, results in impaired ovulation and dramatic
reduction in litter size (Tilley et al., 1999; Kennedy et al., 1999;
Hizaki et al., 1999), whereas ablation of the FP receptor in mice
results in loss of parturition (Narumiya and FitzGerald, 2001).
3. Vascular function in the endometrium: the role of
COX enzymes, prostanoids and prostanoid receptors
The human endometrium is a dynamic tissue, which in the
absence of pregnancy, undergoes well-defined episodes of tissue
proliferation, differentiation and breakdown on a cyclical basis.
This cyclical nature of tissue breakdown and remodelling is the
menstrual cycle (Critchley et al., 2001b). The menstrual cycle
is clinically described according to its regularity and length of
bleeding (Chiazze et al., 1968; Treloar et al., 1967). The mean
menstrual cycle length during a woman's reproductive years is
between 28 and 32 days with the duration of menses lasting 4-5
days.
Menstruation is an active process whereby the upper two
thirds of the endometrium (functional layer) is shed and regen¬
erated on a repetitive basis, once every cycle in response to with¬
drawal of the circulating ovarian steroids. After menstruation,
the functional layer is replenished by the sequential exposure to
estradiol and progesterone (Critchley et al„ 2001b; Lockwood
et al., 2004), which are known to modulate the expression of
a diverse array of effector molecules, including cytokines and
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prostanoids, which in turn modulate vascular function in the
endometrium to facilitate tissue regeneration.
In addition to replenishment of the superficial epithelium, the
vascular compartment of the endometrium comprising the spiral
arteries and arterioles also needs to be reconstructed following
menstruation. Hence, new endothelial cells are encouraged to
sprout and recruit pericytes to form capillaries and smooth mus¬
cle cells to form larger vessels (Smith, 1998; Gargettaud Rogers,
2001). This process involves degradation of the extracellular
matrix, endothelial cell proliferation and migration and organ¬
isation of the endothelial cells into capillary networks. Several
angiogenic factors have been identified to-date and are believed
to be involved in angiogenesis of the human endometrium
(Gargett and Rogers, 2001). Of the known angiogenic factors,
vascular endothelial growth factor (VEGF), also known as vas¬
cular permeability factor (VPF), is a major specific stimulator
of endothelial cell proliferation and vascular permeability in the
endometrium. VEGF acts through two tyrosine kinase recep-
tuis, VEGFR-1 (fit-1) and VEGFR-2 (KDR), the latter being
considered the more important in regulation of angiogenesis.
Organisation of blood vessel formation, stabilisation, main¬
tenance and regression also involves other factors. These
include the angiopoietins, Ang-1 and Ang-2, which stabilise
and destabilise blood vessels respectively to facilitate angiogen¬
esis (Maisonpierre et ah, 1997). Although the precise mech¬
anism of action of the angiopoietins remains to be clarilied,
it is proposed that Ang-2, acting through its tyrosine kinase
receptor Tie-2, enhances the action of VEGF by reducing
endothelial contact with the extracellular matrix, and hence
with adjacent endothelial cell interactions. In contrast, Ang-
1 acting as a competitive antagonist via Tie-2 enhances the
stability of the newly formed blood vessels by recruiting per¬
icytes (Maisonpierre et ah, 1997). Several other factors includ¬
ing basic libroblast growth factor (bFGF) and platelet-derived
growth factor (PDGF), endocrine gland VEGF (EG-VEGF) and
their respective receptors (Battersby et ah, 2004; Weston and
Rogers, 2000) are also known to stimulate angiogenesis. Thus,
the remodelling of the endometrial vasculature is a complex and
multifactorial process, under the influence of multiple effector
molecules.
Towards the end of the menstrual cycle and concomitant with
the withdrawal of progesterone and sloughing of the functional
layer of the endometrium, COX-2 expression increases in the
endometrial glandular epithelium and lasts through the prolifer¬
ative phase of the cycle (Jones et ah, 1997; Uotila et ah, 2002;
Critchley et ah, 1999). This is accompanied by an elevation
in the expression of EP2, EP4 and FP receptors, which reach
their peak during the mid-late proliferative phase of the men¬
strual cycle, coincident with an elevation in the expression of the
prostaglandin transporter (PGT) (Kang et ah, 2005). Once COX-
2 expression and prostanoid biosynthesis is induced, a positive
feedback system is set in motion to regulate the COX-PG biosyn-
thetic signaling pathway and target genes involved in vascular
function (Fig. 1). Auto-regulation of COX-2 expression has been
reported in several in vitro studies (Tjandrawinata et ah, 1997;
Tjandrawinata and Hughes-Fulford, 1997; Maldve et ah, 2000;
Fujino and Regan, 2003). Following up-regulation of COX-2
Ang-1
Ang-2
Fig. 1. Autocrine/paracrine regulation of prostanoid receptor signaling and the
downstream effects on biological function. In this cartoon, prostaglandins (pro¬
duced either intracellularly via the COX enzyme biosynthetic pathway or present
in seminal plasma) activate specific prostanoid receptors (such as EP or FP),
initiating second messenger production (inositol 1,4,5-trisphosphate, IP; cyclic
adenosine 3',5'-monophosphate, cAMP). Activation of the second messenger
systems can initiate signaling via the small G-protein Ras-extracellular signal-
regulated kinase (ERK1/2) pathway to initiate target gene transcription. Recent
data suggest that target gene transcription can occur via prostanoid-receptor-
mediated transactivation of receptor tyrosine kinases (RTKs) such as the epider¬
mal growth factor receptor (EGFR), either via the release of a heparin-bound
(HB)-EGF-like molecule to directly activate the RTK or by intracellular mech¬
anisms involving non-receptor tyrosine kinases (such as c-SRC). The activation
of target genes such as COX-2 can auto-regulate tumorigenesis by establishing
a positive feedback loop to promote prostanoid-receptor signaling and can also
in turn promote angiogenesis (by modulating vascular function and vascular
tone) by elevating the expression of pro-angiogenic genes such as VEGF, bFGF,
Ang-1 and Ang-2.
expression, the subsequent elevated prostanoid biosynthesis and
signaling can promote the expression of pro-angiogenic factors,
such as VEGF, bFGF, PDGF, Ang-1 and Ang-2 (Fig. 1) (Sales
et al., 2002a; Tsujii et al., 1998) or down-regulate the expres¬
sion of anti-angiogenic genes such as cathepsin-D (Perchick and
Jabbour, 2003).
These angiogenic factors have been shown to act in a
paracrine manner on endothelial cells to enhance endothelial cell
proliferation and promote their rearrangement into tubular struc¬
tures (Tsujii et al., 1998). These data suggest that endometrial
angiogenesis may be under direct control of prostaglandins, pro¬
duced by COX enzymes in the endometrium. Recently the role
of specific prostaglandin receptors in modulating angiogenesis
has been described. In endometrial epithelial cells (Sales et al.,
2004a) and murine model systems (Seno et al., 2002; Sonoshita
et al., 2001), elevated PGE2-EP2 receptor interaction promotes
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the expression of pro-angiogenic genes such as VEGF. Similarly,
elevated PGF2U -FP receptor interaction in endometrial epithelial
cells can also elevate the expression of VEGF in a similar man¬
ner to that of PGE2 via the EP2 receptor to promote angiogenesis
in the endometrium via the activation of convergent intracellular
signaling effector molecules and signal transduction cascades,
such as the ERK1/2 cascade (Sales et al., 2005).
4. COX enzymes and prostaglandins in benign
endometrial pathologies
Problems of menstruation in which prostaglandins appear to
have an etiological role, are those in which the clinical symp¬
toms of pain or bleeding disturbances are prominent. The com¬
mon disorders described here are those of pain associated with
menstruation (dysmenorrhoea), the troublesome pathology of
endometriosis and excessive menstrual blood loss (menorrha-
gia).
4.1. Dysmenorrhoea
Dysmenorrhoea describes painful periods and is a significant
public health burden with up to 50% ofwomen suffering from the
condition at some point in their reproductive lifetime (Brosens
et al., 2000; Dawood, 1985).
Primary dysmenorrhoea is an extremely common condition,
typically occurring in adolescence and in the absence of any
recognisable pathology. Secondary dysmenorrhoea is recog¬
nised as a condition associated with other pelvic pathologies
such as endometriosis, pelvic inflammatory disease and uterine
fibroids. It is much less common than primary dysmenorrhoea
and the role of prostaglandins is less well documented.
Primary dysmenorrhoea is associated with uterine hyper-
contractility. During contractions, uterine blood flow decreases
which leads to relative uterine ischaemia. Good correlation has
been found between uterine blood flow and pain (Brosens et
al., 2000; Dawood, 1985; Fraser, 1992). However, pain has been
documented in the absence of uterine contractility and it is recog¬
nised that prostaglandins have an important alternate role in
the etiology. Prostaglandins have a known role in inflammatory
nocosomial pathways and may have a direct effect in stimulat¬
ing nerve pain pathways (Bley et al., 1998). Excessive synthesis
and secretion of prostaglandins by the endometrium have been
detected in menstrual fluid taken form women with primary dys¬
menorrhoea (Lundstrom et al., 1976; Pickles et al., 1965). A
clear demonstration of increased PGE2 and PGF2Q levels in men¬
strual fluid of women with dysmenorrhoea compared to controls,
shows that this increase was most prominent in the first 2 days
of menstruation and that there is a greater proportional increase
in PGF2c levels (Lumsden et al., 1983). Furthermore, infusion
of PGF2ra into the uterine cavity produces an increase in uterine
contractility and dysmenorrhoea like pain (Lundstrom, 1977),
presumably via interaction with the FP receptor and activation
of intracellular signaling. The role of prostaglandins in dysmen¬
orrhoea is additionally confirmed by the effective use of COX
enzyme inhibitors (Lundstrom, 1978; Rees and Lopez Bernal,
1989) including selective COX-2 enzyme inhibitors (Daniels
et al., 2002). In summary, the vasoconstrictive properties of
PGF2« together with the ability to cause myometrial contractions
could contribute to dysmenorrhoea and in addition the increased
availability of PGE2 could have additional direct pain inducing
properties (Bley et al., 1998).
4.2. Endometriosis
Endometriosis occurs when tissue, histologically similar to
the endometrium, is found in extrauterine sites with tissue
implants most often found over visceral and peritoneal surfaces.
The extent ofdisease is highly variable and endometriosis can be
associated with pelvic pain and infertility. Although not a malig¬
nant disorder, endometriotic tissue exhibits all the hallmarks of
tumorigenic tissue, namely proliferation, cellular invasion and
angiogenesis. According to Sampson's classical theory; retro¬
grade menstruation, peritoneal adhesion of endometrial tissue
and outgrowth are essential in the pathogenesis ofendometriosis.
However, retrograde menstruation is a common occurrence with
viable endometrial cells found in 76-90% of women (Bartosik et
al., 1986), a much higher incidence than endometriosis (2-3%).
Other factors must therefore determine the susceptibility of
women to develop endometriosis. This susceptibility is likely
to be a result of changes to both the peritoneal environment and
to the characteristics of the menstrual tissue.
The etiology of endometriosis is multifactorial and requires
a number of peritoneal substances, in particular angiogenic
factors, to facilitate implantation in ectopic sites (Oral et al.,
1996). The peritoneal fluid contains a variety of free-floating
cells including macrophages, natural killer (NK) cells and lym¬
phocytes. These cells all have immune mediating roles and
can promote cellular growth and viability through the secre¬
tion of growth factors and cytokines. Macrophages are the most
abundant cell type in the peritoneal fluid and have their high¬
est endometrial expression in menstrual tissue. Once activated,
they can release products including prostaglandins (Gazvani
and Templeton, 2002). It has been demonstrated that peritoneal
macrophages from women with endometriosis release more
PGE2 and PGF2a compared to those without endometriosis
(Karck et al., 1996). Further evidence implicating prostaglandins
in the etiology of endometriosis arises from histological anal¬
ysis of endometrial tissue. A higher degree of immunostaining
for COX-2, the rate-limiting enzyme in prostaglandin produc¬
tion, is found in endometrial glandular epithelium in women
suffering from endometriosis compared to control endometrium
(Ota et al., 2001). It is therefore thought that the increased PGE2
and PGF2 biosynthesis may play a role in the regulation of this
disorder.
Although the exact mechanisms whereby prostanoids exert
their function in endometriosis is unclear, PGE2 is known to be
a potent inducer of aromatase activity in endometrial stromal
cells (Noble et al., 1997). Aromatase gives rise to the syn¬
thesis of estrogen, which in turn will feedback positively on
COX enzyme expression and further prostaglandin synthesis.
Endometriosis is classically described as an estrogen depen¬
dent disease, but the lack of ER expression in pre-menstrual
and menstrual tissue (Critchley et al., 2001a) suggests that initi-
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ation of the disease is independent of oestrogen. However, once
implantation has occurred, prostaglandins provide a mechanism
for stimulating estrogen production to sustain the endometriotic
lesions.
COX enzymes, PGE2, PGF2a and their receptors have been
shown to promote the transcription of angiogenic factors such
as VEGF and angiopoietins (Fig. 1). The peritoneal fluid of
women with endometriosis displays greater angiogenic activity
than women without endometriosis (Gazvani and Templeton,
2002). Angiogenic factors may be important for creating a
microvascularised peritoneal environment that would allow for
establishment of endometriotic lesions and this may be regu¬
lated in part by the COX-PG biosynthetic pathway (Sales et al.,
2002a, 2004a, 2005). VEGF and its receptor KDR are dramati¬
cally and specifically up regulated in the superficial stromal cells
of the endometrium in response to the decline of progesterone
(Brenner et al., 2002). It is postulated that VEGF has a unique
role in stimulating matrix metalloproteinase (MMP) expression
within the endometrium. Therefore, the rich content of MMPs,
VEGF and inflammatory prostaglandins found simultaneously
in menstrual fragments could facilitate attachment and angio-
genesis of endometriotic lesions (Brenner et al., 2002), and this
may be facilitated in an autocrine/paracrine manner by activation
of specific prostanoid receptors and their diverse downstream
signaling pathways.
4.3. Menorrhagia
Menorrhagia is the clinical definition describing excessive
menstrual blood loss. Unacceptable heavy menstrual blood loss
affects 10-30% of women of reproductive age and up to 50%
of perimenopausal women (Prentice, 1999,2000). In the United
Kingdom, 5% of women will seek help for this symptom annu¬
ally (Vessey et al., 1992) and the risk of hysterectomy performed
for menstrual disorders is 20% (Coulter et al., 1988).
Treatment using inhibitors of COX enzymes have repeatedly
been shown to reduce menstrual blood loss (Anderson et al.,
1976; Makarainen and Ylikorkala, 1986; Cameron et al., 1990)
implicating disturbances of prostaglandin pathways in the etiol¬
ogy of menorrhagia.
In research studies, the objective definition of menorrhagia
is often based on measurement of menstrual hemoglobin con¬
tent. Scandinavian studies demonstrated that the mean menstrual
blood loss was around 40 ml and that regular menstrual blood
loss in excess of 63 ml was associated with iron deficiency ane¬
mia (Hallberg et al., 1966). The 90th centile for measured blood
loss was 80 ml and this was taken as the upper limit of nor¬
mal (Hallberg et al., 1966). However, in the clinical setting only
40-60% of women with perceived heavy menstrual blood loss
have an objective measurement of greater than 80 ml (Fraser et
al., 1981; Chimbira et al., 1980).
Dysfunctional uterine bleeding (DUB) describes excessive
menstrual blood loss in the absence of any pathology. This con¬
dition accounts for the majority of cases of menorrhagia and
is ovulatory in 80% of cases (Cameron, 1989; Livingstone and
Fraser, 2002). Other causes of menorrhagia are pelvic patholo¬
gies such as fibroids and systemic disease including blood clot¬
ting disorders such as Von Willebrands disease (Makarainen
and Ylikorkala, 1986; Kouides, 2001). Bleeding disorders rep¬
resent a small proportion of women presenting with menor¬
rhagia. Reduced clotting is a known feature of menstruation
(Livingstone and Fraser, 2002) however the exact mechanisms
that lead to excessive menstrual blood loss for many systemic
diseases are poorly understood. Pelvic pathologies such as
fibroids are common, affecting between 20 and 25% of women
and it is reported that around a third of women with fibroids
complain of excessive menstrual blood loss (Buttram and Reiter,
1981). There is a large body ofevidence linking local mediators,
in particular prostaglandins, to ovulatory DUB and this is dis¬
cussed below. However, the role of prostaglandins in excessive
menstrual blood loss secondary to pathologies such as fibroids is
unclear. There is evidence that the use of NSAIDs is less effec¬
tive in treating women with menorrhagia when fibroids exist
(Makarainen and Ylikorkala, 1986).
Investigations into the etiology of ovulatory DUB have not
been able to discover any differences in circulating steroid hor¬
mone levels in women with excessive menstrual blood loss
compared to women with normal menstruation (Eldred and
Thomas, 1994). Additionally, there are no specific histological
differences within the endometrium of women with excessive
menstrual blood loss (Rees et al., 1984a,b). Of note, no differ¬
ences in expression of estrogen and progesterone receptors have
been discovered (Critchley et al., 1994). However, substantial
evidence does exist implicating local mediators, in particular
disturbances of arachidonic acid metabolism and disturbances
of angiogenic processes. Elevated levels of PGE2 have been
found in endometrium of women complaining of heavy peri¬
ods (Willman et al., 1976). Further experiments confirmed an
elevation of total prostaglandins with an apparent shift in syn¬
thesis in favour of PGE2 over PGF2a in the endometrium of
women with DUB (Smith etal., 1981). Additionally, an increase
in PGE2 binding sites has been reported in uterine tissue asso¬
ciated with menorrhagia (Adelantado et al., 1988), although the
specific prostanoid receptors mediating this pathology remain
to be elucidated. Mefenamic acid, a COX inhibitor and mem¬
ber of the Fenamate family of drugs, is routinely used as a first
line of treatment for menorrhagia. A dual mode of action has
been documented for this family of drugs; as well as inhibiting
prostaglandin synthesis they also inhibit binding of PGE2 to its
receptors (Rees et al., 1988). It is thus plausible that one or multi¬
ple EP receptors may mediate the role of PGE2 in this disorder.
PGE2 has vasodilatory properties and it is interesting to note
that prostacyclin (PGI2) and nitric oxide synthesis, vasodilatory
substances, are also both elevated in uterine tissue of women
with excessive menstrual blood loss (Smith et al., 1981; Zervou
et al., 1999). It appears that local mediators with vasodila¬
tory effects on the endometrial vasculature are implicated in
menorrhagia.
As mentioned prostaglandins and PGE2 signaling have been
shown to promote angiogenesis via autocrine-paracrine mech¬
anisms (Fig. 1). Endothelial cells in the endometrium of women
with heavy periods have been shown to proliferate more as
compared to controls (Kooy et al., 1996). In addition the spiral
arterioles in menorrhagic endometrium have a less established
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covering of vascular smooth muscle cells (VSMC) (Abberton et
al., 1996, 1999). Lack of cellular support to the spiral arterioles
prevents sufficient vasoconstriction of these blood vessels, hence
potentially increasing menstrual blood loss. However, hystero-
scopic appearance of endometrial surface vessels appears to
be very similar between women with DUB compared to nor¬
mal endometrium (Hickey et al., 2000). The hypothesis that
menorrhagia arises as a result of poor vascular maturation is
supported by the finding of decreased Ang-1 mRNA expression
in the endometrium of women with menorrhagia (Hewett et al.,
2002). Immunohistochemical studies have additionally demon¬
strated an increase in expression of Ang-2 and it is receptor
Tie-2 in menorrhagic endometrium (Blumenthal et al., 2002).
These disturbances of angiopoietin expression with reduced
Ang-1:Ang-2 ratio would be in favour of vessel destabilisation.
Since there is evidence that Ang-1 and Ang-2 are regulated by
PGE2 (Sales et al., 2002a), immature vessels in turn could be
more susceptible to the vasodilatory actions of prostaglandins
such as PGE2, leading to heavier menstruation, and this may
be enhanced via the autocrine/paracrine actions of PGE2 via
one or multiple EP receptors and their intracellular signaling
pathways.
5. COX enzymes and prostaglandins in neoplastic
pathology of the endometrium
Adenocarcinoma of the endometrium is one of the most fre¬
quently diagnosed malignancies of the female genital tract in
the Western world, ranking fourth in incidence among invasive
tumors in women, following breast, lung, and colon cancers.
Incidence rates of the disease are described as 10-25 women
per 100,000 with a clear geographic variation between Euro¬
pean (United Kingdom, France and Spain) and North American
(United States of America and Canada) countries, with a greater
incidence recorded in North America (Parazzini et al., 1991).
Adenocarcinoma of the endometrium is typically a disease of
postmenopausal women with approximately 85% of the patients
being over 50 years of age. The etiology of endometrial ade¬
nocarcinoma is poorly understood, however, menopause after
age 52, nulliparity, obesity, diabetes and the administration of
unopposed estrogen and tamoxifen are the main factors that are
known to predispose women to this type of cancer, making the
disease a significant factor in women's health in an aging popu¬
lation. Owing to symptoms such as abnormal vaginal bleeding,
the disease is often diagnosed early, and this is reflected in the
86% 5-year survival rate (Ellenson and Wu, 2004). Endometrial
adenocarcinomas arise from several cell types with adenocar¬
cinoma arising from the glandular epithelium being the most
common type, accounting for 80-90% of all uterine tumors
(Gordon and Ireland, 1994; Mant and Vessey, 1994; Wingo et al.,
1995).
Over the last 10 years, numerous studies using gene-
disruption and gene overexpression systems in cell lines and
laboratory animals have provided conclusive evidence to support
a role for COX enzymes, prostanoids and prostanoid recep¬
tors in pathology (Chulada et al., 2000), including cancer of
the endometrium (Sales and Jabbour, 2003a,b). Recent studies
have indicated a correlation between up-regulated COX enzyme
expression and incidence of uterine carcinomas. In all studies
reported thus far, expression of COX-1 appears to be unaltered
in endometrial carcinomas (Tong et al., 2000; Uotila et al., 2002;
Sales and Jabbour, 2003a), indicating a possible housekeep¬
ing function. In other reproductive tract pathologies such as
ovarian and cervical carcinomas, COX-1 expression is elevated
above normal indicating a divergence of function in these tis¬
sues compared with that observed in the endometrium (Sales et
al., 2002a; Dore et al., 1998). By contrast, COX-2 expression
is up-regulated in neoplastic epithelial and endothelial cells of
endometrial carcinomas (Tong et al., 2000; Jabbour et al., 2001;
Ferrandina et al., 2002; Uotila et al., 2002). These findings have
lead to the suggestion that COX enzyme inhibitors may be of
potential benefit as therapeutic regimens for endometrial carci¬
nomas.
Non-selective NSAID use has, however, been associated with
gastrointestinal toxicity, ulceration, platelet dysfunction and kid¬
ney damage in at least 1% of users (Fosslien, 1998; Smith
et al., 2000). Even highly selective NSAID derivatives, which
showed enormous potential as a therapy for pathologies highly
expressing COX-2 have recently been shown to pose a poten¬
tial risk of myocardial infarction and sudden cardiac death in
certain individuals (Graham et al., 2005). More recently it has
been proposed that small molecule antagonists of prostaglandin
receptor function may be more effective strategies against the
effects of prostanoids in pathologies highly expressing COX
enzymes. These ideas stem from the observations that expres¬
sion and signaling of prostanoid receptors, such as EP2, EP4,
FP and PPAR8 are up-regulated in uterine carcinomas coin¬
cident with the elevation of COX-2 expression and synthesis
and secretion of PGE2 and PGF2a (Tong et al., 2000; Jabbour
et al., 2001; Sales et al., 2001; Ryu et al., 2000; Kulkarni et
al., 2001). Indeed elevated PGE2-EP2 and PGF2a-FP receptor
signaling has been shown to promote endometrial tumor cell
proliferation and induce the expression of potent pro-angiogenic
factors, like VEGF. This is mediated via convergent pathways
by inducing the transactivation of growth factor receptors, such
as the epidermal growth factor receptor (EGFR) in a predom¬
inantly ligand-independent manner leading to the activation of
mitogenic signaling to ERK1/2 (Fig. 1) (Sales et al., 2004a,b,
2005).
In animal model systems, blockade of EGFR signaling with
an orally active EGFR tyrosine kinase inhibitor has been used
successfully in carcinomas of nude mice to inhibit tumor angio-
genesis, by reducing VEGF expression (Kedar et al., 2002).
Similarly the use of orally active inhibitors of the Ras-ERK
cascade have proved efficacious in treatment of metastatic
melanoma (Collisson et al., 2003). More, recently a combina¬
torial approach using a non-selective COX-enzyme inhibitor
in combination with an inhibitor of EGFR kinase has been
shown to reduce polyp formation in APCa716 mice more effec¬
tively than either compound on their own (Torrance et al.,
2000). In light of these findings and the fact that different
prostanoids can activate convergent signaling pathways to per¬
form a common function in promoting endometrial tumorigene-
sis, targeted disruption of specific common signaling pathways
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such as ERK1/2 or EGFR may also be efficacious intervention
strategies.
6. Modulation of endometrial pathologies by seminal
plasma
There is much emerging evidence to suggest that the introduc¬
tion of semen into the female reproductive tract during coitus
orchestrates molecular and cellular changes to facilitate con¬
ception. Seminal plasma is known to contain estrogen, proges¬
terone, cytokines and growth factors (Robertson, 2005), all of
which have the capacity to modulate cellular function via their
actions on their cognate receptors. Indeed, seminal plasma has
been shown to influence the expression of genes in endometrial
epithelial and stromal cells, where expression of a number of
pro-inflammatory mediators such as IL-1 (3, IL-8 and VEGF is
increased following treatment with seminal plasma (Gutsche et
al„ 2003).
In addition, it is well established that prostaglandins are
present in high concentrations in the semen of primate species
including man. Seminal plasma concentrations ofprostaglandins
are 10,000-fold greater than that detected at the site of inflam¬
mation and PGE2 is one of the major types detected (Templeton
et al., 1978).
This has prompted the suggestion that seminal plasma
prostaglandins may exacerbate endometrial pathologies by acti¬
vating intracellular signaling via the elevated prostanoid recep¬
tors (Fig. 1).
Recently, seminal plasma and PGE2 have been shown to
promote COX-2 and EP receptor expression and signaling in
cervical adenocarcinoma cells (Sales et al., 2002b). In addition
to contact with cervical tissue where semen is deposited during
intercourse, seminal plasma is transported into the uterine cavity
in humans (Kunz et al., 1997). Research using labelled albumin
macrospheres deposited at the external cervical os demonstrates
that the spheres can travel into the uterine cavity within minutes
of deposition. The proportion of spheres entering the uterine
cavity increases with increased intensity of uterine contractions
during the menstrual cycle (Kunz et al., 1997). Similarly, in vivo
studies show that the constituents of seminal plasma, bound to
the post-acrosomal region of sperm, are carried together with
the sperm into the uterus and higher tract, served by the peri¬
staltic contractions observed in the reproductive tract, during
the menstrual cycle (Chu et al., 1996; Kunz and Leyendecker,
2002). Therefore, in sexually active women, in addition to
regulation by endogenous prostaglandins produced as a con¬
sequence of up-regulated COX enzyme expression, reproduc¬
tive tract pathologies with elevated prostaglandin receptors
may also be modulated by prostaglandins in seminal plasma
(Fig. 1).
This highlights further the advantages of utilising combina¬
torial therapeutic approaches of COX inhibitors with receptor
antagonists or signaling inhibitors in sexually active women with
pathologies of the reproductive tract that are associated with ele¬
vated prostanoid receptor expression. The effectiveness of these
combinatorial approaches as means of therapy will need to be
extensively investigated.
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Abstract
Progestogen only contraceptives (POC) provide a safe and effective method of fertility regulation. Unfortunately,
they are commonly associated with the problem of endometrial break through bleeding (BTB), often leading to
discontinuation of use. An increase in endometrial vascular fragility has been demonstrated as an important
mechanism that contributes to BTB but our understanding of the interaction between exogenous steroid use and
endometrial vasculature remains incomplete. This review sets out to describe a number of commonly used POC,
their effects on endometrial morphology and possible molecular and cellular mechanisms that may lead to
unscheduled bleeding.
Abbreviations: Ang - angiopoietin; BM - basement membrane; BTB - breakthrough bleeding; ER - oestrogen receptor;
HEEC - human endometrial endothelial cells; HESC - human endometrial stromal cells; HIF-la - hypoxia inducible
factor-la; IL-1 yS - interleukin-1 [I; LNG - levonorgestrel; LNG-IUS - levonorgestrel intrauterine system; MMP - matrix
metalloproteinases; MPA - medroxyprogesterone acetate; PD-ECGF - platelet derived endothelial cell growth factor; POC
- progestogen only contraceptives; PR - progesterone receptor; TF - tissue factor; TGF-/1/ - transforming growth factor
pi: TIMP - tissue inhibitor of matrix metalloproteinases; TP - thymidine phosphorylase; VEGF - vascular endothelial
growth factor; VSMC - vascular smooth muscle cells
Introduction
The search for improved forms of contraception will al¬
ways remain of importance. The world's population fig¬
ures, around 6057 million in the year 2000, are due to
rise to 9322 million by the year 2050 [1], Virtually all
this increase in population will occur in developing
countries, leading to significant social and health impli¬
cations. The 'perfect' contraceptive should combine
safety and efficacy with convenience of use and ideally
be able to offer additional health benefits. Progestogen
only contraceptives (POCs) have a worldwide usage and
are able to provide safe and effective contraception.
Unfortunately the unwanted side effect of endometrial
break through bleeding (BTB) is a universal problem
for all modalities of POC and this is the commonest
cause for discontinuation of contraceptive use [2, 3],
The exact mechanism of progestogen induced BTB
has yet to be explained, with much evidence pointing
towards superficial blood vessel fragility. In addition
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to enhanced blood vessel fragility, local changes in
endometrial steroid response, structural integrity, tis¬
sue perfusion and local angiogenic factors are likely to
contribute to the mechanism of progestogen induced
BTB.
As yet there is no established long-term intervention
available to manage BTB and thus a greater under¬
standing of the mechanisms involved is required.
Progesterone and oestrogen are naturally occurring
steroid hormones derived through steroidogenesis from
cholesterol. In the normal menstruating woman, they
are responsible for orchestrating the morphological
characteristics in the endometrium required for its
functional endpoints - implantation or menstruation
with associated regeneration and repair.
Progestogens are often defined as any synthetic com¬
pound that can sustain human secretory endometrium.
Small molecular changes to the structure of progester¬
one have led to dramatic changes in pharmacological
properties such as absorbance, half-life, tissue avail¬
ability and side effects. Hence, a variety of synthetic
progestogens are used in contraceptive formulations
(Table 1). The gonanes and estranes [4] are structural
classifications for derivatives of 19-nortestosterone. All
estranes require conversion into norethindrone for
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biological activity. Gonanes include the common
contraceptive progestogen levonorgestrel as well as
newer third generation agents developed to reduce
drug androgenicity. A third group of progestogens,
pregnanes, are derived from 17 a-hydroxy progester¬
one and include cyproterone acetate and medroxypro¬
gesterone acetate (MPA), commonly used in a depot
contraceptive.
A recently developed progestogen called drospiro-
none, is not derived from testosterone or progesterone
but from spironolactone, a mineralocorticoid receptor
antagonist.
POCs prevent pregnancy via a number of mecha¬
nisms depending upon the contraceptive type [5], These
include suppression of ovulation, suppression of nor¬
mal luteal activity, production of hostile cervical mu¬
cous and changes to endometrial morphology. There
are a wide variety of POCs available (summarised in
Table 2), all of which deliver a variety of progestogens,
administered via different routes in different doses.
All POCs lead to problematic break through bleed¬
ing, the type of contraceptive use influences the
amount and character of bleeding with many women
reporting an improvement with time [5], BTB can oc¬
cur in up to 55% of women after 3 months' use of the
levonorgestrel intra-uterine releasing system (LNG-
IUS) [6] and over 50% of women using Norplant have
been reported to request removal within the first year
of use on account of menstrual disturbances [7].
Effects of progesterone and progestogens on
endometrial morphology
The sequential exposure of the endometrium to oestro¬
gen and progesterone leads to a series of classical mor¬
phological changes [8]. Exogenous steroids may not
always lead to similar histological changes within the
endometrium, as the response of this target organ is
dependent upon the dose of steroid, the mode of deliv¬
ery and duration of therapy. To understand the mecha¬
nisms of BTB, an understanding of normal endometrial
morphology is required. The following description of
morphological changes is summarised in Table 3.
Endometrial steroid receptors
The two layers of the endometrium are the superficial
functional layer, which is shed during menstruation
and the basal layer from which the endometrium has
always been considered to regenerate. Three phases of
endometrial development are recognised: a preovula¬
tory proliferative phase, a postovulatory secretory phase
and a menstrual phase. Oestrogen is responsible for the
endometrial proliferative changes. Exposure to proges¬
terone in the second half of the cycle results in secre¬
tory differentiation. The decline in circulating levels of
steroid hormones, oestrogen and progesterone, in the
absence of pregnancy, are responsible for the onset of
menstruation. Overall progesterone exerts an anti-oes-
trogenic effect with inhibition of endometrial growth
and induction of glandular differentiation. These ef¬
fects require the progesterone receptor to be present
which paradoxically only exists in an oestrogen primed
endometrium. The expression of endometrial sex ste¬
roid receptors varies both temporally and spatially
within the endometrium (reviewed by Critchley et al.
[9]). Both oestrogen (ER) and progesterone (PR)
receptors are upregulated in stromal and glandular tis¬
sue during the proliferative phase of the menstrual cy¬
cle. During the secretory phase, ER and PR are down
regulated in the glands with ER expression also being
suppressed in the stroma [10].
Steroid receptors are expressed as various subtypes.
The ER has two structurally related subtypes, com¬
monly known as ER-a and ER-/?. The endometrium
demonstrates differing levels of ER subtype expression
within all cellular compartments [11]. ERa and ER/?
mRNAs are present in glandular epithelial cells,
stromal cells and smooth muscle of the uterine wall at
every stage of the menstrual cycle with higher levels of
ERa expression than ER/?. ERa, however, does show
the greater decline within the superficial layer of the
endometrium during the secretory stage [11], A similar
decline in ERa protein expression has also been
reported within a study that demonstrated only ER/?
expression within the endometrial endothelial cells of
the vasculature. Both ER subtypes, however, were
expressed in the perivascular cells [9],
Table 1. Classification of progestogenic compounds.
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Table 2. Common progestogen contraceptives.

























Table 3. Summary of progestogen effects on endometrial morphology.
Endometrial type Oestrogen Progesterone
receptor (ER) receptor (PR)
Vascular
morphology
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Dilated thin walled Increased
Fragile










Empty cells indicate unknown findings.
The PR also exists as two subtypes PRA and
PRB. These structurally related gene products are
expressed from a single gene as a result of transcrip¬
tion from two alternative promoters [12]. The two
isoforms can display distinct transactivational proper¬
ties that are specific to cell type and ligand. For the
few genes regulated by both receptors, PRB appears
to function as a stronger activation of transcription
[13]. PRA and PRB are differentially regulated with
spatio-temporal variations in expression. Both
subtypes are demonstrated within the glandular and
stromal compartments during the proliferative phase,
with both receptor types dramatically declining in
the glandular cells during the secretory stage. How¬
ever, PRA remains the predominant progesterone
receptor within the stroma during the secretory
phase and would appear to mediate progesterone
effects on endometrium during this phase of the
cycle [14],
Progestogen effects on steroid receptor expression
As POC are associated with breakthrough bleeding, an
imbalance of either sex steroid concentration or recep¬
tor expression may contribute to the mechanisms
responsible for aberrant endometrial bleeding.
The short term administration of synthetic progesto¬
gens decreases the expression of the progesterone
receptor in endometrial stromal and epithelial cells
[15]. However, not all POC have the same effect on
steroid receptor expression as this phenomenon is the
result of differences of dose, duration and mode of
administration.
The use of the 20 pg LNG-IUS leads to an initial
down regulation in both ER and PR expression [16,
17]. The study by Critchley et al. [17] also found that
during 6-12 months exposure to intrauterine LNG,
there was an increase in the subtype A receptor (PRA)
relative to PRB.
Interestingly, although a decrease in PR is noted
with initial progestogen use, there is no difference in
expression between women experiencing BTB com¬
pared to those with no BTB. It is therefore suggested
that local factors rather than systemic hormones are
finally responsible for the control of endometrial bleed¬
ing. However, progestogen induced decidualisation
varies from one region to another and it is possible
that exogenous sex steroids may have an effect in areas
where decidualisation is weak, leading to BTB [16].
Paradoxically, the use of subdermal levonorgestrel
(Norplant) has been reported to raise [18] or lead to a
persistence [19] of PR expression in the endometrium,
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although the functionality of these receptors has not
been examined. Although PR protein expression may
remain elevated, studies investigating mRNA levels of
PR have shown a decline within the glands and stroma
with Norplant use. However, amenorrhoeic women
did demonstrate more PR mRNA in the stroma than
women with BTB [20], It is likely that the differential
PR expression in response to exposure to LNG is a
result of local endometrial progestogen concentrations.
The local endometrial LNG concentrations in women
using a LNG-IUS are 1000-fold greater than serum
concentrations or LNG levels among subdermal LNG
(Norplant) users [21],
In summary, functional responses to progestogen
use include alterations in sex steroid receptor expres¬
sion, with a general trend towards down regulation in
glandular and stromal cells. This decrease in expres¬
sion will impact upon a cascade of downstream events
as a consequence of altered ligand receptor binding.
However, the data are not yet available to demon¬
strate effects of progestogens on endometrial endothe¬
lial cells. This absence of data along with the lack of
evidence linking progestogen induced receptor level
changes with clinical BTB, suggests that the mecha¬
nism of BTB may be locally mediated.
Endometrial vasculature
The mechanism of normal menstruation has been
shown in classical studies to principally involve the
constriction of endometrial spiral arterioles [22].
Break through bleeding is usually lighter in charac¬
ter and shorter in duration than menstruation. The
pattern and character of BTB suggest that it likely oc¬
curs from a different vascular source as compared with
normal menstrual bleeding.
Important hysteroscopic investigations of women
complaining of BTB with both low and high dose pro¬
gestogens have shown that bleeding occurs focally in
the endometrium and originates from superficial, di¬
lated vessels [23], These vessels were also prone to con¬
tact bleeding during hysteroscopy. Vascular fragility,
as examined during hysteroscopy, was also increased
in Norplant users when compared to control women
with normal menstrual cycles [24],
Progestogen use has also been shown to cause
dilated venules in histological studies [25]. It is
interesting that large, thin walled vessels have also
been observed in the superficial endometrial stroma of
women using the LNG-IUS [26], It may be that such
vessel abnormalities do not persist with prolonged
LNG-IUS use as a result of ensuing LNG induced
endometrial atrophy. If these dilated veins are a source
of bleeding, this would correlate with the clinical pic¬
ture of improved BTB with long term LNG-IUS use.
Despite the observations of abnormal vessel develop¬
ment as a result of long term progestogen only contra¬
ceptive use, the exact mechanism that causes aberrant
angiogenesis and vascular fragility is as yet unknown.
Understanding changes in endometrial vessel mor¬
phology with exogenous progestogen use is essential to
understanding mechanisms of BTB.
Normal endometrial vasculature
Blood supplies the uterus via the uterine arteries. In
the myometrium, arcuate arteries then form, which
branch at 90° towards the endometrium to form radial
arteries. These radial arteries then branch to form
basal arteries and spiral arterioles. The basal arteries
supply the basal layer of the endometrium and the
larger spiral arterioles supply the functional layer of
the endometrium [27]. The endometrial microvascula-
ture of capillaries and venous plexuses are formed
downstream of the spiral arterioles. The spiral arteri¬
oles are under the control of steroid hormones [28],
with both growth and differentiation mediated by
presence of ER and PR of the vascular smooth muscle
cells. Direct endothelial steroid receptor expression has
been difficult to prove with recent data demonstrating
human endometrium endothelial cells do not express
ERa or PR but do express ER/I [9], The mechanism
for control of the microvasculature is poorly
understood. Endometrial microvessels consist only of
endothelial cells linked by tight junctions and are sup¬
ported by their basal lamina. This specialised form of
extracellular matrix contributes more than support,
aiding vessel growth, differentiation and permeability
[21].
Progestogen effects on endometrial blood vessels
Vessel density
During the normal menstrual cycle, vessel density does
not substantially change [25, 29]. The effects of pro¬
gestogens on the endometrial vasculature seem to be
dose and type dependent. A low dose LNG implant
system leads to an increase in microvessel density [29]
from as early as after 3 weeks of use, with an associa¬
tion between higher vascular density in atrophic
endometrium and bleeding patterns detected [30].
In contrast, in women exposed to higher doses of
norethisterone or medroxyprogesterone acetate (MPA),
a decrease in vessel density is seen [25]. Although dif¬
fering in their effects, these results do indicate that
exogenous steroid administration may cause a disrup¬
tion in normal vessel formation. This variability of
vascular structure in LNG exposed endometrium
compared to normal endometrium has also been shown
in vitro, in 3-dimensional culture systems [31]. These
studies demonstrated uncannulated clumps of endothe¬
lial cells continuous with vessel-like structures. Dilated,
thin walled vessels were also found within the
functional layers of Norplant users.
Implanon is a subdermal implant, which delivers a
progestogen, etonogestrel (3-keto-desogestrel). Investi¬
gations into endometrial effects of Implanon have not
shown any change in endothelial density [32].
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Structural integrity
During the first month of Implanon use, analysis of
endometrial biopsies, showed that there was a signifi¬
cant reduction in the number of vessels surrounded by
the basement membrane components; laminin, colla¬
gen IV and heparan sulphate proteoglycan [33],
Rogers et al. [34] have also reported a reduction in
vascular smooth muscle a-actin in the endometrium of
women using subdermal LNG (Norplant).
There is therefore considerable evidence that the
integrity and support of endometrial small vessels is
altered by POC, in particular implants, such as Nor¬
plant. Subdermal exogenous progestogens are thus
likely to make small vessels more fragile and prone to
break through bleeding. In addition to the loss of
structural support, basement membrane components
also have local effects on vessel formation and perme¬
ability. Basement membrane abnormalities could
therefore lead to an increased incidence of endothelial
break down. However, in a study by Hickey et al. [33],
no correlation was found between bleeding episodes
and basement membrane components. In addition, not
all studies have demonstrated this reduction of base¬
ment membrane components with subdermal LNG use
[35]. The large variability in immunohistochemical
findings within biopsies of subjects make interpretation
of these results difficult [36], Assuming that a decrease
in BM integrity does contribute to the mechanism of
BTB, it is yet to be determined whether there is a de¬
crease in BM components production or an increase in
local proteolytic activity.
A breakdown in vascular structure only partially
contributes to our current understanding about mecha¬
nisms of break through bleeding and a disruption of
the endometrial epithelium is also required for bleed¬
ing to be clinically evident. This would explain the
hysteroscopic findings of subepithelial bleeds seen as
petechiae and ecchymoses in women when vaginal
bleeding has not been noted [24], Cytokeratin deposi¬
tion within the epithelium is significantly reduced in
Norplant users [37], This change in epithelial struc¬
tural component could allow for break down and
therefore bleeding reaching the endometrial cavity.
Local mediators
Progestogen use has been shown to cause superficial
vascular dilatation, new vessel formation, to increase
microvessel density and to increase vascular fragility.
These changes suggest that exogenous progestogen
administration interferes with normal angiogenesis.
Direct progestogenic effects on endometrial blood
vessels are difficult to prove and increasing evidence is
accumulating to show that changes in local mediators
could contribute to the changes. The following descrip¬
tion of progestogenic effects upon angiogenic factors
and MMP activity is briefly summarised in Table 4.
Angiogenesis in the endometrium
This subject area has been addressed in more detail in
this issue by Girling & Rogers, and thus only brief
mention is made herein. A number of reviews have
highlighted the need for continuing angiogenesis
during the various stages of remodelling within the
endometrium. Repair of the endometrium begins on
the second day of menstruation, with general increases
of proliferation indices noted from day five. After ovu¬
lation, under the influence of progesterone, stromal
cells undergo differentiation and dense coiling of the
spiral arterioles is noted. The above changes of endo¬
metrial structure and function require a concomitant
development of vasculature (reviewed by Smith [38]).
There are varying reports on endothelial cell prolifera¬
tion during the menstrual cycle. Small peaks in
Table 4. Progestogen effects on local mediators of endometrial function.












Increased in Ishikawa cell with MPA,
levonorgestrel and norethisterone
Decreased in endometrial fibroblasts
but increased in epithelial cells with MPA
Suppressed in baboon endometrial
glandular and stromal cells
Increased in human breast tissue
Increased, especially in macrophages







General suppression of MMP
activity




Decreased TIMP in all endometrial
compartments
Menstrual-like expression of stromal
MMPs
MPA - Medroxyprogesterone acetate.
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proliferation have been noted in the mid to late prolif¬
erative stage and later again in the secretory stage of
the cycle [39]. A third peak in proliferation has also
been shown during the menstrual stage [40]. Within
the endometrium, most changes in proliferative activ¬
ity occur in the superficial functional layer rather than
the basal layer and new vessels are deemed to develop
from intersusceptive mechanisms rather than sprouting
[41]. Development of these new vessels is closely reli¬
ant on supporting mesenchymal cells such as vascular
smooth muscle cells (VSMC). If no connection to
VSMC has been established then vascular endothelial
growth factor (VEGF) is required to prevent endothe¬
lial cell apoptosis [38], This mechanism of increased
endothelial cell stability by association with VSMC
may involve other growth factors termed angiopoietins
(Ang-1 and Ang-2). Ang-1 is expressed by VSMC and
via binding to its receptor, tie-2, a stable endothelial-
mesenchyme structure is formed. Interestingly, Ang-2
also binds to the same tie-2 receptor but without
signal and therefore reduces endothelial stability [42].
VEGF is a growth factor responsible for angiogene-
sis and promotes permeability and dilatation in
vessels. It is therefore a prime candidate for a role
mediating the progestogen induced changes in angio-
genesis. The VEGF family of genes has 6 members; A,
B, C, D, E and placental growth factor. Three recep¬
tors have been noted, VEGFR 1, 2 and 3. The human
endometrium is capable of synthesising all members of
the VEGF A family which contains five splice vari¬
ants. Interestingly, the VEGF A gene has two regions
that are homologous to oestrogen response elements
(ERE) and numerous studies demonstrate an increase
of VEGF production in response to oestrogen [43, 44],
Hypoxia has also been shown to increase VEGF pro¬
duction [45]. It is postulated that hypoxia inducible
factor-la (HIF-la) leads to an induction of VEGF
gene transcription. In addition hypoxic conditions may
lead to structural changes in the transcript, which pro¬
mote stability of the mRNA [45]. The role of hypoxia
in the endometrium is discussed later.
The exact mechanisms controlling angiogenesis in
the endometrium have yet to be elucidated but angio¬
genic activity is a consequence of the balance between
angiogenic and angiostatic factors. The effect of POC
upon these factors is therefore of great interest.
Progestogen effects on angiogenic factors
The use of the Ishikawa cell line as an endometrial
model has demonstrated that the steroid hormone oes¬
trogen leads to an increase in VEGF protein and
mRNA production. Various progestogens were shown
to increase VEGF expression as well, MPA producing
a stronger rise than norethindrone and levonorgestrel
[44]. In primary cultures of epithelial and stromal cells
isolated from human endometrium, oestrogen was also
shown to induce VEGF expression [46, 47]; however,
the reports with regard to the effects of progestogens
are conflicting. MPA alone was shown to decrease
VEGF production by stromal cells, but increase pro¬
duction by epithelial cells [48], When applied together,
MPA augmented the 17/1-oestradiol response of VEGF
expression in human endometrial epithelial cells and
inhibited the 17/?-oestradiol-induced VEGF expression
in the stromal cells [48], In contrast, studies in ovariec-
tomised baboons have demonstrated that the addition
of physiological doses of progesterone suppresses an
oestradiol induced rise in VEGF [43], Other in vivo
studies using a mouse sponge assay to measure angio¬
genesis, demonstrated an increase with low dose LNG
but not with higher doses of the same progestogen.
The same study also showed an increase in angiogene¬
sis with the use of MPA, norethisterone and nomeges-
trol [49],
The effect of exogenous steroids on VEGF levels is
varied. Difference in findings may be due to cell type,
progestogen formulation, dose and route of adminis¬
tration and even in vivo/in vitro laboratory techniques.
It is therefore important to look at POC use and their
effects on angiogenic factors within the human
endometrium in vivo.
The LNG-IUS has been shown to cause an increase
in VEGF levels in the endometrium at 3 and 6 months
time points [50]. Importantly, this study demonstrated
a positive correlation between changes in VEGF levels
and clinically reported irregular bleeding, a correlation
rarely shown in other studies. Studies investigating
progestogen effects on tissues other than endometrium
have shown that within breast cancer cells, progester¬
one and progestogens cause an increase in VEGF
expression, which is mediated via the progesterone
receptor [51], However, the finding that LNG-IUS
leads to a decrease in progesterone receptor levels [17],
suggests that changes in steroid receptor expression
alone is not fully responsible for progestogen induced
changes in angiogenic factors within the endometrium.
Local paracrine mechanisms of angiogenic control
are likely to involve a variety of cytokines. For exam¬
ple, \L-ip has been shown to cause a rise in VEGF in
cultured human endometrial cells [52]. Additionally,
endometrial biopsies taken from LNG-IUS users have
shown that much of the increase in VEGF immuno-
staining is demonstrated in macrophage cells [32], This
migratory cell population could be a source of cyto¬
kine production leading to aberrant angiogenesis. A
review on endometrial angiogenesis by Gargett and
Rogers [41] documents changes of VEGF levels in the
endometrial glands and stroma but is unable to corre¬
late these changes with endothelial cell proliferation. It
concludes that neutrophils, marginalised and adherent
to the endothelium, release focal VEGF. It has been
proposed that the neutrophils may be a source of
angiogenic factor that are responsible for superficial
microvessel development.
Implanon is a long term progestogen only subder-
mal implant that delivers the gestogen etonogestrel for
contraception. In contrast to LNG-IUS, it has been
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shown to decrease glandular VEGF expression [32],
This study demonstrated a correlation between endo¬
thelial cell density and stromal VEGF levels although
no correlation with BTB was shown. Changes in glan¬
dular VEGF levels could therefore be less biologically
important compared to stromal levels. This could
explain why no change in endothelial cell density was
demonstrated with Implanon despite a decline in
VEGF expression within endometrial glands.
Platelet-derived endothelial cell growth factor (PD-
ECGF), also known to be the intracellular enzyme
thymidine phosphorylase (TP) [53], is a key player in
endometrial angiogenesis. Its expression is spatio-tem-
porally regulated within the human endometrium.
Expression is mainly stromal during the proliferative
phase of the menstrual cycle, changing to strongly
glandular during the secretory stage [54], Work carried
out to elucidate steroid hormone control of this
enzyme in a normal endometrial epithelial (NEE) cell
culture, demonstrated that progesterone will only lead
to a dramatic increase in PD-ECGF/TP expression
when co-cultured with TGF-/I1 [54],
Thrombin and hypoxia
Other factors acting as angiogenic and angiostatic fac¬
tors are also influenced by progestogen use. The role
of angiopoietins in angiogenesis is influenced with
POC use and also linked to thrombin formation and
tissue hypoxia. Break through bleeding will cause
thrombin formation within the endometrium. Throm¬
bin has been shown to decrease Ang-1 protein and
mRNA expressed in HESC but only minimally
decrease Ang-2, expressed within HEEC [55]. The out¬
come of this change in angiopoietin levels is a decrease
in endothelial cell stability with an enhancement of
further aberrant angiogenesis.
Tissue factor (TF) is an initiator of haemostasis,
and levels of the protein are raised with LNG-IUS
use, therefore aiding thrombin formation [56]. In con¬
trast, levels are initially decreased with LNG subder-
mal system but levels rebound to a persistent elevated
level after one year of use [57], These elevated TF lev¬
els are significant in endometrial biopsies taken from
bleeding sites identified during hysteroscopy. In addi¬
tion to aiding haemostasis and thrombin formation,
TF can act as an angiogenic factor with prolonged
expression as seen with exogenous progestogen use.
Thrombin elevates levels of the pro-inflammatory and
angiogenic factor, cytokine IL-8, levels of which are
usually decreased with decidualisation. Hypoxia has
also been demonstrated to cause an increase in IL-8
[56], This is of importance as studies investigating uter¬
ine blood flow with Norplant use have shown a signifi¬
cant decrease in endometrial perfusion [58]. Therefore
the use of LNG-IUS and LNG implant systems may
lead to aberrant angiogenesis as a result of increasing
TF levels and increased IL-8 levels secondary to both
hypoxia and enhanced thrombin formation.
Hypoxia and reperfusion secondary to decreased
endometrial blood flow with progestogen use may con¬
tribute to BTB by other mechanisms.
The link between HIF-loc and increased VEGF pro¬
duction has already received mention. It has also been
shown that hypoxia, via free radical production, leads
to an inhibition of Ang-1, leaving unopposed the
expression of Ang-2 [59], POC induced bleeding can
therefore occur as a result of vessel damage secondary
to hypoxia induced free radical changes in angiogenic
factors.
In summary, progestogen effects on angiogenesis
and angiogenic factors are varied but evident. Differ¬
ences in findings could belie differences in dose, mode
of administration and progestogen type as well as
methods (in vivo or in vitro) used for investigation. It is
interesting that much of the evidence showing
increases in angiogenic factors, in particular VEGF, is
in response to administration of synthetic progestogens
whereas the use of progesterone does not lead to chan¬
ges in VEGF expression. Progesterone has been shown
to increase the angiogenic inhibitor thrombospondin-1
(TSP-1) whereas synthetic progestogens have little ef¬
fect [60], This discrepancy between progestogens could
be one reason why aberrant angiogenesis is not
normally seen in response to progesterone during the
physiological menstrual cycle.
PD-ECGF/TP is upregulated in response to proges¬
terone but only in combination with TGF-/I1. This
required combination may also explain the differences
in angiogenesis between POC use and raised progester¬
one levels during the menstrual cycle.
Matrix metalloproteinases
Tissue repair and remodelling is a necessary process in
the female reproductive tract. Menstruation is
preceded by an increase in proteolytic substances
including matrix metalloproteinases (MMPs), which
are able to effect tissue breakdown. The trigger for
this change in local tissue characteristics is thought to
be the decline in steroid progesterone levels and also
involve interactions between a migratory leukocyte
population and the endometrial stroma [61, 62], With
the exception of membrane bound forms (MT)-MMP,
MMPs are secreted as latent proenzymes and require
activation by extracellular proteases [61]. The activity
of MMPs is proportional to the balance of active
enzyme to natural inhibitors, which are termed tissue
inhibitors of metalloproteinases (TIMP).
Progesterone contraception and matrix
metalloproteinases
Progesterone has been shown to have a regulatory
effect on MMP activity (reviewed in [61]). Progester¬
one seems to suppress MMP activation in human
endometrial cell cultures, its withdrawal then leading
to an increase in MMP:TIMP ratio [63],
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Although progesterone has been shown to influence
MMP activity, the focal nature of MMP staining
within the endometrium suggests there are additional
local factors influencing activity as well as endocrine
control.
Studies have identified leukocytes within the endo¬
metrium, the numbers of which rise perimenstrually
[64], High dose progestogens have also been shown to
cause an increase in leukocyte numbers in the endome¬
trium [65]. It is likely that endometrial leukocytes
produce a range of cytokines and proteases, which are
responsible for regulating MMP function. In vitro
studies have shown that 'activation' of MMP requires
co-culture of both endometrial fibroblasts and neu¬
trophils [66] In addition, activated mast cells have also
been shown to have the potential to stimulate MMP
production by endometrial stromal cells [67], The nec¬
essary involvement of these migratory cell populations
could explain the focal nature of MMP expression and
action.
The use of subdermal LNG implants (Norplant) and
DMPA have both been shown to cause similar expres¬
sion of MMP and TIMP to that seen in breaking
down perimenstrual tissue [68]. MMP-1 expression was
significantly higher in Norplant users compared with
DMPA exposed endometrium or menstrual controls.
In addition, activated mast cells, as detected by the
presence of extracellular MC tryptase, predominated
in the endometrium of Norplant users and were also
seen with DMPA use in similar quantities to menstrual
controls [68], Unfortunately, within these findings
there was no correlation between MMP immunostain-
ing and reported number of bleeding days. However,
endometrium exposed to the LNG-IUS has demon¬
strated a significant increase of mast cells containing
MMP-1 in women experiencing BTB compared to
those with no reported bleeding [69],
Further studies have shown an increase in MMP-3
in directed endometrial biopsies taken at the start of
bleeding episodes with Norplant use. Tissue biopsied
from non-bleeding endometrium did not display this
finding [70]. MMP-3 is an important enzyme in the
context of BTB as it is responsible for proteolytic
activation of MMP-1 and/or MMP-9, both of which
have been shown to be present in menstrual biopsies
[71]. The number of MMP-9 positive cells was signifi¬
cantly increased in Norplant exposed endometrium
that displayed a shedding morphology and in biopsies
collected at the time of menses [72] i.e. endometrium
associated with break down and bleeding.
Progestogens can also effect TIMPs thereby increas¬
ing MMP activity. The use of DMPA leads to a de¬
crease in TIMP 1, 2 and 3 in endometrium. However,
no correlation with bleeding patterns was noted [73].
In summary, POCs cause a perimenstrual pattern of
expression of MMPs and their inhibitors. The varia¬
tion in findings between progestogen type and between
studies may in part be explained by sampling
differences since the focal nature of MMP expression
making consistent sampling difficult. This is supported
by studies by Galant et al. [74] which demonstrated
focal expression and activity of MMPs, associated
with a focal tissue breakdown during dysfunctional
bleeding episodes.
Conclusion
Progesterone only contraceptives are commonly associ¬
ated with unscheduled endometrial bleeding.
Increased vascular fragility, as demonstrated by
hysteroscopy, appears to be a key component of
unscheduled bleeding. However, the mechanisms that
lead to vessel fragility have yet to be determined. The
majority of studies conducted to address the aetiology
of BTB have been descriptive in nature. Interpretation
of the data in the context of functional consequences
within the steroid exposed endometrium is difficult.
Thus far the correlation between clinical endpoint; i.e.
bleeding days, and changes in local gene or protein
expression have been disappointing, with no lead
factors being identified. Changes in steroid receptor
expression may cause downstream effects, altering
vascular morphology, vessel density and structural
integrity in the endometrium. These vascular changes
are in turn likely to occur secondarily to alterations in
endometrial local mediators such as angiogenic factors
and MMPs.
The main implication of BTB is discontinuation of
use, further reducing women's contraceptive options.
A greater understanding of POC induced changes in
the endometrium is thus necessary before effective
management strategies for BTB can be achieved.
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Introduction
Menstruation is an active process whereby the upper
two thirds of the endometrium (functional layer) is
shed and regenerated on a repetitive basis. Heavy
menstrual blood loss (HMBL) is one of the most
common gynaecological complaints, affecting 10-
30% of otherwise healthy women. Treatment using
inhibitors of COX enzymes have repeatedly been shown
to reduce menstrual blood loss implicating disturbances
of prostaglandin pathways in the aetiology of HMBL.
Prostaglandin E2 has repeatedly been implicated
in the aetiology of excessive menstruation (1-3)
although the specific prostanoid receptors mediating
this pathology remain to be elucidated.
This study was initiated to elucidate a pattern of expression
of the various components of the COX-prostaglandin
signalling pathways present in the endometrium of
women with normal and heavy menstrual blood loss
(>80ml).
Methods
Patients were recruited from the gynaecological
outpatient clinic with local institutional ethical
approval. Subjects were aged between 18 to 50 years
and reported regular menstrual cycles (21-35 days).
No women had received exogenous hormonal
preparations in the preceding 3 months.Subjects
collected all used sanitary products for one menstrual
period and measurement of menstrual blood loss (MBL)
was performed by a modified alkaline haematin method
(4). Endometrial biopsies were collected by suction
curette (Pipelle) at different stages of the menstrual
cycle.
Patients, phase of menstrual cycle and results of
measured MBL.
Normal MBL (<80ml) Heavy MBL (>80ml)
Patient Numbers n =17 n =12
Proliferative phase n = 7 n = 5
Secretory phase n = 6 n = 5
Mean MBL (ml) 42 255
Median MBL (ml) 45 183
Range MBL (ml) 10-69 82 - 567
Results
Table 1. Relative expression of mRNA (Q-RT-PCR)
in endometrium obtained from women with MBL > 80ml
compared with endometrium obtained from women with
MBL < 80ml. "Indicates significant difference in
endometrium from women with heavy MBL compared to
women with normal MBL (p<0.05).
Prostaglandin Pathway Gene mRNA Expression
COX-1 Increased *
COX-2 Increased *
Prostacyclin Synthase Decreased *
Prostacyclin Receptor (IP) Decreased *
Thromboxane Synthase Decreased *
Thromboxane Receptor (TP) Decreased
PGF2u Synthase No Change
PGF2„ Receptor (FP) Decreased *
PGE2 Synthase No Change
PGE2 Receptor (EP2) No Change
PGE2 Receptor (EP4) No Change
COX-2 PDE4b
EP4
Proliferative Secretory Proliferative Secretory
Figure 1. Relative mRNA expression within endometrium of
women with measured MBL A. Graphs demonstrate signifi¬
cant elevated expression of COX mRNA in secretory endo¬
metrium from women with heavy MBL." indicates significant
difference (p<0.05) B. Graph demonstrates mRNA expression
ofEP2 and EP4 receptors within endometrium of women with
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Figure 4. Graph demonstrating phosphodieste¬
rase 4b (PDE4b) mRNA expression in endometri¬
um from women with normal and HMBL as deter¬
mined by real time quantitative RT-PCR. Results
are expressed as the mean ± S.E.M. of relative
mRNA expression levels * indicates significant
reduction in expression within endometrium from
women with HMBL (p<0.05).
Figure 2. A. Immunohistochemical localisation of COX-1
and COX-2 in mid-proliferative endometrium. Strong sur¬
face epithelial and glandular staining is noted for both
COX enzymes. Stromal immnostaing is noted in the func¬
tional layer but absent in the basal layer. COX-1 immu-
nostaining shows marked localisation to white blood cells
infiltrated within the endometrium.
B. Immunohistochemical localisation of EP2 and EP4 in
mid-proliferative endometrium, Similar immunostaining
patterns are seen for both receptors with greatest immu-
no staining intensity seen in the surface epithelium and
functional glands.
Discussion
To our knowledge, this is the first study
demonstrating significantly higher levels
in expression of COX enzyme mRNA in
endometrium obtained from women with
measured excessive MBL. Furthermore
differences in endometrial prostanoid
synthase and receptor mRNA expression were
demonstrated indicating that dysregulation
of prostaglandin signalling may play a
role in the aetiology of aberrant menstrual
function in disorders such as excessive
menstrual bleeding. Prostaglandin E2
receptor did not demonstrate the reduced
levels of expression seen for other prostanoids
in endometrium from women with
heavy MBL as compared to normal MBL.
An elevated signalling response to PGE2
ligand in endometrium taken from the
same women with excessive MBL further
implicates the PGE2 signalling pathway in the
aetiology of heavy bleeding. This elevated
production of the second messanger, cAMP,
could in part be explained by a reduced
breakdown by phoshodiesterase enzymes
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Figure 3. cAMP production in response to a 10 minute
stimulation with 100nM PGE2 or vehicle. Graph shows the
average fold increase of cAMP production by endometrium
collected from women with heavy MBL and normal MBL.
*Endometrium from women with excessive MBL showed
significantly elevated cAMP production (p<0.05).
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INTRODUCTION Theprostaglandinfamilyfli idmediatorsarinvolv d vascularchangesa dh vbeenimplicat dntme hanismof menstrualfunctiona ddysfu c io . Prostacyclin(PGI)imemberftheprostaglandinfa ly andh smodeofctionviacouplingtheeptah lical G-proteincoupledr stacyclinrece tor(IPt r).Pr vious studiesino rlaboratoryhavdemonstra ednncre s expressionofIPrec pt rinpithelialandndotheliacells oftheendom triumduringmenst alphase(Batt rsby etal.2004).Inddition,ithasb endemonstratedthat ome rium fromwo enithexcessivemenstrualbl odlosi e effectiveanhancingproductionofprostacyclibmy metr um comparedtendomet iumfrwo enithn r albl odloss (Smitheal.1981).Thesedataimplicaterolforprostacyclin andIPreceptorimenstrua i n.Thisst ywasnitiatedto investigatethetracellularsign lransductionpathw ys mediatingtherolefIPeceptorinendometrialpith lia (Ishikawa)cells. METHODS TissueCollection Endometrialbiopsieswerec llect dithasuc ionr te (Pipelle)fromwo enithregularmens rualcycle (25-35days). Nowomanhadreceivedo monalpreparationsinthr monthsprecedingbiopsyc lle tion.Ethi alapprovalwa obtainedfr mLothianRese rchEthicsComm tt eandwrit e informedc ns ntbtainefrallpatie tsriortissu collection. Cellulture HumanIshikawaendometrialaden carcinomacellsw re maintainediDulbecco'sodifiedEaglesiumnutr t mixtureF-12withglutamax-1andpyridoxine,supplement d with10%FCS,andntibiotics(stock50 IU/mlpe i illin 500ug/mlstrepto ycin)at37°Cnd%CO,(v/v). CyclicAMPssay cAMPoncentrationiIshikawaellsrespon et100 M lloprost.aPGInalogue,wasqu ntifiedbyELISAus ngcAMP kitandnormalisedtproteinconcentration.
WesternBlo ti g WesternBlotanalysiswcarriedoun50fjgfprotei
runoa4-20%SDS-polyacrylmidegel.Theroteinsw re transferredontopolyvinylid nedifluor e(PVDF)membranes (Millipore,WatfordUK)ndsubjecttoimm blotnalysis. Membraneswerblockedf1h urat25°Cin4%B viSer m Albuminandthenincubatedwi hsp cificntibodies.Pro ei werereveal dandquantifibyphosphoimageran lysis. Foldincreasephosphorylationwdeterminedbividingt proteinexpressionofthhosphorylatedbrelative expressionobtainedfr mt lprote nimmunoblots. RESULTS IPreceptorsignallinginHumanEndo trium WeinitiallysetoutexamineherolefIPeceptorn thehumanendometrium.Endom ialtissuew si cuba ed overnightinRPMIm diumcontaining3^/g/mlnd m th cina d subsequentlyinc atedthpre nceof100nMllo rost.A significantphosphoryl tionfERK1/2iresponsetallopr st (PGIanalogue)challengewasdetectedft rtreatmentfor10 minutes.Pre-incubationoftissuewi h100nMAG1478,aE FR kinaseinhibitorfornh u ,pr otco-t ea mentwi h100 M lloprostabolishedthehosphorylationfERK1/2(Fig1). Figure1 ActivationofERK1/2inormalhumaendo etrialtissue responseto100nMlloprost(PGIanal gue).Phos horylation issignificantlyreducedbyprei cubatiow thEGFRinhib tor. Graphshowsemi-quantitativeanalysiof=3xperiments.
loprostactivationofIshikawaCellleadstcAMPccumulation andctivationofExtracellularRegula edKinas1/2(ERK1/2) Weinv stigatedcAMPact v tionnIshikawacellsrespon e to100nMll prost.Asignificanttimede e dincrea e accumulationofAMPwasbserved5,10nd5mi t s followingll prostchallenge(p<0.05)Fig.2). TreatmentofIshikawacellswith100nMllopro tlsoresu ted inasignificantphosphoryl tionfERK1/2w thmaximum phosphorylationdetecteda5minutes(Fig3). I S050 Tim#( in) Figure2 FoldincreaseAMPproductionbytheIshik wacelllin responseta100nMllopr tchalle g .'Foldchaisignifi¬ cantlyincreasedate chtimpoi tm ured(p<0.05). ToWERK1/2 Figure3 Westernblotshowingteff ctof100nM lloprostnphosph rylationfERK1/2int e Ishikawacell.Graphsho semi-quantit tivean lysiof n=4experiments.
ERK1/2activationisdependentoncAMPdpidermalGr w h FactorReceptor(EGFR)a tivati n. Furtherexperim ntsinvestigatingthactivationofERK1/2 signallingpathwaysinIshikawacellresponsetollopr st werecarriedoutinthabsencepresefvariousch mi al inhibitorstoeEGFRandRK1/2signallingpathw ys. TreatmentofIshikawacellswith100nMlloprosf r5mi utesd toasignificantincreaseERK1/2phosphorylation. Pre-incubationofcellsf r1h urwiththeEGFRki asein ibi r AG1478(100nM),ProteinKinaseinhibitor(H89,^/ )a d inhibitorofMAPKKinase(PD98059,50/jM)aboli h dt e phosphorylationfERK1/2(Fig4). nI pERK1.2 DMSO Figure4 Westernblotdepicti gthffectsofchemicalin ibitorsnp s- phorylatiorofERK1/2sign llingr te n.H89iacAMP/Protein KinaseAinhibitor,PD98059sMEKi itor(inhiofER phosphoryati n),AG1478isnnhibitorofE FR.'indicatesg¬ nificantrecuctionofphosphorylation(p<0.05). Finally,iordertdete minewhetherhcAMPpat wayould crosstalkwithheERK1/2pathway,reatedIs ika cellswithdibutyrylAMP(allpermeab eanalogue). TreatmentofIshikawacellswith5mMdibutyrylA Pf10 minutessig ificantlyphosphorylatedERK1/2.Ctreatmentf cellswith100nMAG1478inhib edtdibutyrylcAMPmediated ERK1/2phosphorylation,dem nstr ti gt atPGI-mediated cAMPaccumulationo lda tiv teERK1/2sign llingiIshikawa cellsviatheEGFR(Fig5).
OioutyrytcAMP-+ AG1478+
Figure5 RepresentativeWe ternBlod mons atingERK1/2phosph ry¬ lationinresponsetdibutyrylcAMP.Phosphor lationsignifi¬ cantlyreducedinthepres nceofEGFRnhibitor. CONCLUSION Takentogether,urd aemons r tthaPGIcctiv e ERK1/2MAPKsignallingviacAMPdependentm chanism. ThiscAMPdependentactivationofERK1/2ppearstrequ re transactivationofheEpidermalG wthF c orRec p or (AssummarisedchematicallyinFig6).T edownstr m phenotypiceffectofERK1/2activa ionbPGI-IPrecept r interactionremainstobeelucid ted. lloprost—*{_ (PGIAnalogue)! Phenotypicchanges Figure6 CartoondemonstratinghypothesisedIPintrac llul rsig allin leadingtoactivat onoftheERK1/2pathway. References 1)BattersbyS,CritchleHOO.rum-FemandesnJabbourN2004 Temporalexpressionandsignallingoprostacyclirec pt rIthhu nndomet um acrossthemenstrualcycl .Reproduc ion127,79-86 2)SmithK,AbelMH.KellyRWBairdDT.1981ThLanc t(8219):52 -4 Acknowledgements FinancialsupportlortudyprovidedbyUniversityfEdi burghColle lMedicinea VetertnaryM dici efellowshipgrantandthdicalRese cCoun i
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Prof Hilary O D Critchley
Reproductive & Developement Sciences
Obstetrics & Gynaecology, U. of E.
Chancellor's Building, 49 Little France
Edinburgh, EH16 4SB
Date 31 March 2004
Your Ref
Our Ref LREC/2003/6/47
Enquiries to Joyce Clearie
Extension 89022
Direct Line 0131 536 9022
Email joyce.clearie@lhb.scot.nhs.uk
US IRB No.: IRB00001462
Dear Prof Critchley,
THE INVESTIGATION OF CELLULAR SIGNALLING WITHIN ENDOMETRIUM FROM
WOMEN COMPLAINING OF MENSTRUAL DYSFUNCTION.
Thank you for submitting the above research proposal for ethical review. The
Paediatrics/Reproductive Medicine Research Ethics Committee of the Lothian Research
Ethics Committee has reviewed this proposed research and has given it a favourable
ethical opinion. An official Certificate of Ethical Opinion outlining the conditions of this
opinion is enclosed together with a list of members present at the meeting. Please note
that the LREC reference number LREC/2003/6/47 must be quoted on all correspondence.
Correspondence received without the LREC reference number will be returned.
Under the terms of the Scottish Executive Health Department Research Governance
Framework for Health and Community Care this opinion has been notified to the Research
& Development Office of the relevant NHS Trust(s) where the research is intended to take
place. It is the NHS Trust(s) from whom you must obtain management approval before any
work on the proposed research can proceed.
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Chief Executive James Barbour O.B.E.
Lothian NHS Board is the common name of Lothian Health Board
LOTHIAN RESEARCH ETHICS COMMITTEE
CERTIFICATE OF ETHICAL OPINION
LREC Reference Number: LREC/2003/6/47
Title: The Investigation of Cellular Signalling Within Endometrium from women Complaining of
Menstrual Dysfunction.
Researcher: Prof Hilary O D Critchley
The Paediatrics/Reproductive Medicine Research Ethics Committee of the Lothian Research
Ethics Committee (the Committee) reviewed this proposed research and is of the opinion that it
is ethical and appropriate to be carried out in the Lothian Area. This opinion encompasses all
aspects of the application including the Patient/Subject Information Sheet and all other
accompanying documentation provided.
The LREC application form, protocol, subject information sheet, information on compensation
arrangements, payments to researchers and the provision of expenses to subjects (where
appropriate) were reviewed and approved and the members of the Committee present at the
meeting are shown on the attached Membership List.
This opinion is issued subject to the following conditions and is invalid if they are not followed:
• You must obtain appropriate management approval from the relevant NHS Trust(s)
before starting the proposed research. It is the NHS Trust(s) that ultimately decide
whether or not this research should go ahead taking account of the advice of the Local
Research Ethics Committee.
• You must notify the Sub-Committee and the relevant NHS Trust(s), in advance, of any
significant proposed deviation from the original protocol or application form and obtain
approval for any such amendments using the Amendment Approval Request Form.
• You must submit reports to the Sub-Committee and the NHS Trust(s) once the study is
underway if there are any unusual or unexpected results which raise questions about
the safety of the research.
• You must report annually on successes, or difficulties, in recruiting subjects in order to
provide useful feedback on perceptions of the study among patients and volunteers
using the Progress Report Form.
• Where the study is terminated prematurely you must report within fifteen days indicating
the reasons for early termination.
• You must submit a final report within three months of the completion of the study using
the Progress Report Form.
Peter Reith
Secretary
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Patient information sheet
LREC//2002/6/8
The rote ofprostaglandins in menstrual dysfunction
We would like to seek your help with the above study in which we are investigating the mechanisms
regulating normal menstruation. It is particularly important that we seek the help of women like yourself
who have been referred to our clinic with heavy periods. The information obtained from these studies will
help us develop treatments for problems with heavy and troublesome menstruation.
We are asking for your help in several different ways: -
1. We would like to collect the sanitary protection from your next (or a future period) in order that we
can measure in the laboratory the actual amount of blood lost during your period. Although this may sound
an unusual request, helping us in this way will enable us to conduct crucial research. We will make every
effort to ensure that the collection process is as easy and discreet as possible for you and we can provide
airtight, sealable bags and all the packaging required. Furthermore, we would supply your sanitary
protection (pads and / or tampons) in order that the sanitary products from which we measure the blood loss
are the same for each patient participating in our study. We will also arrange uplifting of this collection by
one of our team of research nurses, who are employed specifically to assist us with medical research
projects.
2. The second request, if you agree to participate in the study is that you permit us to collect a sample
of the lining of the womb (biopsy). The sample will be collected with a slim plastic sampler. The tissue
thereafter would be used anonymously and processed in the laboratory in several different ways to allow us
to investigate the function of the womb lining. Occasionally, patients experience a mild period pain type
feeling following collection of the sample. I would like to emphasise that this is a routine procedure
conducted in the outpatient clinic for women referred with menstrual bleeding problems.
3. It is also important that we seek your permission for the sample you have given to be stored
anonymously at the Centre for Reproductive Biology, University of Edinburgh for possible use in future
projects.
4. In addition, we would like to collect a small sample of blood for the measurement of hormone
levels.
Your confidentiality will be strictly maintained throughout the study. Although we would like you to
participate in the study if you agree to volunteer you are under no obligation or commitment and may
withdraw at any time. Withdrawal would in no way affect your future treatment or management.
Should you wish to contact an independent adviser concerning this study please feel free to contact Dr C P
West, Centre for Reproductive Health, Royal Infirmary of Edinburgh at Little France, 51 Little France
Crescent, Edinburgh EH 16 4SA.
For further information about the study, please contact: - Professor Hilary O D Critchley at the above
address or telephone 0131 242 6441
Date: 11th March, 2002
INSTRUCTIONS FOR MENSTRUAL COLLECTION
Thank you for agreeing to collect your used products.
We will provide you with the necessary items required for the collection including
sanitary products. Please contact me for additional bags etc.
Here is a reminder of what we would like you to do:
1. Every time you change your sanitary protection please:
put the used product(s) immediately into a storage bag.
It does not matter how many pads /tampons you put in each bag
i. Tie the neck of the bag.
ii. As soon as possible, put the bagged product into the inner plastic bag,
inside the outer courier bag.
2. If you use tampons, and you wish to bathe or to swim, please remove and
collect the tampon you are wearing, just before you get into the water. If you
want to wear another tampon while you are bathing, that is fine, but remove
and discard it once out of the water. Then use a new tampon, which you will
later collect in the normal way.
3. Please try to collect as carefully as you can, so as the measurement is as
accurate as possible. Please note and record if you loose clots to the toilet, or
fail to collect any pads etc. We would also like you to complete a simple
menstrual chart throughout your period. The timing of product changes etc.
may be completed on this.
4. Please enclose the piece of paper with your name, date of birth, hospital
number and the date your period started, inside the courier bag.
5. When you are sure your period has finished, please telephone me, to arrange
the hand-over of your collection. The completed menstrual chart should be
handed in at the same time as the courier bag.
6. It may be necessary for you to have a sample of blood taken at the time you
return your collection. This is for part of the laboratory process.
'What if I have to go out?'
This is very likely and should not be a problem. Please just take spare products and
storage bags with you. When you need to change you can bag and tie your used
product, to take home, for placing in the collection later.
'What if I need to change and I have no bags with me?'
In an emergency any plastic bag will do.
'What if I can't get collection in immediately?'
The test is not affected by time, therefore if for example holidays intervene, just bring
the collection in at your convenience.
If you have any concerns please contact Oliver Milling Smith via one of the numbers
below. Thank you again.
Radio Page -Tel: 07659547016 and leave your phone number followed by hash
key;
or via Professor Critchley's secretary on: 0131 242 2512
Study Number: LREC/ SL003 /& /4-7"
Patient Identification Number for this trial:
CONSENT FORM
Department of Obstetrics and Gynaecology
Study Title The investigation of cellular signalling within the endometrium.
Name of Researcher:
Professor HOD Critchley
New Royal Infirmary of Edinburgh
Simpson Centre for Reproductive Health
51 Little France Crescent
Edinburgh EH16 4SA
Tel: 0131 242 2670
Or: 0131 242 6441
1. I confirm that I have read and understand the information sheet dated .
for the above study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to withdraw at any time,
without giving any reason, and without my medical care or legal rights being affected.
3. I agree to a letter being sent to my General Practioner about my participation in this study.
4. I agree to the provision of any clinically significant information to my General Practioner.
5 I understand that my medical notes may be looked at by the researchers involved in the study
or from regulatory authorities where it is relevant to my taking part in research.
I give permission for these individuals to have access to my records.
6. I agree that the sample I have given and the information gathered from me may be stored
by Professor Hilary O D Critchley at the Centre for Reproductive Biology, University of
Edinburgh for possible use in future projects, as described in the attached information sheet.
I understand that some of these projects may be carried out by researchers other than
Professor Critchley's laboratory who ran the first project.
7. I understand that this is non-therapeutic research from which I cannot expect to derive any benefit.
8. I agree to take part in the above study.
Name of Patient Date Signature
Name of Person taking consent Date Signature
(if different from researcher)
Researcher Date Signature
1 for patient; 1 for researcher; 1 to be kept with hospital notes
Lothian Research Ethics Committee Consent Form
Optimising protocols for immunohistochemical staining
The purpose of immunohistochemical experimentation is to maximise specific
protein staining with minimal background staining. Staining for each individual protein
examined had to be optimised, often over the course of two to three experiments.
Before running the initial optimising experiments, literature searches were
performed to look for any previous examples of immunohistochemistry for the target
protein. The manufacture's recommendation for concentrations to use for individual
antibodies was also recognised. During all optimisation experiments negative controls
were included using species-specific IgG at a matched concentration or a peptide pre-
absorbed antibody if available.
1) Optimising immunohistochemistryfor the PGE2 receptors EP2 and EP4:
Separate experimental staining runs were carried out for each of the EP receptors.
However conditions utilised for each were identical and therefore described together.
Previous immunostaining for these receptors had been performed on a variety of tissues
within the laboratory (unpublished data). A concentration range for the primary antibody
was therefore decided upon. Slides were divided to those for antigen retrieval by
pressure-cooking and those not for antigen retrieval. Within these two groups, two
concentrations of primary antibody (1:400 and 1:800) were also chosen. This
optimisation run therefore had four subsets of slides. Slides are clearly labelled at the
outset to avoid confusion during experimentation. The same tissue blocks were utilised to
provide positive and negative slides for experimentation to allow for accurate comparison
of staining results. The general immunohistochemical protocol was then followed as
detailed in section 3.2.2.
This optimisation experiment demonstrated that the use of pressure-cooking for
antigen retrieval enhanced the clarity of staining and also that staining was optimal with a
primary antibody concentration of 1 in 400. The lower primary antibody staining
produced staining that was too faint for accurate assessment. A full immunohistochemical
run was then run with the best-assessed conditions.
2) Optimising immunohistochemistry for the PGI receptor IP:
The commercially obtained antibody for the IP had not previously been utilised
within the laboratory. The first optimisation run was therefore run too try and assess a
concentration to utilise this antibody at. 1:10, 1:50, 1:100, 1:200, 1:400, 1:800
concentrations of primary antibody were therefore prepared. Full section endometrial
slides were utilised, as myometrial vasculature was known to express the prostacyclin
receptor, thereby incorporating a control for the antibody's effectiveness. The general
immunohistochemical protocol was then followed as detailed in section 3.2.2.
Concentrations of primary antibody below 1:50 produced immunohistochemical staining
that was too faint for assessment. A concentration of 1:10 produced staining that was too
strong and had an increase of faint background staining. A second optimisation
experiment was therefore run to try concentrations of 1:20, 1:30 and 1:40. The use of
antigen retrieval with a primary antibody concentration of 1:30 produced the optimal
immunostaining and these conditions were hence used for a full immunohistochemical
run.
3) Optimising immunohistochemistry for COX-1 and COX-2:
Separate experimental staining runs were carried out for each of the COX
enzymes. However conditions utilised for each were identical. Previous
immunohistochemical staining had been carried out upon these proteins using the general
immunohistochemical protocol detailed in section 3.2.2. However, within the work
carried out for this thesis, the staining for these proteins was carried out utilising Bond
Automated immunohistochemistry system. This system was able to deliver a efficient
staining method with an improved quality and reproducibility of immunostaining. An
optimisation run was therefore required to detect the best concentration for the primary
antibody and also to ensure the systems specific reagents allowed for optimal staining.
(The tertiary detection used with this system was ABC Horseradish peroxidase rather
than ABC Elite used in the general immunohistochemical protocol). Clear and precise
immunostaining was achieved with both primary antibodies at a concentration of 1 in
500.
